Compounds and compositions for the treatment of coronavirus-related diseases

Abstract

Provided herein are compounds and compositions for treating, managing or preventing coronavirus-related disease. Specifically, provided herein are compounds that are inhibitors of SARS-CoV-2 main protease (Mpro), pharmaceutical compositions comprising such compounds, methods of synthesizing such compounds, and methods of using such compounds and compositions for treating, managing or preventing coronavirus-related disease.

Description

[Technical Field]

[0001] Related applications This application claims priority and benefit therefrom to U.S. Provisional Patent Application No. 63 / 224793 filed July 22, 2021, and to U.S. Provisional Patent Application No. 63 / 289009 filed December 13, 2021, the contents of which are incorporated herein by reference as a whole.

[0002] Sequence List This application includes a sequence listing, which has been submitted electronically in XML format and is incorporated herein by reference in its entirety. The XML copy prepared on 30 June 2022 is named PAT059164-WO-PCT Sequence listing.xml and has a size of 3930 bytes.

[0003] This invention relates to compounds and compositions for the treatment, management and / or prevention of coronavirus-related diseases. Specifically, this invention relates to SARS-CoV-2 main protease (M pro The present invention relates to compounds that are inhibitors of ), pharmaceutical compositions containing such compounds, methods for synthesizing such compounds, and methods for using such compounds and compositions for the treatment, management, or prevention of coronavirus-related diseases. [Background technology]

[0004] SARS-CoV-2 is a single-stranded positive-sense RNA virus belonging to the genus Coronavirus β. The SARS-CoV-2 genome is approximately 30 kb long and has untranslated regions (UTRs) at both ends and at least six complete open reading frame genes (ORFs). Of these ORFs, ORF 1a / b directly encodes two polyproteins: polyprotein 1a (pp1a) and polyprotein 1ab (pp1ab). These polypeptides are the main protease (M pro), also known as 3C-like protease (3CLpro) and papain-like protease (PLpro), cleave into 16 non-structural proteins (nsp). These nsp play a crucial role in the generation of subgenomic RNAs encoding four major structural proteins: surface spike glycoprotein (S), envelope protein (E), membrane protein (M), and nucleocapsid protein (N). Therefore, M pro It plays a crucial role in the replication cycle of SARS-CoV-2. Therefore, M pro Inhibiting its activity could block viral replication and provide an effective therapeutic approach to treat COVID-19, a disease caused by SARS-CoV-2, or other diseases caused by betacoronaviruses.

[0005] M proThe identification of inhibitors has been the subject of several reports. Most of these inhibitors are peptide mimetic drugs and are generally derived from previously studied protease inhibitors (Dai, W. et al. (2020) Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science, 368(6497), 1331-1335; Zhang, L., et al. (2020) Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science, 368(6489), 409-412; Ma, C. et al. (2020) Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Research, 30(8), 678-692; Jin, Z. et al. (2020) Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors.Nature, 582(7811), 289-293).

[0006] Peptide mimetic drugs, originally developed for the SARS-CoV virus, are now available in clinics as intravenous treatments for COVID-19 (Hoffman, R. Let al. (2020). Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19. Journal of Medicinal Chemistry, 63(21), 12725-12747).

[0007] A small number of publications describe non-peptide small molecule inhibitors (Riva, L. et al. (2020). Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature, 586(7827), 113-119; Ghahremanpour, M. et al. (2020). Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2. ACS Med Chem Lett, 11, 2526; Guenther, S. et al. (2021) X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease. Science. https: / / doi.org / 10.1126 / science.abf7945; Douangamath, A. et al. (2020). Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main The protease (Nature Communications, 11(1):5047) indicates that there remains a need for effective treatments for diseases caused by beta-coronaviruses, particularly COVID-19. [Overview of the Initiative]

[0008] Therefore, in one embodiment, the present invention relates to formula (I) [ka] (In the formula, X1, X2, R 1 and R 2 (as defined herein) The present invention provides compounds, stereoisomers thereof, or pharmaceutically acceptable salts thereof.

[0009] Another aspect of the present invention is a pharmaceutical composition comprising a therapeutically effective amount of the compound of the present invention, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

[0010] Another aspect of the present invention is a pharmaceutical composition comprising the compound of the present invention, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

[0011] In another embodiment, the present invention provides a method for treating, preventing and / or managing coronavirus-related illnesses or disorders, the method comprising administering to a subject requiring such treatment, prevention or management a therapeutic or prophylactic effective amount of the compound of the present invention, its stereoisomer, or a pharmaceutically acceptable salt thereof. In specific embodiments, coronavirus-related illnesses include COVID-19, other acute respiratory syndromes, non-respiratory coronavirus syndromes, and post-infection coronavirus syndromes.

[0012] In another embodiment, the present invention provides a method for treating, preventing and / or managing a coronavirus-related illness or disorder, the method comprising administering a compound of the present invention, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof to a subject in need of such treatment, prevention, or management. In a particular embodiment, the coronavirus-related illness is COVID-19.

[0013] In another embodiment, the present invention provides the use of the compounds of the present invention, their stereoisomers, or pharmaceutically acceptable salts thereof in the manufacture of agents for treating, preventing and / or managing coronavirus-related diseases or disorders.

[0014] In another aspect, the present invention provides the use of the compounds of the present invention, their stereoisomers, or pharmaceutically acceptable salts thereof in the manufacture of agents for treating, preventing, and / or managing COVID-19.

[0015] In another aspect, the present invention provides the use of the compounds of the present invention, their stereoisomers, or pharmaceutically acceptable salts thereof in the treatment, prevention, and / or management of coronavirus-related diseases or disorders.

[0016] In another aspect, the present invention provides the use of the compounds of the present invention, their stereoisomers, or pharmaceutically acceptable salts thereof in the treatment, prevention, and / or management of COVID-19.

[0017] In another embodiment, the present invention provides compounds of the present invention, stereoisomers thereof, or pharmaceutically acceptable salts thereof for use in the treatment, prevention and / or management of coronavirus-related diseases or disorders.

[0018] In another aspect, the present invention provides the use of the compounds of the present invention, their stereoisomers, or pharmaceutically acceptable salts thereof for use in the treatment, prevention, and / or management of COVID-19.

[0019] In another embodiment, the present invention provides a kit comprising the compound of the present invention, its stereoisomer, or a pharmaceutically acceptable salt thereof for treating, preventing and / or managing coronavirus-related illnesses.

[0020] In another embodiment, the present invention provides a kit comprising the compound of the present invention, its stereoisomer, or a pharmaceutically acceptable salt thereof for treating, preventing, and / or managing COVID-19.

[0021] In another embodiment, the present invention provides combinations for treating, preventing and / or managing coronavirus-related illnesses, in which a compound of the present invention, its stereoisomer, or a pharmaceutically acceptable salt thereof is used in combination with one or more other activators. In certain embodiments, the activator is selected from neutralizing antibodies and antiviral agents. In certain embodiments, the activator is selected from neutralizing antibodies, antiviral agents, and other agents selected from alberestat, Lenzilumab, Octagam, Remestemcel-L, RPH-104+orokizumab, bucillamine, CD24FC (MK-7110), trazipitant, ifenprodil, tocilizumab, leronlimab, fenretinide, ATYR-1923, CYTO-205, APN-01, and Ampion. In certain embodiments, the neutralizing antibody is bamranivimab, bamranivimab + etesevimab, bamranivimab + VIR-7831, REGN-COV2, VIR-7831, AZD7442, regdanvimab / CT-P59, ABP The following were selected from 300, COVI-AM / STI-2020, VIR-7832, SAB-185, JS016 / etesevimab, C-135LS / C-144LS, BRII-196, BRII-198, SCTA-01, MW-33, DXP593, HFB-30132A, ADG20, COVI-GUARD (STI-1499) and convalescent plasma, and the antiviral agents were remdesivir, Avigan / favipiravir, EIDD-2801 / mornupiravir, AT-527, PF-00835231, PF-07321332, Ens The following drugs are selected: ovibep / DARPin, galidesivir, lopinavir-ritonavir, Virazole (ribavirin), levovir, elsulfavirine, thimerosal, UNI91103, silmitasertib / CX-4945, RBT-9, AT-301, Traneurocin / Neurosivir, opaganib, ABX-464, SNG001, arisporivir, nafamostat mesylate, vidofludimus / IMU-838, emvodostat / PTC299, brachynal, ATR-002, and maraviroc.

[0022] In another embodiment, the present invention provides a combination for treating, preventing and / or managing coronavirus-related illnesses, wherein the compounds of the present invention are used in combination with remdesivir (also known as 2-ethylbutyl((((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate). [Brief explanation of the drawing]

[0023] [Figure 1] This shows a typical powder X-ray diffractogram (PXRD) curve for (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-3-yl)imidazolidined-4-carbonitrile variant A. The x-axis represents the scattering angle at 2θ, and the y-axis represents the intensity of the scattered X-ray beam in relation to the count of detected photons. [Figure 2] A typical differential scanning thermal analysis (DSC) curve for (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-3-yl)imidazolidined-4-carbonitrile variant A is shown. The x-axis represents temperature in degrees Celsius (°C), and the y-axis represents heat flow in watts per gram (W / g) as the endothermic peak rises. [Figure 3] A typical thermogravimetric analysis (TGA) curve for (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-3-yl)imidazolidined-4-carbonitrile variant A is shown. The x-axis represents temperature in degrees Celsius (°C), and the y-axis represents the mass (loss) of the sample in weight percentage (W%). [Figure 4] This shows a typical powder X-ray diffractogram (PXRD) curve for (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-3-yl)imidazolidined-4-carbonitrile variant B. The x-axis represents the scattering angle at 2θ, and the y-axis represents the intensity of the scattered X-ray beam in relation to the count of detected photons. [Figure 5]A representative differential scanning calorimetry (DSC) curve of (R)-3-(isoquinolin-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridin-3-yl)imidazolidine-4-carbonitrile Form B is shown. The x-axis represents temperature in degrees Celsius (°C), and the y-axis represents heat flow in watts per gram (W / g) associated with the rise of the endothermic peak. [Figure 6] A representative thermogravimetric analysis (TGA) curve of (R)-3-(isoquinolin-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridin-3-yl)imidazolidine-4-carbonitrile Form B is shown. The x-axis represents temperature in degrees Celsius (°C), and the y-axis represents the mass (loss) of the sample in weight percent (wt%). MODE FOR CARRYING OUT THE INVENTION

[0024] Definitions As used herein, the term "alkyl" refers to a fully saturated branched or straight-chain hydrocarbon chain. In certain embodiments, the alkyl group is "C1-C2 alkyl", "C1-C3 alkyl", "C1-C4 alkyl", "C1-C5 alkyl", "C1-C6 alkyl", "C1-C7 alkyl", "C1-C8 alkyl", "C1-C9 alkyl" or "C1-C 10 alkyl", and the terms "C1-C2 alkyl", "C1-C3 alkyl", "C1-C4 alkyl", "C1-C5 alkyl", "C1-C6 alkyl", "C1-C7 alkyl", "C1-C8 alkyl", "C1-C9 alkyl" and "C1-C 10 alkyl", as used herein, refer to alkyl groups containing at least 1, up to 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, respectively. Non-limiting examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl and n-decyl.

[0025] As used herein, the term “alkenyl” refers to a partially saturated branched or linear hydrocarbon chain having one or more double bonds. In certain embodiments, the alkenyl group is a “C2-C3 alkenyl”, “C2-C4 alkenyl”, “C2-C5 alkenyl”, “C2-C6 alkenyl”, “C2-C7 alkenyl”, “C2-C8 alkenyl”, “C2-C9 alkenyl”, or “C2-C 10 "Alkenyl" is the term "C2-C3 Alkenyl", "C2-C4 Alkenyl", "C2-C5 Alkenyl", "C2-C6 Alkenyl", "C2-C7 Alkenyl", "C2-C8 Alkenyl", "C2-C9 Alkenyl", and "C2-C 10 As used herein, "alkenyl" refers to an alkenyl group containing at least two and up to three, four, five, six, seven, eight, nine, or ten carbon atoms. Non-limiting examples of alkenyl groups include ethenyl, n-propenyl, isopropenyl, n-butenyl, isobutenyl, sec-butenyl, tert-butenyl, n-pentenyl, isopentenyl, n-hexenyl, n-heptenyl, n-octenyl, n-nonenyl, and n-decenyl.

[0026] As used herein, the term "alkoxy" refers to -O-alkyl or -alkyl-O-, and "alkyl" is as defined herein. In certain embodiments, the alkoxy group is "C1-C2 alkoxy", "C1-C3 alkoxy", "C1-C4 alkoxy", "C1-C5 alkoxy", "C1-C6 alkoxy", "C1-C7 alkoxy", "C1-C8 alkoxy", "C1-C9 alkoxy", or "C1-C 10 The term is "alkoxy," and the terms are "C1-C3 alkoxy," "C1-C4 alkoxy," "C1-C5 alkoxy," "C1-C6 alkoxy," "C1-C7 alkoxy," "C1-C8 alkoxy," "C1-C9 alkoxy," and "C1-C 10When used herein, "alkoxy" refers to -O-C1~C2 alkyl, -O-C1~C3 alkyl, -O-C1~C4 alkyl, -O-C1~C5 alkyl, -O-C1~C6 alkyl, -O-C1~C7 alkyl, -O-C1~C8 alkyl, -O-C1~C9 alkyl, or -O-C1~C 10 This refers to alkyl groups. Non-exclusive examples of "alkoxy" groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentoxy, isopentoxy, hexoxy, heptoxy, octoxy, nonoxy, and decoxoxy.

[0027] As used herein, the term "C3-C8 cycloalkyl" refers to a fully saturated monocyclic hydrocarbon ring system having 3 to 8 carbon atoms as ring members. Non-limiting examples of such "C3-C8 cycloalkyl" groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.

[0028] As used herein, the term “bicyclic C3-C8 cycloalkyl” refers to a fully saturated condensed bicyclic hydrocarbon ring system having 3 to 8 carbon atoms as ring members, or as used herein, the term “bicyclic C3-C8 cycloalkyl” refers to a fully saturated bridging bicyclic hydrocarbon ring system having 3 to 8 carbon atoms as ring members, or as used herein, the term “bicyclic C3-C8 cycloalkyl” refers to a fully saturated spiro-bicyclic hydrocarbon ring system having 3 to 8 carbon atoms as ring members. Non-limiting examples of such “bicyclic C3-C8 cycloalkyl” groups include bicyclo[1.1.1]pentanyl, spiro[3.3]heptanyl, and spiro[2.3]hexanyl.

[0029] As used herein, the term "C5-C6 cycloalkenyl" refers to a partially saturated (but non-aromatic) monocyclic hydrocarbon ring system having 5-6 carbon atoms as ring members. As used herein, non-limiting examples of "C5-C6 cycloalkenyl" include cyclopenta-1-enyl, cyclopenta-1,3-dienyl, cyclohexa-1-enyl, and cyclohexa-1,3-dienyl.

[0030] As used herein, the term "C1-C6 alkylphenyl" refers to the C1-C6 alkyl groups defined above, which are substituted with a phenyl group. A non-limiting example of a C1-C6 alkylphenyl is benzyl.

[0031] As used herein, the term “haloalkyl” refers to an alkyl group as defined herein, wherein at least one hydrogen atom of the alkyl is replaced by a halo group (as defined herein). A haloalkyl may be a monohaloalkyl, dihaloalkyl, trihaloalkyl, or polyhaloalkyl, including a perhaloalkyl. A monohaloalkyl may have one iodine, bromo, chloro, or fluoro group within the alkyl group. Dihaloalkyls and polyhaloalkyls may have two or more identical halo atoms or combinations of different halo groups within the alkyl group. Typically, a polyhaloalkyl contains up to six, four, three, or two halo groups. Non-limiting examples of haloalkyls include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, and dichloropropyl. Perhalo-alkyl refers to an alkyl group in which all hydrogen atoms are replaced by halo atoms, such as trifluoromethyl. Unless otherwise specified, preferred haloalkyl groups include monofluoro, difluoro, and trifluoro-substituted methyl and ethyl groups, such as CF3, CHF2, CH2F, CH2CHF2, and CH2CF3.

[0032] As used herein, the term “C1-C6 haloalkyl” refers to each “C1-C6 alkyl” as defined herein, wherein at least one hydrogen atom of the “C1-C6 alkyl” is replaced by a halo group (as defined herein). A C1-C6 haloalkyl can be a mono-C1-C6 haloalkyl, such a C1-C6 haloalkyl having one iodine, one bromo, one chloro, or one fluoro. Furthermore, a C1-C6 haloalkyl can be a di-C1-C6 haloalkyl, such a C1-C6 haloalkyl may have two halo atoms independently selected from iodine, bromo, chloro, or fluoro. Furthermore, a C1-C6 haloalkyl can be a poly-C1-C6 haloalkyl, such a C1-C6 haloalkyl may have two or more identical halo atoms or a combination of two or more different halo atoms. These polyC1-C6 haloalkyls may be perhalo-C1-C6 haloalkyls, in which all hydrogen atoms of each C1-C6 alkyl are replaced by halo atoms, and the halo atoms may be the same or a combination of different halo atoms. Non-limiting examples of the "C1-C6 haloalkyl" group include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, difluoropropyl, dichloroethyl, and dichloropropyl.

[0033] As used herein, the term "haloalkoxy" refers to the -O-haloalkyl group, and the term "haloalkyl" is as defined herein. Non-limiting examples of haloalkoxys include fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, trichloromethoxy, pentafluoroethoxy, heptafluoropropoxy, difluorochloromethoxy, dichlorofluoromethoxy, difluoroethoxy, difluoropropoxy, dichloroethoxy, and dichloropropoxy. Perhaloalkoxy refers to an alkoxy in which all hydrogen atoms are replaced by halo atoms, such as trifluoromethoxy. Unless otherwise specified, preferred haloalkoxy groups include monofluoro, difluoro, and trifluoro-substituted methoxy and ethoxy groups, such as -OCF3, -OCHF2, -OCH2F, -OCH2CHF2, and -OCH2CF3.

[0034] As used herein, the term "C1-C6 haloalkoxy" refers to the group -O-C1-C6 haloalkyl, and the term C1-C6 haloalkyl is as defined herein. Non-limiting examples of the "C1-C6 haloalkoxy" group include fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, trichloromethoxy, pentafluoroethoxy, heptafluoropropoxy, difluorochloromethoxy, dichlorofluoromethoxy, fluoroethoxy, difluoroethoxy, trifluoroethoxy, difluoropropoxy, dichloroethoxy, and dichloropropoxy.

[0035] As used herein, the terms "halogen" or "halo" refer to fluoro(F), chloro(Cl), bromo(Br), and iodine(I).

[0036] As used herein, the term “heteroatom” refers to a nitrogen (N), oxygen (O), or sulfur (S) atom.

[0037] As used herein, the term "heteroaryl" refers to an aromatic ring system containing one or more heteroatoms, which may be the same or different. As used herein, the term "heteroaryl" refers to N, NR 6 , also refers to aromatic ring systems having one or more ring members independently selected from O and S, R 6 A heteroaryl group is defined herein as follows: A heteroaryl group may be a monocyclic or fused bicyclic ring system. A monocyclic heteroaryl ring has 5 to 6 ring atoms. A bicyclic heteroaryl ring has 7 to 12 ring member atoms. A bicyclic heteroaryl ring includes ring systems in which a heteroaryl ring is fused to a phenyl ring. Non-limiting examples of heteroaryl groups as used herein include benzofuranyl, benzo[c]thiophenyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, cinnolinyl, flazanyl, furyl, imidazolyl, indolyl, indolidinyl, indazolyl, isoindolyl, isoquinolinyl, isoxazolyl, isothiazolyl, oxazolyl, oxaindolyl, oxadiazolyl (1,3,4-oxa Examples include diazolyl and 1,2,4-oxadiazolyl), prinyl, pyrazolyl, pyrrolyl, phthalazinyl, pyridyl (including 2-, 3- and 4-pyridyl), pyridadinyl, pyrazinyl, pyrimidinyl, quinoxalinyl, quinolinyl, quinazolinyl, tetradinyl, tetrazolyl, tetrazolo[1,5-a]pyridinyl, thiazolyl, thiadiazolyl (including 1,3,4-thiadiazolyl), thienyl, triazinyl, and triazolyl.

[0038] As used herein, the term “5 or 6-membered heteroaryl” refers to an aromatic monocyclic ring system with 5 or 6 members, where 1, 2, 3, or 4 ring members are N, NR 6 , selected independently from O and S, R 6These are defined herein. When used herein, non-limiting examples of such five or six-membered heteroaryl groups include furyl, imidazolyl, isoxazolyl, isothiazolyl, oxazolyl, pyrrolyl, pyrazolyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, tetrazolyl, pyridyl (including 2-, 3-, and 4-pyridyl), pyridazinyl, pyrazinyl, and pyrimidinyl. In certain embodiments, when used herein, the term "five or six-membered heteroaryl" means that one, two, or three ring members are N, NR 6 , selected independently from O and S, R 6 This also refers to aromatic five- or six-membered monocyclic ring systems, as defined herein. Non-exclusive examples of such five- or six-membered heteroaryl groups as used herein include furyl, imidazolyl, isoxazolyl, isothiazolyl, oxazolyl, pyrrolyl, pyrazolyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, pyridyl (including 2-, 3-, and 4-pyridyl), pyridazinyl, pyrazinyl, and pyrimidinyl.

[0039] As used herein, the term “six-membered heteroaryl” refers to an aromatic six-membered monocyclic ring system in which one, two, or three ring members are independently selected from N, O, and S. As used herein, non-exclusive examples of such six-membered heteroaryl groups include pyridyl (including 2-, 3-, and 4-pyridyl), pyridazinyl, pyrazinyl, and pyrimidinyl.

[0040] As used herein, the term “five-membered heteroaryl” refers to an aromatic five-membered monocyclic ring system, where one, two, three, or four ring members are N, NR 6 , selected independently from O and S, R 6These are defined herein. Non-limiting examples of such five-membered heteroaryl groups as used herein include furyl, imidazolyl, isoxazolyl, isothiazolyl, oxazolyl, pyrrolyl, pyrazolyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, and tetrazolyl. In certain embodiments, as used herein, the term “five-membered heteroaryl” means that one, two, or three ring members are N, NR 6 , selected independently from O and S, R 6 This also refers to aromatic five-membered monocyclic ring systems, as defined herein. Non-exclusive examples of such five-membered heteroaryl groups as used herein include furyl, imidazolyl, isoxazolyl, isothiazolyl, oxazolyl, pyrrolyl, pyrazolyl, thiadiazolyl, thiazolyl, thienyl, and triazolyl.

[0041] As used herein, the term “9 or 10-membered bicyclic heteroaryl” refers to a 9 or 10-membered condensed bicyclic aromatic ring system in which 1, 2, 3, 4, or 5 ring members are N, NR 6 , selected independently from O and S, R 6 This is defined as described herein. As used herein, non-limiting examples of such bicyclic heteroaryl groups include indolyl, quinolinyl, isoquinolinyl, indazolyl, prinyl, phthalazinyl, naphthylidinyl, quinazolinyl, synnolinyl, thieno[2,3-b]furanil, 1H-pyrazolo[4,3-d]-oxazolyl, imidazo[2,1-b]thiazolyl, imidazo[1,2-c]pyrimidinyl, imidazo[1,2-a]pyradinyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyradinyl, pyrazino[2,3-d]pyridadinyl, imidazo[1,2-b][1,2,4]triazinyl, benzoxazolyl, benzimidazolyl, imidazopyridinyl, benzo[c]isoxazolyl, and benzothiazolyl.

[0042] As used herein, the term "4- to 7-membered heterocycloalkyl" refers to a saturated hydrocarbon ring with 4 to 7 members, where 1, 2, 3, or 4 ring members are N, NR 6 , independently selected from O or S, R 6A heterocycloalkyl group is defined herein. A heterocycloalkyl group may be bonded to another group at a nitrogen or carbon atom. Non-limiting examples of 4- to 6-membered heterocycloalkyl groups as used herein include azetadinyl (including azetadin-1-yl, azetadin-2-yl and azetadin-3-yl), oxetanyl (including oxetan-2-yl, oxetan-3-yl and oxetan-4-yl), thietanyl (including thietan-2-yl, thietan-3-yl and thietan-4-yl), pyrrolidinyl (pyrrolidine-1-yl, pyrrolidine-2-yl, pyrrolidine-3-yl, pyrrolidine-4-yl and pyrrolidine- (including 5-yl), tetrahydrofuranyl (including tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrofuran-4-yl and tetrahydrofuran-5-yl), tetrahydrothienyl (including tetrahydrothien-2-yl, tetrahydrothien-3-yl, tetrahydrothien-4-yl and tetrahydrothien-5-yl), piperidinyl (including piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperidin-5-yl and piperidin- (including 6-yl), tetrahydropyranyl (including tetrahydropyran-2-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydropyran-5-yl and tetrahydropyran-6-yl), tetrahydrothiopyranyl (including tetrahydrothiopyran-2-yl, tetrahydrothiopyran-3-yl, tetrahydrothiopyran-4-yl, tetrahydrothiopyran-5-yl and tetrahydrothiopyran-6-yl), piperazinyl (piperazine-1-yl, piperazine-2- (containing piperazine-3-yl, piperazine-4-yl, piperazine-5-yl and piperazine-6-yl), morpholinyl (containing morpholin-2-yl, morpholin-3-yl, morpholin-4-yl, morpholin-5-yl and morpholin-6-yl), thiomorpholinyl (containing thiomorpholin-2-yl, thiomorpholin-3-yl, thiomorpholin-4-yl, thiomorpholin-5-yl and thiomorpholin-6-yl), oxathianyl (containing oxathian-2-yl, oxathian-3-yl,(containing oxatian-5-yl and oxatian-6-yl), dithianyl (containing dithian-2-yl, dithian-3-yl, dithian-5-yl and dithian-6-yl), dioxolanil (containing dioxolan-2-yl, dioxolan-4-yl and dioxolan-5-yl), thioxanil (containing thioxan-2-yl, thioxan-3-yl, thioxan-4-yl and thioxan-5-yl), dithiola Examples include yl (containing dithiolan-2-yl, dithiolan-4-yl, and dithiolan-5-yl) and pyrazolidinyl (containing pyrazolidine-1-yl, pyrazolidine-2-yl, pyrazolidine-3-yl, pyrazolidine-4-yl, and pyrazolidine-5-yl), azepanil, diazepanil, triazepanil, ozazepanil, oxadiazepanil, oxepanil, thiepanil, thiazepanil, and thiadiazepanil.

[0043] As used herein, the term "3- to 6-membered heterocycloalkyl" refers to a saturated hydrocarbon ring with 3 to 6 members, where 1, 2, or 3 ring members are N, NR 6 , independently selected from O or S, R 6A heterocycloalkyl group is defined herein. A heterocycloalkyl group may be bonded to another group at a nitrogen or carbon atom. Non-limiting examples of 3- to 6-membered heterocycloalkyl groups as used herein include oxyranil, azilidinil, thyranil, azetadinil (including azetadinil-1-yl, azetadinil-2-yl and azetadinil-3-yl), oxetanil (including oxetan-2-yl, oxetan-3-yl and oxetan-4-yl), thietanil (including thietan-2-yl, thietan-3-yl and thietan-4-yl), pyrrolidinil (pyrrolidinil-1-yl, pyrrolidinil-2-yl, pyrrolidinil-3-yl, pyrrolidinil, pyrrolidinil). (containing din-4-yl and pyrrolidine-5-yl), tetrahydrofuranyl (containing tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrofuran-4-yl and tetrahydrofuran-5-yl), tetrahydrothienyl (containing tetrahydrothien-2-yl, tetrahydrothien-3-yl, tetrahydrothien-4-yl and tetrahydrothien-5-yl), piperidinyl (containing piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperidin-5-yl) (containing yl and piperidine-6-yl), tetrahydropyranyl (containing tetrahydropyran-2-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydropyran-5-yl and tetrahydropyran-6-yl), tetrahydrothiopyranyl (containing tetrahydrothiopyran-2-yl, tetrahydrothiopyran-3-yl, tetrahydrothiopyran-4-yl, tetrahydrothiopyran-5-yl and tetrahydrothiopyran-6-yl), piperazinyl (piperazine-1-yl, pipera (contains din-2-yl, piperazin-3-yl, piperazin-4-yl, piperazin-5-yl and piperazin-6-yl), morpholinyl (contains morpholin-2-yl, morpholin-3-yl, morpholin-4-yl, morpholin-5-yl and morpholin-6-yl), thiomorpholinyl (contains thiomorpholin-2-yl, thiomorpholin-3-yl, thiomorpholin-4-yl, thiomorpholin-5-yl and thiomorpholin-6-yl), oxathianyl (contains oxatian-2-yl, oxatian-3-yl,Examples include oxatian-5-yl and oxatian-6-yl, dithianyl (including dithian-2-yl, dithian-3-yl, dithian-5-yl and dithian-6-yl), dioxolanil (including dioxolan-2-yl, dioxolan-4-yl and dioxolan-5-yl), thioxanil (including thioxan-2-yl, thioxan-3-yl, thioxan-4-yl and thioxan-5-yl), dithiolanil (including dithiolan-2-yl, dithiolan-4-yl and dithiolan-5-yl), pyrazolidinyl (including pyrazolidine-1-yl, pyrazolidine-2-yl, pyrazolidine-3-yl, pyrazolidine-4-yl and pyrazolidine-5-yl), hexahydropyridazinyl and hexahydropyrimidinyl.

[0044] As used herein, the term "4-6 membered heterocycloalkyl" refers to a saturated hydrocarbon ring with 4-6 members, where 1, 2, 3, or 4 ring members are N, NR 6 , independently selected from O or S, R 6A heterocycloalkyl group is defined herein. A heterocycloalkyl group may be bonded to another group at a nitrogen or carbon atom. Non-limiting examples of 4- to 6-membered heterocycloalkyl groups as used herein include azetadinyl (including azetadin-1-yl, azetadin-2-yl and azetadin-3-yl), oxetanyl (including oxetan-2-yl, oxetan-3-yl and oxetan-4-yl), thietanyl (including thietan-2-yl, thietan-3-yl and thietan-4-yl), pyrrolidinyl (pyrrolidine-1-yl, pyrrolidine-2-yl, pyrrolidine-3-yl, pyrrolidine-4-yl and pyrrolidine- (including 5-yl), tetrahydrofuranyl (including tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrofuran-4-yl and tetrahydrofuran-5-yl), tetrahydrothienyl (including tetrahydrothien-2-yl, tetrahydrothien-3-yl, tetrahydrothien-4-yl and tetrahydrothien-5-yl), piperidinyl (including piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperidin-5-yl and piperidin- (including 6-yl), tetrahydropyranyl (including tetrahydropyran-2-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydropyran-5-yl and tetrahydropyran-6-yl), tetrahydrothiopyranyl (including tetrahydrothiopyran-2-yl, tetrahydrothiopyran-3-yl, tetrahydrothiopyran-4-yl, tetrahydrothiopyran-5-yl and tetrahydrothiopyran-6-yl), piperazinyl (piperazine-1-yl, piperazine-2- (containing piperazine-3-yl, piperazine-4-yl, piperazine-5-yl and piperazine-6-yl), morpholinyl (containing morpholin-2-yl, morpholin-3-yl, morpholin-4-yl, morpholin-5-yl and morpholin-6-yl), thiomorpholinyl (containing thiomorpholin-2-yl, thiomorpholin-3-yl, thiomorpholin-4-yl, thiomorpholin-5-yl and thiomorpholin-6-yl), oxathianyl (containing oxathian-2-yl, oxathian-3-yl,Examples include oxatian-5-yl and oxatian-6-yl, dithianyl (including dithian-2-yl, dithian-3-yl, dithian-5-yl and dithian-6-yl), dioxolanil (including dioxolan-2-yl, dioxolan-4-yl and dioxolan-5-yl), thioxanil (including thioxan-2-yl, thioxan-3-yl, thioxan-4-yl and thioxan-5-yl), dithiolanil (including dithiolan-2-yl, dithiolan-4-yl and dithiolan-5-yl), pyrazolidinyl (including pyrazolidine-1-yl, pyrazolidine-2-yl, pyrazolidine-3-yl, pyrazolidine-4-yl and pyrazolidine-5-yl), hexahydropyridazinyl and hexahydropyrimidinyl.

[0045] As used herein, the term “5- or 6-membered heterocycloalkyl” means a saturated hydrocarbon ring with 5 or 6 members, where 1, 2, 3, or 4 ring members are N, NR 6 , independently selected from O or S, R 6A heterocycloalkyl group is defined herein. A heterocycloalkyl group may be bonded to another group at a nitrogen or carbon atom. Non-limiting examples of 5- or 6-membered heterocycloalkyl groups as used herein include pyrrolidinyl (including pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, pyrrolidin-4-yl, and pyrrolidin-5-yl), tetrahydrofuranyl (including tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrofuran-4-yl, and tetrahydrofuran-5-yl), and tetrahydrothienyl (tetrahydrothien-2-yl, tetrahydrothien-3-yl, tetrahydrothien-4-yl). -yl and tetrahydrothien-5-yl), piperidinyl (containing piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperidin-5-yl and piperidin-6-yl), tetrahydropyranyl (containing tetrahydropyran-2-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydropyran-5-yl and tetrahydropyran-6-yl), tetrahydrothiopyranyl (containing tetrahydrothiopyran-2-yl, tetrahydrothiopyran-3- (containing piperadin-1-yl, piperadin-2-yl, piperadin-3-yl, piperadin-4-yl, piperadin-5-yl and piperadin-6-yl), piperadinyl (containing piperadin-1-yl, piperadin-2-yl, piperadin-3-yl, piperadin-4-yl, piperadin-5-yl and piperadin-6-yl), morpholinyl (containing morpholin-2-yl, morpholin-3-yl, morpholin-4-yl, morpholin-5-yl and morpholin-6-yl), thiomorpholinyl (containing thiomorpholin-2-yl, thiomorpholin-3- (containing thiomorpholin-4-yl, thiomorpholin-5-yl and thiomorpholin-6-yl), oxathianyl (containing oxathian-2-yl, oxathian-3-yl, oxathian-5-yl and oxathian-6-yl), dithianyl (containing dithian-2-yl, dithian-3-yl, dithian-5-yl and dithian-6-yl), dioxolanil (containing dioxolan-2-yl, dioxolan-4-yl and dioxolan-5-yl), thioxanyl (containing thioxan-2-yl, thioxan-3-yl,Examples include thioxan-4-yl and thioxan-5-yl, dithiolanyl (including dithiolan-2-yl, dithiolan-4-yl and dithiolan-5-yl), pyrazolidinyl (including pyrazolidine-1-yl, pyrazolidine-2-yl, pyrazolidine-3-yl, pyrazolidine-4-yl and pyrazolidine-5-yl), hexahydropyridazinyl, and hexahydropyrimidinyl.

[0046] As used herein, the term "six-membered heterocycloalkyl" refers to a six-membered saturated hydrocarbon ring, where one, two, three, or four ring members are N, NR 6 , independently selected from O or S, R 6This is defined herein. Heterocycloalkyl groups may be bonded to another group at the nitrogen or carbon atom. When used herein, non-limiting examples of six-membered heterocycloalkyl groups include piperidinyl (including piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperidin-5-yl and piperidin-6-yl), tetrahydropyranyl (including tetrahydropyran-2-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydropyran-5-yl and tetrahydropyran-6-yl), tetrahydrothiopyranyl (including tetrahydrothiopyran-2-yl, tetrahydrothiopyran-3-yl, tetrahydrothiopyran-4-yl, tetrahydrothiopyran-5-yl and tetrahydrothiopyran-6-yl), piperazinyl (including piperazine-1-yl, piperazine-2-yl, piperazine-3-yl, piperazine-4-yl, piperazine- (containing 5-yl and piperazine-6-yl), morpholinyl (containing morpholin-2-yl, morpholin-3-yl, morpholin-4-yl, morpholin-5-yl and morpholin-6-yl), thiomorpholinyl (containing thiomorpholin-2-yl, thiomorpholin-3-yl, thiomorpholin-4-yl, thiomorpholin-5-yl and thiomorpholin-6-yl), oxathianyl (oxathian-2 Examples include -yl, oxatian-3-yl, oxatian-5-yl and oxatian-6-yl), dithianyl (including dithian-2-yl, dithian-3-yl, dithian-5-yl and dithian-6-yl), oxanyl (including thioxan-2-yl, thioxan-3-yl, thioxan-4-yl and thioxan-5-yl), hexahydropyridazinyl and hexahydropyrimidinyl.

[0047] As used herein, the term "three-membered heterocycloalkyl" refers to a three-membered saturated hydrocarbon ring, where one or two ring members are N, NR 6 , independently selected from O or S, R 6A heterocycloalkyl group is defined herein. A heterocycloalkyl group may be bonded to another group at a nitrogen or carbon atom. Non-exclusive examples of three-membered heterocycloalkyl groups as used herein include oxyranil, azilidinyl, and thyranil.

[0048] As used herein, the term “5 or 6-membered heterocyclyl” refers to a partially saturated (but not aromatic) 5 or 6-membered monocyclic ring system, where 1, 2, or 3 ring members are N, NR 6 , independently selected from O or S, R 6 This is as defined herein. In certain embodiments, as used herein, the term “5 or 6-membered heterocyclyl” means that one, two, or three ring members are independently selected from W, Y, and Z, respectively, and W is NR 6 , O, S, S=O or S(=O)², and Y is NR 6 , O, S, S=O or S(=O)², and Z is NR 6 This also refers to partially saturated 5- or 6-membered monocyclic ring systems in which the O or S group is optionally substituted with an oxo group. The 5- or 6-membered heterocyclyl group may be bonded to another group at the nitrogen or carbon atom. Non-limiting examples of the 5- or 6-membered heterocyclyl group as used herein include 1,2-dihydropyridinyl and 2,3-dihydro-1H-pyrrolyl.

[0049] As used herein, the term "six-membered heterocyclyl" refers to a partially saturated (but not aromatic) six-membered monocyclic ring system in which one, two, or three ring members are N, NR 6 , independently selected from O or S, R 6 This is as defined herein. In certain embodiments, as used herein, the term “six-membered heterocyclyl” means that one, two, or three ring members are independently selected from W, Y, and Z, respectively, and W is NR 6 , O, S, S=O or S(=O)², and Y is NR 6 , O, S, S=O or S(=O)², and Z is NR 6This also refers to a partially saturated six-membered monocyclic ring system in which the six-membered heterocyclyl group is optionally substituted with an oxo group, and is either O or S. The six-membered heterocyclyl group may be bonded to another group at nitrogen or carbon. As used herein, a non-limiting example of a six-membered heterocyclyl group is 1,2-dihydropyridinyl.

[0050] As used herein, the term “5-membered heterocyclyl” refers to a partially saturated (but not aromatic) 5-membered monocyclic ring system in which one, two, or three ring members are N, NR 6 , independently selected from O or S, R 6 This is as defined herein. In certain embodiments, as used herein, the term “5-membered heterocyclyl” means that one, two, or three ring members are independently selected from W, Y, and Z, respectively, and W is NR 6 , O, S, S=O or S(=O)², and Y is NR 6 , O, S, S=O or S(=O)², and Z is NR 6 This also refers to a partially saturated five-membered monocyclic ring system in which the five-membered heterocyclyl group is optionally substituted with an oxo group, and is either O or S. The five-membered heterocyclyl group may be bonded to another group at nitrogen or carbon. As used herein, a non-limiting example of a five-membered heterocyclyl group is 2,3-dihydro-1H-pyrrolyl.

[0051] As used herein, the term “9 or 10-membered bicyclic heterocyclyl” refers to a partially saturated (but not aromatic) 9 or 10-membered bicyclic ring system, where 1, 2, 3, 4, or 5 ring members are N, NR 6 , independently selected from O or S, R 6 These are defined herein. The C5-C6 heterocycloalkenyl group may be bonded to another group at the nitrogen or carbon atom. Non-limiting examples of 9 or 10-membered bicyclic heterocyclyl groups as used herein include isochromanil, 1,2-dihydroquinolinyl, 3a,7a-dihydro-1H-pyrrolo[2,3-c]pyridinyl, and 3a,7a-dihydro-1H-indazolyl.

[0052] As used herein, the term "oxo" refers to the base = O.

[0053] As used herein, the term “spiro bond” refers to a bond between one ring system and another ring system via a single carbon atom common to both rings.

[0054] As used herein, the term "located at the beta (β) position relative to the bond site" means R to the rest of the molecule. 2 This refers to the position of a heteroatom or substituent relative to the bond site. For example, in the structure below, the N heteroatom is located at the beta (β) position relative to the bond site indicated by the asterix (*). [ka]

[0055] Similarly, in the structure below, the oxo-substituted ring member carbon atom is located at the beta (β) position relative to the bond site indicated by the asterix (*). [ka]

[0056] As used herein, the term "isomer" refers to various compounds having the same molecular formula but different atomic arrangements and stereoconfigurations. Also as used herein, the terms "optical isomer" or "stereoisomer" refer to any of the various stereoisomer configurations, including geometric isomers, that may exist with respect to a given compound of the present invention. Substituents are understood to be bonded at the chiral center of a carbon atom. The term "chiral" refers to a molecule that cannot be superimposed on its mirror image partner, while the term "achiral" refers to a molecule that can be superimposed on its mirror image partner. Therefore, the present invention includes enantiomers, diastereomers, or racemates of compounds. An "enantiomer" is a pair of stereoisomers that are mirror images of each other and cannot be superimposed. A 1:1 mixture of a pair of enantiomers is a "racemic" mixture. This term is used, as needed, to indicate a racemic mixture. A "diastereomer" is a stereoisomer having at least two chiral atoms but not being mirror images of each other. Absolute stereochemistry is specified according to the Cahn-Ingold-Prelog RS system. When a compound is a pure enantiomer, the stereochemistry at each chiral carbon may be specified by either R or S. Divided compounds whose absolute configuration is unknown may be indicated by (+) or (-) depending on the direction of rotation of plane polarization at the wavelength of the sodium D line (dextrorotatory or levorotatory). Certain compounds described herein contain one or more chiral centers or axes, and thus may give rise to enantiomers, diastereomers, and other stereoisomeric forms that can be defined as (R)- or (S)- with respect to absolute stereochemistry.

[0057] As used herein, the term “pharmaceutically acceptable carrier” includes, as is well known to those skilled in the art, any solvent, dispersion medium, coating, surfactant, antioxidant, preservative (e.g., antibacterial, antifungal), isotonic agent, absorption retarder, salt, preservative, drug stabilizer, binder, excipient, disintegrant, lubricant, sweetener, flavoring agent, colorant, etc., and combinations thereof (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289–1329). Any conventional carrier is to be considered for use in the therapeutic or pharmaceutical composition unless it is incompatible with the active ingredient.

[0058] As used herein, the term “optionally substituted” means either unsubstituted or substituted with the substituents listed below.

[0059] The term “coronavirus-related illness” refers to illness caused by a member of the Coronaviridae family (i.e., any virus that may belong to the Coronaviridae family). Coronaviruses (CoVs) are positive-strand RNA viruses that have a crown-like appearance under an electron microscope due to the presence of a spike glycoprotein on their envelope. Any member of the Coronaviridae family with respiratory components (e.g., belonging to the genera Alphacoronavirus, Betacoronavirus, Deltacoronavirus, or Gammacoronavirus) will be considered in the methods and uses described herein. In a non-limiting range of examples, respiratory viruses may be betacoronaviruses such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), OC43, and HKU1, or alphacoronaviruses such as 229E and NL63. Respiratory viruses may also be coronaviruses other than SARS-CoV, SARS-CoV-2, MERS-CoV, OC43, HKU1, 229E, or NL63. Patients infected with SARS-CoV-2 present with a wide range of clinical severity, from asymptomatic to severe interstitial pneumonia, which can progress to acute respiratory distress syndrome (ARDS), severe acute lung injury (ALI), and a form of diffuse alveolar injury, and is a serious lung disease associated with decreased blood oxygenation, respiratory failure and / or multiple organ failure (MOF), and can be fatal. Clinical symptoms of COVID-19 patients include fever, cough, malaise, loss of smell, and shortness of breath within 2 to 14 days of exposure. SARS-CoV-2 uses the same receptor as SARS-CoV, angiotensin-converting enzyme 2 (ACE2), and spreads primarily through the respiratory tract. Cytokine profiling of patients with severe COVID-19 shows elevated levels of interleukin (IL)-2, IL-7, IL-6, IL-1, granulocyte colony-stimulating factor, interferon-gamma-inducing protein 10, monocyte chemotactic protein 1, macrophage inflammatory protein 1-α, and tumor necrosis factor-α.

[0060] As used herein, the terms “inhibit,” “inhibit,” or “to inhibit” refer to the reduction or suppression of a given condition, symptom, disorder, or disease, or a significant reduction in the baseline activity of a biological activity or process.

[0061] As used herein, the term “subject” may refer to an animal, which may be a mammal. The subject may also refer to, for example, primates (e.g., male or female humans), cattle, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds, etc. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is a human. Unless otherwise noted, the terms “patient” and “subject” are used interchangeably herein.

[0062] As used herein, the terms “to treat,” “to treat,” or “to treat” any disease or disorder mean, in one embodiment, improving the disease or disorder (i.e., slowing, preventing, or reducing the development of at least one of the disease or its clinical symptoms). In another embodiment, “to treat,” “to treat,” or “to treat” means reducing or improving at least one physical parameter, including one that may not be identifiable by the patient. In yet another embodiment, “to treat,” “to treat,” or “to treat” means modulating the disease or disorder either or both physically (e.g., stabilization of identifiable symptoms) or physiologically (e.g., stabilization of physical parameters).

[0063] As used herein, the terms “prevent,” “prevent,” or “prevention” with respect to any disease or disorder mean the preventive treatment of the disease or disorder or the delay of the onset or progression of the disease or disorder.

[0064] As used herein and unless otherwise noted, the terms “to manage,” “to control,” and “to administer” include preventing a relapse of a particular disease or disorder in a patient who already has a disease or disorder and / or extending the time a patient with a disease or disorder maintains remission. The terms also include regulating the onset, progression, and / or duration of a disease or disorder or altering the way a patient responds to a disease or disorder.

[0065] The term "therapeutic dose" of the compound of the present invention refers to the amount of the compound that induces a biological or medical response in a subject, such as a reduction or inhibition of enzyme or protein activity, or relieves symptoms, controls or alleviates a condition, slows or delays the progression of a disease, or prevents a disease. In one non-limiting embodiment, the term "therapeutic dose" means that, when administered to a subject, (1)(i)SARS-CoV-2 main protease (M pro (ii) SARS-CoV-2 main protease (M pro ) associated with or mediated by the activity, or (iii) SARS-CoV-2 main protease (M pro (2) SARS-CoV-2 main protease (M) is characterized by the activity (normal or abnormal) of a condition, disorder or disease, which is to be at least partially alleviated, inhibited, preventively controlled and / or brought into remission, or (2) SARS-CoV-2 main protease (M) pro This refers to the amount of the compound of the present invention that is effective in reducing or inhibiting the activity of SARS-CoV-2 main protease (Mpro). In another non-limiting embodiment, the term “therapeutic effective dose” refers to the amount of the compound of the present invention that, when administered to cells, or tissues, or non-cellular biological materials, or culture media, is effective in at least partially reducing or inhibiting the activity of SARS-CoV-2 main protease (Mpro).

[0066] The term "co-administration" refers to the presence of two different activators in an individual's bloodstream. Co-administered activators can be delivered simultaneously or sequentially.

[0067] The terms “a,” “an,” and “it,” as used herein, and similar terms used in connection with the present invention (particularly in connection with the claims), should be interpreted as encompassing both singular and plural forms unless otherwise specifically indicated herein or unless otherwise clearly inconsistent with the context.

[0068] Unless otherwise specified, the terms “compound of the invention,” “multiple compounds of the invention,” “compounds of the present invention,” or “multiple compounds of the present invention” refer to the compounds of formula (I) or its subformulas, for example, formulas (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), and (Ii), as well as the exemplary compounds and their salts, and all of their stereoisomers (including diastereomers and enantiomers).

[0069] Various listed embodiments of the present invention are described herein. It will be recognized that further embodiments of the present invention can be provided by combining the features specified in each embodiment with other specified features.

[0070] Compound of the present invention The present invention relates to formula (I) [ka] (In the formula, X1 is CR 3a R 3b , C=O or NR 3c And, X2 is CR 4a R 4b Or C=O, R 1 teeth, i) 1, 2, 3 or 4 ring members are N, NR 6 A 5 or 6-membered heteroaryl, independently selected from O and S, which is unsubstituted or has 1 to 4 R 5 A 5- or 6-membered heteroaryl substituted with a group ii) Unsubstituted or with 1 to 4 R 5Phenyl groups substituted with a group iii) 1, 2, 3 or 4 ring members are N, NR 6 A 4, 5, or 6-membered heterocycloalkyl group independently selected from O and S, which is either unsubstituted or has 1 to 4 R groups. 5 A heterocycloalkyl group substituted with a group, and a 5 or 6-membered heterocycloalkyl group optionally substituted with an oxo group, iv) Unsubstituted or with 1 to 4 R 5 C3-C8 cycloalkyl groups substituted with a group v) Unsubstituted C1-C6 alkyl groups, vi) A 5 or 6-membered heterocycline in which 1, 2 or 3 ring members are independently selected from W, Y and Z, where W is NR 6 , O, S, S=O or S(=O)², and Y is NR 6 , O, S, S=O or S(=O)², and Z is NR 6 The heterocyclyl is O or S, and has 5 or 6 members, either unsubstituted or with 1, 2, 3 or 4 R 12 A 5- or 6-membered heterocyclyl that is substituted with a group and optionally substituted with an oxo group, vii) 1, 2, 3, 4 or 5 ring members are N, NR 6 A 9 or 10-membered bicyclic heterocycline independently selected from O and S, which is unsubstituted or has 1 to 4 R 5 A 9 or 10-membered bicyclic heterocycline substituted with a group, viii) Unsubstituted or with 1 to 4 R 5 Spirobond C3-C8 cycloalkyl groups substituted with a group ix) Unsubstituted or with 1 to 4 R 5 Bicyclic C3-C8 cycloalkyl groups substituted with a group x) C5~C6 cycloalkenyl, xi) A 9 or 10-membered bicyclic heteroaryl in which 1, 2, 3, 4, or 5 ring members are independently selected from N, O, and S, and is unsubstituted or has 1 to 4 R 59 or 10-membered bicyclic heteroaryl substituted with a group selected from the group consisting of, R 2 is, i)-(CH2) 0-6 CHR 13 R 14 , ii) benzyl which is unsubstituted or substituted with 1, 2, 3 or 4 R 12 groups, iii) a 6-membered heteroaryl wherein 1, 2 or 3 ring members are each independently selected from N, O and S, which is unsubstituted or substituted with 1, 2, 3 or 4 R 12 groups, the 6-membered heteroaryl, iv) a 10-membered bicyclic heteroaryl having a point of attachment at a carbon atom ring member and having an N heteroatom as a ring member located in the beta (β) position relative to the point of attachment, which has 0, 1, 2 or 3 additional N heteroatoms as ring members, and is unsubstituted or substituted with 1, 2, 3 or 4 R 12 groups, the 10-membered bicyclic heteroaryl, v) a 10-membered bicyclic heteroaryl having a point of attachment at a carbon atom ring member and having an N heteroatom as a ring member located in the beta (β) position relative to the point of attachment, which further has 0, 1, 2, 3 or 4 ring members each independently selected from N, O and S, and is unsubstituted or substituted with 1, 2, 3 or 4 R 12 groups, the 10-membered bicyclic heteroaryl, vi) a 9-membered bicyclic heteroaryl having a point of attachment at a carbon atom ring member and having an N heteroatom as a ring member located in the beta (β) position relative to the point of attachment, which has 0, 1, 2, 3 or 4 additional N heteroatoms as ring members, and is unsubstituted or substituted with 1, 2, 3 or 4 R 12 groups, the 9-membered bicyclic heteroaryl, vii) a 9-membered bicyclic heteroaryl having a point of attachment at a carbon atom ring member and having an N heteroatom as a ring member located in the beta (β) position relative to the point of attachment, which is N, NR 6and further has 0, 1, 2, 3 or 4 ring members each independently selected from O and S, which is unsubstituted or substituted with 1, 2, 3 or 4 R 12 groups, a 9-membered bicyclic heteroaryl, viii) a 5- or 6-membered heterocycloalkyl which has a point of attachment at a carbon ring member and has NR as a ring member located in the beta (β) position relative to the point of attachment, 6 which further has 0, 1 or 2 ring members each independently selected from N, NR 6 , O and S, and is substituted with 1 or 2 oxo, or is unsubstituted, or is substituted with 1, 2, 3 or 4 R 12 groups and is optionally substituted with 1 or 2 oxo, a 5- or 6-membered heterocycloalkyl, ix) a 5- or 6-membered heterocyclyl which has a point of attachment at a carbon ring member and has NR as a ring member located in the beta (β) position relative to the point of attachment, 6 which further has 0, 1 or 2 ring members each independently selected from N, NR 6 , O and S, and is substituted with 1 or 2 oxo, or is unsubstituted, or is substituted with 1, 2, 3 or 4 R 12 groups and is optionally substituted with 1 or 2 oxo, a 5- or 6-membered heterocyclyl, x) a 9- or 10-membered bicyclic heterocyclyl which has a point of attachment at a carbon ring member and has NR as a ring member located in the beta (β) position relative to the point of attachment, 6 which further has 0, 1, 2, 3 or 4 ring members each independently selected from N, NR 6 , O and S, and is substituted with 1 or 2 oxo, or is unsubstituted, or is substituted with 1, 2, 3 or 4 R 12 groups and is optionally substituted with 1 or 2 oxo, a 9- or 10-membered bicyclic heterocyclyl, xi) a 9- or 10-membered bicyclic heterocyclyl which has a point of attachment at a carbon ring member and has an O heteroatom as a ring member located in the beta (β) position relative to the point of attachment, which further has N, NR 6It further has 0, 1, 2, 3, or 4 ring members independently selected from O and S, which are substituted with 1 or 2 oxos, or unsubstituted, or 1, 2, 3, or 4 R 12 A 9 or 10-membered bicyclic heterocycline that is substituted with a group and optionally substituted with one or two oxos, xii) 1, 2, 3, 4 or 5 ring members are N, NR 6 A 9 or 10-membered bicyclic heteroaryl, independently selected from O and S, which is either unsubstituted or has 1, 2, 3, or 4 R 12 A 9 or 10-membered bicyclic heteroaryl substituted with a group, xiii) 1, 2 or 3 ring members are N, NR 6 A 5 or 6-membered heterocycloalkyl group independently selected from O and S, which is substituted with 1 or 2 oxos, or unsubstituted, or has 1, 2, 3 or 4 R atoms. 12 A 5- or 6-membered heterocycloalkyl group that is substituted with a group and optionally substituted with one or two oxos, xiv) 1, 2, or 3 ring members are N, NR 6 A 5 or 6-membered heterocycline independently selected from O and S, which is substituted with 1 or 2 oxos, or unsubstituted, or has 1, 2, 3 or 4 Rs. 12 A 5- or 6-membered heterocycline that is substituted with a group and optionally substituted with one or two oxos, xv) A six-membered heterocycline having a bond site in a carbon atom ring member, which is substituted with an oxo, and which has a carbon atom as a ring member located at the beta (β) position relative to the bond site, wherein N,NR 6 It further has one or two ring members independently selected from O and S, and is unsubstituted, or has one, two, three or four R 12 A six-membered heterocycline that is substituted with a group and optionally substituted with an oxo group. xvi) 1, 2, 3, 4 or 5 ring members are N, NR 6A 9 or 10-membered bicyclic heterocycline independently selected from O and S, which is substituted with 1 or 2 oxos, or unsubstituted, or has 1, 2, 3 or 4 Rs. 12 A 9 or 10-membered bicyclic heterocycline that is substituted with a group and optionally substituted with one or two oxos, xvii) One ring member is NR 6 A six-membered heterocyclyl selected from, which is a six-membered heterocyclyl substituted with an oxo, xviii) A six-membered heteroaryl having a bond site in a carbon atom ring member and a N heteroatom located at the beta (β) position relative to the bond site, wherein the ring member has 0, 1 or 2 additional N heteroatoms and is unsubstituted, or has 1, 2, 3 or 4 R 12 A 6-membered heteroaryl substituted with a group, and xix) A 10-membered bicyclic heterocycline having a bond site in one of its carbon atom ring members, which is substituted with an oxo, and having a carbon atom as a ring member located at the beta (β) position relative to the bond site, wherein N,NR 6 It further has 1, 2, 3, or 4 ring members independently selected from O and S, and is unsubstituted, or has 1, 2, 3, or 4 R 12 A 10-membered bicyclic heterocycline that is substituted with a group and optionally substituted with an additional oxo group. Selected from the group consisting of, R 3a This is H, -CN, C3-C8 cycloalkyl, with 1, 2, or 3 ring members being N, NR 6 , a 4-7 member heterocycloalkyl group independently selected from O and S, unsubstituted or with one or more R 15 C1-C6 alkyl groups substituted with a group, or unsubstituted, or with one or more R groups. 15The C2-C6 alkenyls are substituted with a group, and the cycloalkyl and heterocycloalkyl groups are either unsubstituted, or substituted with one or two substituents independently selected from the group consisting of CN, -C(=O)OH, NH2, OH, C1-C6 haloalkyl and unsubstituted, or C1-C6 alkyl groups substituted with -C(=O)OH, -OH, CN, or NH2. R 3b This is H, -CN, C3-C8 cycloalkyl, with 1, 2, or 3 ring members being N, NR 6 , a 4-7 member heterocycloalkyl group independently selected from O and S, unsubstituted or with one or more R 15 C1-C6 alkyl groups substituted with a group, or unsubstituted, or with one or more R groups. 15 The C2-C6 alkenyls are substituted with a group, and the cycloalkyl and heterocycloalkyl groups are either unsubstituted, or substituted with one or two substituents independently selected from the group consisting of CN, -C(=O)OH, NH2, OH, C1-C6 haloalkyl and unsubstituted, or C1-C6 alkyl groups substituted with -C(=O)OH, -OH, CN, or NH2. R 4a This is H, -CN, C3-C8 cycloalkyl, with 1, 2, or 3 ring members being N, NR 6 , a 4-7 member heterocycloalkyl group independently selected from O and S, unsubstituted or with one or more R 15 C1-C6 alkyl groups substituted with a group, or unsubstituted, or with one or more R groups. 15 The C2-C6 alkenyls are substituted with a group, and the cycloalkyl and heterocycloalkyl groups are either unsubstituted, or substituted with one or two substituents independently selected from the group consisting of CN, -C(=O)OH, NH2, OH, C1-C6 haloalkyl and unsubstituted, or C1-C6 alkyl groups substituted with -C(=O)OH, -OH, CN, or NH2. R 4bThis is H, -CN, C3-C8 cycloalkyl, with 1, 2, or 3 ring members being N, NR 6 , a 4-7 member heterocycloalkyl group independently selected from O and S, unsubstituted or with one or more R 15 C1-C6 alkyl groups substituted with a group, or unsubstituted, or with one or more R groups. 15 The C2-C6 alkenyls are substituted with a group, and the cycloalkyl and heterocycloalkyl groups are either unsubstituted, or substituted with one or two substituents independently selected from the group consisting of CN, -C(=O)OH, NH2, OH, C1-C6 haloalkyl and unsubstituted, or C1-C6 alkyl groups substituted with -C(=O)OH, -OH, CN, or NH2. R 3c This is H, -C(=O)C2~C6 alkenyl or one or more R 15 These are C1-C6 alkyl groups substituted with a group. Each R 5 -CN, -OH, -NR 7 R 8 , NR 6 C(=O)C2~C6 alkenyl, -SF5, S(=O)2C1~C6 alkyl, -C(=O)N(R) 7 )2, C1-C6 haloalkyl, halo, C1-C6 haloalkoxy, C1-C6 alkoxy, C3-C8 cycloalkyl, 1, 2, 3 or 4 ring members are N, NR 6 A cycloalkyl group is independently selected from the group consisting of a 4-6 member heterocycloalkyl group independently selected from O and S, a 5- or 6 member heteroaryl group in which 1, 2, or 3 ring members are independently selected from N, O, and S, and a C1-C6 alkyl group that is unsubstituted or substituted with CN, NH2, or OH, wherein the cycloalkyl and heterocycloalkyl groups are either unsubstituted or have 1, 2, 3, or 4 R groups. 9 It is substituted with the base, Each R 6 These are H, C1-C6 haloalkyl, C1-C6 haloalkoxy, -S(=O)2N(R 7)2, S(=O)2C1~C6 alkyl, S(=O)2C1~C6 haloalkyl, -S(=O)2C3~C6 cycloalkyl, -C(=O)R 7 -C(=O)N(R 7 )2. Independently selected from the group consisting of C3-C6 cycloalkyl and C1-C6 alkyl which are unsubstituted or substituted with -OH, CN, or -C(=O)OH, Each R 7 This is independently selected from the group consisting of H and C1-C6 alkyl groups that are either unsubstituted or substituted with OH or C1-C6 alkoxy groups. R 8 H, unsubstituted C1-C6 alkyl, C3-C8 cycloalkyl, or 1, 2, 3 or 4 ring members are N, NR 6 A 4-6 member heterocycloalkyl group independently selected from O and S, wherein the cycloalkyl and heterocycloalkyl groups are unsubstituted or have 1, 2, 3, or 4 R groups. 9 It is substituted with the base, Each R 9 , NR 10 R 11 -C(=O)N(R 7 )2 and -OH or -N(R 7 Independently selected from the group consisting of C1-C6 alkyl groups substituted with )2, R 10 is H or an unsubstituted C1-C6 alkyl group. R 11 This is H, an unsubstituted C1-C6 alkyl or -S(=O)2C1-C6 alkyl, Each R 12 is -C(=O)N(R 7 )2, -C(=O)OH, -N(R 7 )2, -CN, -OH, -S(=O)2R 6 -S(=O)2R 7 -S(=O)2N(R 7 )2, [ka] Halo, phenyl, C3-C8 cycloalkyl, 1, 2, 3 or 4 ring members are N, NR 6 A phenyl, heterocycloalkyl, and heteroaryl group is independently selected from the group consisting of a 4-6 member heterocycloalkyl group independently selected from O and S, a 5 or 6 member heteroaryl group in which 1, 2, or 3 ring members are independently selected from N, O, and S, and a C1-C6 alkyl group that is unsubstituted or substituted with NH2, CN, or OH. The phenyl, heterocycloalkyl, and heteroaryl groups are either unsubstituted or substituted with one or two substituents independently selected from the group consisting of OH. R 13 H, -C(=O)N(R 7 )2 or 1, 2, 3 or 4 ring members are N, NR 6 , a 5 or 6-member heteroaryl selected independently from O and S, R 14 teeth, i) 1, 2, 3 or 4 ring members are N, NR 6 A 5 or 6-membered heterocycline independently selected from O and S, which is unsubstituted or has 1, 2, 3 or 4 R 12 A 5- or 6-membered heterocyclyl that is substituted with a group and optionally substituted with one or two oxos, and ii) 1, 2, 3 or 4 ring members are N, NR 6 A 5 or 6-membered heteroaryl, independently selected from O and S, which is either unsubstituted or has 1, 2, 3, or 4 R 12 Five or six-membered heteroaryls substituted with a specific group Selected from the group consisting of, Each R 15 is CN, NH2, -OH, -C(=O)OH, -C(=O)N(R 7 )2, -C(=O)C(=O)OH, C1-C6 alkoxy, halo, C1-C6 haloalkyl, C3-C8 cycloalkyl, 1, 2, 3 or 4 ring members are N, NR 6 , a 5 or 6-membered heteroaryl selected independently from O and S, and 1, 2 or 3 ring members are N, NR 6The cycloalkyl, heteroaryl, and heterocycloalkyl groups are independently selected from the group consisting of 3-6 member heterocycloalkyl groups independently selected from O and S, and the cycloalkyl, heteroaryl, and heterocycloalkyl groups are either unsubstituted or substituted with 1, 2, or 3 substituents independently selected from the group consisting of CN, -C(=O)OH, NH2, OH, and unsubstituted C1-C6 alkyl groups. However, R 3a , R 3b , R 4a or R 4b (Provided that at least one of them is not hydrogen.) The present invention provides compounds, stereoisomers thereof, or pharmaceutically acceptable salts thereof.

[0071] Various embodiments of the compounds of the present invention are described herein. It will be recognized that the features specified in each embodiment can be combined with other specified features to provide further embodiments. The embodiments listed below are representative of the compounds of formula (I) of the present invention.

[0072] Embodiment 1. Formula (I) [ka] (In the formula, X1 is CR 3a R 3b , C=O or NR 3c And, X2 is CR 4a R 4b Or C=O, R 1 teeth, i) 1, 2, 3 or 4 ring members are N, NR 6 A 5 or 6-membered heteroaryl, independently selected from O and S, which is unsubstituted or has 1 to 4 R 5 A 5- or 6-membered heteroaryl substituted with a group ii) Unsubstituted or with 1 to 4 R 5 Phenyl groups substituted with a group iii) 1, 2, 3 or 4 ring members are N, NR 6A 4, 5, or 6-membered heterocycloalkyl group independently selected from O and S, which is either unsubstituted or has 1 to 4 R groups. 5 A heterocycloalkyl group substituted with a group, and a 5 or 6-membered heterocycloalkyl group optionally substituted with an oxo group, iv) Unsubstituted or with 1 to 4 R 5 C3-C8 cycloalkyl groups substituted with a group v) Unsubstituted C1-C6 alkyl groups, vi) A 5 or 6-membered heterocycline in which 1, 2 or 3 ring members are independently selected from W, Y and Z, where W is NR 6 , O, S, S=O or S(=O)², and Y is NR 6 , O, S, S=O or S(=O)², and Z is NR 6 The heterocyclyl is O or S, and has 5 or 6 members, either unsubstituted or with 1, 2, 3 or 4 R 12 A 5- or 6-membered heterocyclyl that is substituted with a group and optionally substituted with an oxo group, vii) 1, 2, 3, 4 or 5 ring members are N, NR 6 A 9 or 10-membered bicyclic heterocycline independently selected from O and S, which is unsubstituted or has 1 to 4 R 5 A 9 or 10-membered bicyclic heterocycline substituted with a group, viii) Unsubstituted or with 1 to 4 R 5 Spirobond C3-C8 cycloalkyl groups substituted with a group ix) Unsubstituted or with 1 to 4 R 5 Bicyclic C3-C8 cycloalkyl groups substituted with a group x) C5~C6 cycloalkenyl, xi) A 9 or 10-membered bicyclic heteroaryl in which 1, 2, 3, 4, or 5 ring members are independently selected from N, O, and S, and is unsubstituted or has 1 to 4 R 5 9 or 10-membered bicyclic heteroaryls substituted with a specific group Selected from the group consisting of, R2 teeth, i)-(CH2) 0-6 CHR 13 R 14 , ii) Unsubstituted, or 1, 2, 3, or 4 R 12 benzyl substituted with a group iii) A six-membered heteroaryl in which one, two, or three ring members are independently selected from N, O, and S, and is unsubstituted, or has one, two, three, or four R 12 A 6-membered heteroaryl substituted with a base, iv) A 10-membered bicyclic heteroaryl having a bond site in a carbon atom ring member and a N heteroatom located at the beta (β) position relative to the bond site, wherein the ring member has 0, 1, 2, or 3 additional N heteroatoms and is unsubstituted, or has 1, 2, 3, or 4 R 12 A 10-membered bicyclic heteroaryl substituted with a group v) A 10-membered bicyclic heteroaryl having a bond site in a carbon atom ring member and a N heteroatom as a ring member located at the beta (β) position relative to the bond site, further comprising 0, 1, 2, 3, or 4 ring members independently selected from N, O, and S, and being unsubstituted or having 1, 2, 3, or 4 R 12 A 10-membered bicyclic heteroaryl substituted with a group vi) A nine-membered bicyclic heteroaryl having a bond site in a carbon atom ring member and a N heteroatom located at the beta (β) position relative to the bond site, wherein the ring member has 0, 1, 2, 3, or 4 additional N heteroatoms and is unsubstituted, or has 1, 2, 3, or 4 R 12 A 9-membered bicyclic heteroaryl substituted with a group vii) A nine-membered bicyclic heteroaryl having a bond site in a carbon atom ring member and a N heteroatom located at the beta (β) position relative to the bond site, wherein N,NR 6 It further has 0, 1, 2, 3, or 4 ring members independently selected from O and S, and is unsubstituted, or has 1, 2, 3, or 4 R 12A 9-membered bicyclic heteroaryl substituted with a group viii) A ring member having a bond point and located at the beta (β) position relative to the bond point is NR 6 A 5 or 6-membered heterocycloalkyl having N, NR 6 It further has 0, 1, or 2 ring members independently selected from O and S, which are substituted with 1 or 2 oxos, or unsubstituted, or 1, 2, 3, or 4 R 12 A 5- or 6-membered heterocycloalkyl group that is substituted with a group and optionally substituted with one or two oxos, ix) A ring member having a bond point and located at the beta (β) position relative to the bond point is NR 6 A 5 or 6-membered heterocycline having N, NR 6 It further has 0, 1, or 2 ring members independently selected from O and S, which are substituted with 1 or 2 oxos, or unsubstituted, or 1, 2, 3, or 4 R 12 A 5- or 6-membered heterocycline that is substituted with a group and optionally substituted with one or two oxos, x) A ring member having a bond point and located at the beta (β) position relative to the bond point is NR 6 A 9 or 10-membered bicyclic heterocycline having N, NR 6 It further has 0, 1, 2, 3, or 4 ring members independently selected from O and S, which are substituted with 1 or 2 oxos, or unsubstituted, or 1, 2, 3, or 4 R 12 A 9 or 10-membered bicyclic heterocycline that is substituted with a group and optionally substituted with one or two oxos, xi) A 9 or 10-membered bicyclic heterocycline having a bond site in a carbon atom ring member and an O heteroatom located at the beta (β) position relative to the bond site, wherein N, NR 6It further has 0, 1, 2, 3, or 4 ring members independently selected from O and S, which are substituted with 1 or 2 oxos, or unsubstituted, or 1, 2, 3, or 4 R 12 A 9 or 10-membered bicyclic heterocycline that is substituted with a group and optionally substituted with one or two oxos, xii) 1, 2, 3, 4 or 5 ring members are N, NR 6 A 9 or 10-membered bicyclic heteroaryl, independently selected from O and S, which is either unsubstituted or has 1, 2, 3, or 4 R 12 A 9 or 10-membered bicyclic heteroaryl substituted with a group, xiii) 1, 2 or 3 ring members are N, NR 6 A 5 or 6-membered heterocycloalkyl group independently selected from O and S, which is substituted with 1 or 2 oxos, or unsubstituted, or has 1, 2, 3 or 4 R atoms. 12 A 5- or 6-membered heterocycloalkyl group that is substituted with a group and optionally substituted with one or two oxos, xiv) 1, 2, or 3 ring members are N, NR 6 A 5 or 6-membered heterocycline independently selected from O and S, which is substituted with 1 or 2 oxos, or unsubstituted, or has 1, 2, 3 or 4 Rs. 12 A 5- or 6-membered heterocycline that is substituted with a group and optionally substituted with one or two oxos, xv) A six-membered heterocycline having a bond site in a carbon atom ring member, which is substituted with an oxo, and which has a carbon atom as a ring member located at the beta (β) position relative to the bond site, wherein N,NR 6 It further has one or two ring members independently selected from O and S, and is unsubstituted, or has one, two, three or four R 12 A six-membered heterocycline that is substituted with a group and optionally substituted with an oxo group. xvi) 1, 2, 3, 4 or 5 ring members are N, NR 6A 9 or 10-membered bicyclic heterocycline independently selected from O and S, which is substituted with 1 or 2 oxos, or unsubstituted, or has 1, 2, 3 or 4 Rs. 12 A 9 or 10-membered bicyclic heterocycline that is substituted with a group and optionally substituted with one or two oxos, xvii) One ring member is NR 6 A six-membered heterocyclyl selected from, which is a six-membered heterocyclyl substituted with an oxo, xviii) A six-membered heteroaryl having a bond site in a carbon atom ring member and a N heteroatom located at the beta (β) position relative to the bond site, wherein the ring member has 0, 1 or 2 additional N heteroatoms and is unsubstituted, or has 1, 2, 3 or 4 R 12 A 6-membered heteroaryl substituted with a group, and xix) A 10-membered bicyclic heterocycline having a bond site in one of its carbon atom ring members, which is substituted with an oxo, and having a carbon atom as a ring member located at the beta (β) position relative to the bond site, wherein N,NR 6 It further has 1, 2, 3, or 4 ring members independently selected from O and S, and is unsubstituted, or has 1, 2, 3, or 4 R 12 A 10-membered bicyclic heterocycline that is substituted with a group and optionally substituted with an additional oxo group. Selected from the group consisting of, R 3a This is H, -CN, C3-C8 cycloalkyl, with 1, 2, or 3 ring members being N, NR 6 , a 4-7 member heterocycloalkyl group independently selected from O and S, unsubstituted or with one or more R 15 C1-C6 alkyl groups substituted with a group, or unsubstituted, or with one or more R groups. 15The C2-C6 alkenyls are substituted with a group, and the cycloalkyls and heterocycloalkyls are either unsubstituted or substituted with one or two substituents independently selected from the group consisting of CN, -C(=O)OH, NH2, OH, C1-C6 haloalkyl, C1-C6 alkyl, or C1-C6 alkyl substituted with -C(=O)OH, -OH, CN, or NH2. R 3b This is H, -CN, C3-C8 cycloalkyl, with 1, 2, or 3 ring members being N, NR 6 , a 4-7 member heterocycloalkyl group independently selected from O and S, unsubstituted or with one or more R 15 C1-C6 alkyl groups substituted with a group, or unsubstituted, or with one or more R groups. 15 The C2-C6 alkenyls are substituted with a group, and the cycloalkyls and heterocycloalkyls are either unsubstituted or substituted with one or two substituents independently selected from the group consisting of CN, -C(=O)OH, NH2, OH, C1-C6 haloalkyl, C1-C6 alkyl, or C1-C6 alkyl substituted with -C(=O)OH, -OH, CN, or NH2. R 4a This is H, -CN, C3-C8 cycloalkyl, with 1, 2, or 3 ring members being N, NR 6 , a 4-7 member heterocycloalkyl group independently selected from O and S, unsubstituted or with one or more R 15 C1-C6 alkyl groups substituted with a group, or unsubstituted, or with one or more R groups. 15 The C2-C6 alkenyls are substituted with a group, and the cycloalkyls and heterocycloalkyls are either unsubstituted or substituted with one or two substituents independently selected from the group consisting of CN, -C(=O)OH, NH2, OH, C1-C6 haloalkyl, C1-C6 alkyl, or C1-C6 alkyl substituted with -C(=O)OH, -OH, CN, or NH2. R 4bThis is H, -CN, C3-C8 cycloalkyl, with 1, 2, or 3 ring members being N, NR 6 , a 4-7 member heterocycloalkyl group independently selected from O and S, unsubstituted or with one or more R 15 C1-C6 alkyl groups substituted with a group, or unsubstituted, or with one or more R groups. 15 The C2-C6 alkenyls are substituted with a group, and the cycloalkyls and heterocycloalkyls are either unsubstituted or substituted with one or two substituents independently selected from the group consisting of CN, -C(=O)OH, NH2, OH, C1-C6 haloalkyl, C1-C6 alkyl, or C1-C6 alkyl substituted with -C(=O)OH, -OH, CN, or NH2. R 3c This is H, -C(=O)C2~C6 alkenyl or one or more R 15 These are C1-C6 alkyl groups substituted with a group. Each R 5 -CN, -OH, -NR 7 R 8 , NR 6 C(=O)C2~C6 alkenyl, -SF5, S(=O)2C1~C6 alkyl, -C(=O)N(R) 7 )2, C1-C6 haloalkyl, halo, C1-C6 haloalkoxy, C1-C6 alkoxy, C3-C8 cycloalkyl, 1, 2, 3 or 4 ring members are N, NR 6 A cycloalkyl group is independently selected from the group consisting of a 4-6 member heterocycloalkyl group independently selected from O and S, a 5- or 6 member heteroaryl group in which 1, 2, or 3 ring members are independently selected from N, O, and S, and a C1-C6 alkyl group that is unsubstituted or substituted with CN, NH2, or OH, wherein the cycloalkyl and heterocycloalkyl groups are either unsubstituted or have 1, 2, 3, or 4 R groups. 9 It is substituted with the base, Each R 6 These are H, C1-C6 haloalkyl, C1-C6 haloalkoxy, -S(=O)2N(R 7)2, S(=O)2C1~C6 alkyl, S(=O)2C1~C6 haloalkyl, -S(=O)2C3~C6 cycloalkyl, -C(=O)R 7 -C(=O)N(R 7 )2. Independently selected from the group consisting of C3-C6 cycloalkyl and C1-C6 alkyl which are unsubstituted or substituted with -OH, CN, or -C(=O)OH, Each R 7 This is independently selected from the group consisting of H and C1-C6 alkyl groups that are either unsubstituted or substituted with OH or C1-C6 alkoxy groups. R 8 H, unsubstituted C1-C6 alkyl, C3-C8 cycloalkyl, or 1, 2, 3 or 4 ring members are N, NR 6 A 4-6 member heterocycloalkyl group independently selected from O and S, wherein the cycloalkyl and heterocycloalkyl groups are unsubstituted or have 1, 2, 3, or 4 R groups. 9 It is substituted with the base, Each R 9 , NR 10 R 11 -C(=O)N(R 7 )2 and -OH or -N(R 7 Independently selected from the group consisting of C1-C6 alkyl groups substituted with )2, R 10 is H or an unsubstituted C1-C6 alkyl group. R 11 This is H, an unsubstituted C1-C6 alkyl or -S(=O)2C1-C6 alkyl, Each R 12 is -C(=O)N(R 7 )2, -C(=O)OH, -N(R 7 )2, -CN, -OH, -S(=O)2R 7 -S(=O)2N(R 7 )2, [ka] Halo, phenyl, C3-C8 cycloalkyl, 1, 2, 3 or 4 ring members are N, NR 6A phenyl, heterocycloalkyl, and heteroaryl group is independently selected from the group consisting of a 4-6 member heterocycloalkyl group independently selected from O and S, a 5 or 6 member heteroaryl group in which 1, 2, or 3 ring members are independently selected from N, O, and S, and a C1-C6 alkyl group that is unsubstituted or substituted with NH2, CN, or OH. The phenyl, heterocycloalkyl, and heteroaryl groups are either unsubstituted or substituted with one or two substituents independently selected from the group consisting of OH. R 13 H, -C(=O)N(R 7 )2 or 1, 2, 3 or 4 ring members are N, NR 6 , a 5 or 6-member heteroaryl selected independently from O and S, R 14 teeth, i) 1, 2, 3 or 4 ring members are N, NR 6 A 5 or 6-membered heterocycline independently selected from O and S, which is unsubstituted or has 1, 2, 3 or 4 R 12 A 5- or 6-membered heterocyclyl that is substituted with a group and optionally substituted with one or two oxos, and ii) 1, 2, 3 or 4 ring members are N, NR 6 A 5 or 6-membered heteroaryl, independently selected from O and S, which is either unsubstituted or has 1, 2, 3, or 4 R 12 Five or six-membered heteroaryls substituted with a specific group Selected from the group consisting of, Each R 15 is CN, NH2, -OH, -C(=O)OH, -C(=O)N(R 7 )2, -C(=O)C(=O)OH, C1-C6 alkoxy, halo, C1-C6 haloalkyl, C3-C8 cycloalkyl, 1, 2, 3 or 4 ring members are N, NR 6 , a 5 or 6-membered heteroaryl selected independently from O and S, and 1, 2 or 3 ring members are N, NR 6The cycloalkyl, heteroaryl, and heterocycloalkyl groups are independently selected from the group consisting of 3-6 member heterocycloalkyl groups independently selected from O and S, and the cycloalkyl, heteroaryl, and heterocycloalkyl groups are either unsubstituted or substituted with 1, 2, or 3 substituents independently selected from the group consisting of CN, -C(=O)OH, NH2, OH, and unsubstituted C1-C6 alkyl groups. However, R 3a , R 3b , R 4a or R 4b (Provided that at least one of them is not hydrogen.) Compounds thereof, their stereoisomers, or pharmaceutically acceptable salts thereof.

[0073] Embodiment 2. [ka] (In the formula, X1 is CR 3a R 3b , C=O or NR 3c And, X2 is CR 4a R 4b Or C=O, R 1 teeth, i) Unsubstituted or with 1 to 4 R 5 Phenyl groups substituted with a group ii) Unsubstituted or with 1 to 4 R 5 Spirobond C3-C8 cycloalkyl groups substituted with a group iii) Unsubstituted or with 1 to 4 R 5 Bicyclic C3-C8 cycloalkyl groups substituted with a group iv) Unsubstituted or with 1 to 4 R 5 C3-C8 cycloalkyl groups substituted with a group v) 1, 2, 3 or 4 ring members are N, NR 6 A 5 or 6-membered heteroaryl, independently selected from O and S, which is unsubstituted or has 1 to 4 R 5 A 5- or 6-membered heteroaryl substituted with a group vi) Unsubstituted C1-C6 alkyl groups, vii) C5-C6 cycloalkenyl, viii) A 5 or 6-membered heterocycline in which 1, 2 or 3 ring members are independently selected from W, Y and Z, respectively, where W is NR 6 , O, S, S=O or S(=O)², and Y is NR 6 , O, S, S=O or S(=O)², and Z is NR 6 , O or S, 5 or 6 member heterocyclyl, 5 or 6 member heterocyclyl, which is optionally substituted with oxo, ix) 1, 2, 3, 4 or 5 ring members are N, NR 6 A 9 or 10-membered bicyclic heterocycline independently selected from O and S, which is unsubstituted or has 1 to 4 R 5 A 9 or 10-membered bicyclic heterocycline substituted with a group, x) 1, 2, 3 or 4 ring members are N, NR 6 A 5 or 6-membered heterocycloalkyl group independently selected from O and S, which is either unsubstituted or has 1 to 4 R groups. 5 A 5- or 6-membered heterocycloalkyl group that is substituted with a group and optionally substituted with an oxo group, and xi) A 9 or 10-membered bicyclic heteroaryl in which 1, 2, 3, 4, or 5 ring members are independently selected from N, O, and S, and is unsubstituted or has 1 to 4 R 5 9 or 10-membered bicyclic heteroaryls substituted with a specific group Selected from the group consisting of, R 2 teeth, i)-(CH2) 0-6 CHR 13 R 14 , ii) Unsubstituted, or 1, 2, 3, or 4 R 12 benzyl substituted with a group iii) A six-membered heteroaryl in which one, two, or three ring members are independently selected from N, O, and S, and is unsubstituted, or has one, two, three, or four R 12A 6-membered heteroaryl substituted with a base, iv) A 10-membered bicyclic heteroaryl having a bond site in a carbon atom ring member and a N heteroatom located at the beta (β) position relative to the bond site, wherein the ring member has 0, 1, 2, or 3 additional N heteroatoms and is unsubstituted, or has 1, 2, 3, or 4 R 12 A 10-membered bicyclic heteroaryl substituted with a group v) A 10-membered bicyclic heteroaryl having a bond site in a carbon atom ring member and a N heteroatom as a ring member located at the beta (β) position relative to the bond site, further comprising 0, 1, 2, 3, or 4 ring members independently selected from N, O, and S, and being unsubstituted or having 1, 2, 3, or 4 R 12 A 10-membered bicyclic heteroaryl substituted with a group vi) A nine-membered bicyclic heteroaryl having a bond site in a carbon atom ring member and a N heteroatom located at the beta (β) position relative to the bond site, wherein the ring member has 0, 1, 2, 3, or 4 additional N heteroatoms and is unsubstituted, or has 1, 2, 3, or 4 R 12 A 9-membered bicyclic heteroaryl substituted with a group vii) A nine-membered bicyclic heteroaryl having a bond site in a carbon atom ring member and a N heteroatom located at the beta (β) position relative to the bond site, wherein N,NR 6 It further has 0, 1, 2, 3, or 4 ring members independently selected from O and S, and is unsubstituted, or has 1, 2, 3, or 4 R 12 A 9-membered bicyclic heteroaryl substituted with a group viii) A ring member having a bond point and located at the beta (β) position relative to the bond point is NR 6 A 5 or 6-membered heterocycloalkyl having N, NR 6 It further has 0, 1, or 2 ring members independently selected from O and S, which are substituted with 1 or 2 oxos, or unsubstituted, or 1, 2, 3, or 4 R 12A 5- or 6-membered heterocycloalkyl group that is substituted with a group and optionally substituted with one or two oxos, ix) A ring member having a bond point and located at the beta (β) position relative to the bond point is NR 6 A 5 or 6-membered heterocycline having N, NR 6 It further has 0, 1, or 2 ring members independently selected from O and S, which are substituted with 1 or 2 oxos, or unsubstituted, or 1, 2, 3, or 4 R 12 A 5- or 6-membered heterocycline that is substituted with a group and optionally substituted with one or two oxos, x) A ring member having a bond point and located at the beta (β) position relative to the bond point is NR 6 A 9 or 10-membered bicyclic heterocycline having N, NR 6 It further has 0, 1, 2, 3, or 4 ring members independently selected from O and S, which are substituted with 1 or 2 oxos, or unsubstituted, or 1, 2, 3, or 4 R 12 A 9 or 10-membered bicyclic heterocycline that is substituted with a group and optionally substituted with one or two oxos, xi) A 9 or 10-membered bicyclic heterocycline having a bond site in a carbon atom ring member and an O heteroatom located at the beta (β) position relative to the bond site, wherein N, NR 6 It further has 0, 1, 2, 3, or 4 ring members independently selected from O and S, which are substituted with 1 or 2 oxos, or unsubstituted, or 1, 2, 3, or 4 R 12 A 9 or 10-membered bicyclic heterocycline that is substituted with a group and optionally substituted with one or two oxos, xii) 1, 2, 3, 4 or 5 ring members are N, NR 6 A 9 or 10-membered bicyclic heteroaryl, independently selected from O and S, which is either unsubstituted or has 1, 2, 3, or 4 R 12 A 9 or 10-membered bicyclic heteroaryl substituted with a group, xiii) 1, 2 or 3 ring members are N, NR 6 A 5 or 6-membered heterocycloalkyl group independently selected from O and S, which is substituted with 1 or 2 oxos, or unsubstituted, or has 1, 2, 3 or 4 R atoms. 12 A 5- or 6-membered heterocycloalkyl group that is substituted with a group and optionally substituted with one or two oxos, xiv) 1, 2, or 3 ring members are N, NR 6 A 5 or 6-membered heterocycline independently selected from O and S, which is substituted with 1 or 2 oxos, or unsubstituted, or has 1, 2, 3 or 4 Rs. 12 A 5- or 6-membered heterocycline that is substituted with a group and optionally substituted with one or two oxos, xv) A six-membered heterocycline having a bond site in a carbon atom ring member, which is substituted with an oxo, and which has a carbon atom as a ring member located at the beta (β) position relative to the bond site, wherein N,NR 6 It further has one or two ring members independently selected from O and S, and is unsubstituted, or has one, two, three or four R 12 A six-membered heterocycline that is substituted with a group and optionally substituted with an oxo group. xvi) 1, 2, 3, 4 or 5 ring members are N, NR 6 A 9 or 10-membered bicyclic heterocycline independently selected from O and S, which is substituted with 1 or 2 oxos, or unsubstituted, or has 1, 2, 3 or 4 Rs. 12 A 9 or 10-membered bicyclic heterocycline that is substituted with a group and optionally substituted with one or two oxos, xvii) One ring member is NR 6 A six-membered heterocyclyl selected from, which is a six-membered heterocyclyl substituted with an oxo, xviii) A six-membered heteroaryl having a bond site in a carbon atom ring member and a N heteroatom located at the beta (β) position relative to the bond site, wherein the ring member has 0, 1 or 2 additional N heteroatoms and is unsubstituted, or has 1, 2, 3 or 4 R 12 A 6-membered heteroaryl substituted with a group, and xix) A 10-membered bicyclic heterocycline having a bond site in one of its carbon atom ring members, which is substituted with an oxo, and having a carbon atom as a ring member located at the beta (β) position relative to the bond site, wherein N,NR 6 It further has 1, 2, 3, or 4 ring members independently selected from O and S, and is unsubstituted, or has 1, 2, 3, or 4 R 12 A 10-membered bicyclic heterocycline that is substituted with a group and optionally substituted with an additional oxo group. Selected from the group consisting of, R 3a This is H, -CN, C3-C8 cycloalkyl, with 1, 2, or 3 ring members being N, NR 6 , a 4-7 member heterocycloalkyl group independently selected from O and S, unsubstituted or with one or more R 15 C1-C6 alkyl groups substituted with a group, or unsubstituted, or with one or more R groups. 15 The C2-C6 alkenyls are substituted with a group, and the cycloalkyls and heterocycloalkyls are either unsubstituted or substituted with one or two substituents independently selected from the group consisting of CN, -C(=O)OH, NH2, OH, C1-C6 haloalkyl, C1-C6 alkyl, or C1-C6 alkyl substituted with -C(=O)OH, -OH, CN, or NH2. R 3b This is H, -CN, C3-C8 cycloalkyl, with 1, 2, or 3 ring members being N, NR 6 , a 4-7 member heterocycloalkyl group independently selected from O and S, unsubstituted or with one or more R 15 C1-C6 alkyl groups substituted with a group, or unsubstituted, or with one or more R groups.15 The C2-C6 alkenyls are substituted with a group, and the cycloalkyls and heterocycloalkyls are either unsubstituted or substituted with one or two substituents independently selected from the group consisting of CN, -C(=O)OH, NH2, OH, C1-C6 haloalkyl, C1-C6 alkyl, or C1-C6 alkyl substituted with -C(=O)OH, -OH, CN, or NH2. R 4a This is H, -CN, C3-C8 cycloalkyl, with 1, 2, or 3 ring members being N, NR 6 , a 4-7 member heterocycloalkyl group independently selected from O and S, unsubstituted or with one or more R 15 C1-C6 alkyl groups substituted with a group, or unsubstituted, or with one or more R groups. 15 The C2-C6 alkenyls are substituted with a group, and the cycloalkyls and heterocycloalkyls are either unsubstituted or substituted with one or two substituents independently selected from the group consisting of CN, -C(=O)OH, NH2, OH, C1-C6 haloalkyl, C1-C6 alkyl, or C1-C6 alkyl substituted with -C(=O)OH, -OH, CN, or NH2. R 4b This is H, -CN, C3-C8 cycloalkyl, with 1, 2, or 3 ring members being N, NR 6 , a 4-7 member heterocycloalkyl group independently selected from O and S, unsubstituted or with one or more R 15 C1-C6 alkyl groups substituted with a group, or unsubstituted, or with one or more R groups. 15 The C2-C6 alkenyls are substituted with a group, and the cycloalkyls and heterocycloalkyls are either unsubstituted or substituted with one or two substituents independently selected from the group consisting of CN, -C(=O)OH, NH2, OH, C1-C6 haloalkyl, C1-C6 alkyl, or C1-C6 alkyl substituted with -C(=O)OH, -OH, CN, or NH2. R3c This is H, -C(=O)C2~C6 alkenyl or one or more R 15 These are C1-C6 alkyl groups substituted with a group. Each R 5 -OH, -NR 7 R 8 , NR 6 C(=O)C2~C6 alkenyl, -SF5, -C(=O)N(R) 7 )2, C1-C6 haloalkyl, halo, C1-C6 haloalkoxy, C1-C6 alkoxy, C3-C8 cycloalkyl, 1, 2, 3 or 4 ring members are N, NR 6 A cycloalkyl group is independently selected from the group consisting of a 4-6 member heterocycloalkyl group independently selected from O and S, a 5- or 6 member heteroaryl group in which 1, 2, or 3 ring members are independently selected from N, O, and S, and a C1-C6 alkyl group that is unsubstituted or substituted with CN, NH2, or OH, wherein the cycloalkyl and heterocycloalkyl groups are either unsubstituted or have 1, 2, 3, or 4 R groups. 9 It is substituted with the base, Each R 6 H, -S(=O)2N(R 7 )2, -C(=O)N(R 7 )2 and C1-C6 alkyl groups that are unsubstituted or substituted with -OH, CN, or -C(=O)OH are independently selected from the group consisting of these groups. Each R 7 These are independently selected from the group consisting of H and unsubstituted C1-C6 alkyl groups. R 8 H, unsubstituted C1-C6 alkyl, C3-C8 cycloalkyl, or 1, 2, 3 or 4 ring members are N, NR 6 A 4-6 member heterocycloalkyl group independently selected from O and S, wherein the cycloalkyl and heterocycloalkyl groups are unsubstituted or have 1, 2, 3, or 4 R groups. 9 It is substituted with the base, Each R 9 , NR 10 R 11 -C(=O)N(R 7 )2 and -OH or -N(R 7Independently selected from the group consisting of C1-C6 alkyl groups substituted with )2, R 10 is H or an unsubstituted C1-C6 alkyl group. R 11 This is H, an unsubstituted C1-C6 alkyl or -S(=O)2C1-C6 alkyl, Each R 12 is -C(=O)N(R 7 )2, -C(=O)OH, -N(R 7 )2, -CN, -OH, -S(=O)2R 6 -S(=O)2N(R 7 )2, [ka] Halo, phenyl, C3-C8 cycloalkyl, 1, 2, 3 or 4 ring members are N, NR 6 A phenyl, heterocycloalkyl, and heteroaryl group is independently selected from the group consisting of a 4-6 member heterocycloalkyl group independently selected from O and S, a 5 or 6 member heteroaryl group in which 1, 2, or 3 ring members are independently selected from N, O, and S, and a C1-C6 alkyl group that is unsubstituted or substituted with NH2, CN, or OH. The phenyl, heterocycloalkyl, and heteroaryl groups are either unsubstituted or substituted with one or two substituents independently selected from the group consisting of OH. R 13 H, -C(=O)N(R 7 )2 or 1, 2, 3 or 4 ring members are N, NR 6 , a 5 or 6-member heteroaryl selected independently from O and S, R 14 teeth, i) 1, 2, 3 or 4 ring members are N, NR 6 A 5 or 6-membered heterocycline independently selected from O and S, which is unsubstituted or has 1, 2, 3 or 4 R 12 A 5- or 6-membered heterocyclyl that is substituted with a group and optionally substituted with one or two oxos, and ii) 1, 2, 3 or 4 ring members are N, NR6 A 5 or 6-membered heteroaryl, independently selected from O and S, which is either unsubstituted or has 1, 2, 3, or 4 R 12 Five or six-membered heteroaryls substituted with a specific group Selected from the group consisting of, Each R 15 is CN, NH2, -OH, -C(=O)OH, -C(=O)N(R 7 )2, -C(=O)C(=O)OH, C1-C6 alkoxy, halo, C1-C6 haloalkyl, C3-C8 cycloalkyl, 1, 2, 3 or 4 ring members are N, NR 6 , a 5 or 6-membered heteroaryl selected independently from O and S, and 1, 2 or 3 ring members are N, NR 6 The cycloalkyl, heteroaryl, and heterocycloalkyl groups are independently selected from the group consisting of 3-6 member heterocycloalkyl groups independently selected from O and S, and the cycloalkyl, heteroaryl, and heterocycloalkyl groups are either unsubstituted or substituted with 1, 2, or 3 substituents independently selected from the group consisting of CN, -C(=O)OH, NH2, OH, and unsubstituted C1-C6 alkyl groups. However, R 3a , R 3b , R 4a or R 4b (Provided that at least one of them is not hydrogen.) The compound described in Embodiment 1, its stereoisomer, or a pharmaceutically acceptable salt thereof.

[0074] Embodiment 3.X1 is CR 3a R 3b , C=O or NR 3c And, X2 is CR 4a R 4b Or C=O, R 1 teeth, i) 1, 2, 3 or 4 ring members are N, NR 6 A 5 or 6-membered heteroaryl, independently selected from O and S, which is unsubstituted or has 1 to 4 R 5 A 5- or 6-membered heteroaryl substituted with a group ii) Unsubstituted or with 1 to 4 R 5 Phenyl groups substituted with a group iii) 1, 2, 3 or 4 ring members are N, NR 6 A 4, 5, or 6-membered heterocycloalkyl group independently selected from O and S, which is either unsubstituted or has 1 to 4 R groups. 5 A heterocycloalkyl group substituted with a group, and a 5 or 6-membered heterocycloalkyl group optionally substituted with an oxo group, iv) Unsubstituted or with 1 to 4 R 5 C3-C8 cycloalkyl groups substituted with a group v) Unsubstituted C1-C6 alkyl groups, vi) A 5 or 6-membered heterocycline in which 1, 2 or 3 ring members are independently selected from W, Y and Z, where W is NR 6 , O, S, S=O or S(=O)², and Y is NR 6 , O, S, S=O or S(=O)², and Z is NR 6 The heterocyclyl is O or S, and has 5 or 6 members, either unsubstituted or with 1, 2, 3 or 4 R 12 A 5- or 6-membered heterocyclyl that is substituted with a group and optionally substituted with an oxo group, vii) 1, 2, 3, 4 or 5 ring members are N, NR 6 A 9 or 10-membered bicyclic heterocycline independently selected from O and S, which is unsubstituted or has 1 to 4 R 5 A 9 or 10-membered bicyclic heterocycline substituted with a group, viii) Unsubstituted or with 1 to 4 R 5 Spirobond C3-C8 cycloalkyl groups substituted with a group ix) Unsubstituted or with 1 to 4 R 5 Bicyclic C3-C8 cycloalkyl groups substituted with a group x) C5~C6 cycloalkenyl, xi) A 9 or 10-membered bicyclic heteroaryl in which 1, 2, 3, 4, or 5 ring members are independently selected from N, O, and S, and is unsubstituted or has 1 to 4 R 5 9 or 10-membered bicyclic heteroaryls substituted with a specific group Selected from the group consisting of, R 2 teeth, i)-(CH2) 0-6 CHR 13 R 14 , ii) Unsubstituted, or 1, 2, 3, or 4 R 12 benzyl substituted with a group iii) A six-membered heteroaryl in which one, two, or three ring members are independently selected from N, O, and S, and is unsubstituted, or has one, two, three, or four R 12 A 6-membered heteroaryl substituted with a base, iv) A 10-membered bicyclic heteroaryl having a bond site in a carbon atom ring member and a N heteroatom located at the beta (β) position relative to the bond site, wherein the ring member has 0, 1, 2, or 3 additional N heteroatoms and is unsubstituted, or has 1, 2, 3, or 4 R 12 A 10-membered bicyclic heteroaryl substituted with a group v) A 10-membered bicyclic heteroaryl having a bond site in a carbon atom ring member and a N heteroatom as a ring member located at the beta (β) position relative to the bond site, further comprising 0, 1, 2, 3, or 4 ring members independently selected from N, O, and S, and being unsubstituted or having 1, 2, 3, or 4 R 12 A 10-membered bicyclic heteroaryl substituted with a group vi) A nine-membered bicyclic heteroaryl having a bond site in a carbon atom ring member and a N heteroatom located at the beta (β) position relative to the bond site, wherein the ring member has 0, 1, 2, 3, or 4 additional N heteroatoms and is unsubstituted, or has 1, 2, 3, or 4 R 12 A 9-membered bicyclic heteroaryl substituted with a group vii) A nine-membered bicyclic heteroaryl having a bond site in a carbon atom ring member and a N heteroatom located at the beta (β) position relative to the bond site, wherein N,NR 6 It further has 0, 1, 2, 3, or 4 ring members independently selected from O and S, and is unsubstituted, or has 1, 2, 3, or 4 R 12 A 9-membered bicyclic heteroaryl substituted with a group viii) A ring member having a bond point and located at the beta (β) position relative to the bond point is NR 6 A 5 or 6-membered heterocycloalkyl having N, NR 6 It further has 0, 1, or 2 ring members independently selected from O and S, which are substituted with 1 or 2 oxos, or unsubstituted, or 1, 2, 3, or 4 R 12 A 5- or 6-membered heterocycloalkyl group that is substituted with a group and optionally substituted with one or two oxos, ix) A ring member having a bond point and located at the beta (β) position relative to the bond point is NR 6 A 5 or 6-membered heterocycline having N, NR 6 It further has 0, 1, or 2 ring members independently selected from O and S, which are substituted with 1 or 2 oxos, or unsubstituted, or 1, 2, 3, or 4 R 12 A 5- or 6-membered heterocycline that is substituted with a group and optionally substituted with one or two oxos, x) A ring member having a bond point and located at the beta (β) position relative to the bond point is NR 6 A 9 or 10-membered bicyclic heterocycline having N, NR 6 It further has 0, 1, 2, 3, or 4 ring members independently selected from O and S, which are substituted with 1 or 2 oxos, or unsubstituted, or 1, 2, 3, or 4 R 12 A 9 or 10-membered bicyclic heterocycline that is substituted with a group and optionally substituted with one or two oxos, xi) A 9 or 10-membered bicyclic heterocycline having a bond site in a carbon atom ring member and an O heteroatom located at the beta (β) position relative to the bond site, wherein N, NR 6 It further has 0, 1, 2, 3, or 4 ring members independently selected from O and S, which are substituted with 1 or 2 oxos, or unsubstituted, or 1, 2, 3, or 4 R 12 A 9 or 10-membered bicyclic heterocycline that is substituted with a group and optionally substituted with one or two oxos, xii) 1, 2, 3, 4 or 5 ring members are N, NR 6 A 9 or 10-membered bicyclic heteroaryl, independently selected from O and S, which is either unsubstituted or has 1, 2, 3, or 4 R 12 A 9 or 10-membered bicyclic heteroaryl substituted with a group, xiii) 1, 2 or 3 ring members are N, NR 6 A 5 or 6-membered heterocycloalkyl group independently selected from O and S, which is substituted with 1 or 2 oxos, or unsubstituted, or has 1, 2, 3 or 4 R atoms. 12 A 5- or 6-membered heterocycloalkyl group that is substituted with a group and optionally substituted with one or two oxos, xiv) 1, 2, or 3 ring members are N, NR 6 A 5 or 6-membered heterocycline independently selected from O and S, which is substituted with 1 or 2 oxos, or unsubstituted, or has 1, 2, 3 or 4 Rs. 12 A 5- or 6-membered heterocycline that is substituted with a group and optionally substituted with one or two oxos, xv) A six-membered heterocycline having a bond site in a carbon atom ring member, which is substituted with an oxo, and which has a carbon atom as a ring member located at the beta (β) position relative to the bond site, wherein N,NR 6 It further has one or two ring members independently selected from O and S, and is unsubstituted, or has one, two, three or four R 12A six-membered heterocycline that is substituted with a group and optionally substituted with an oxo group. xvi) 1, 2, 3, 4 or 5 ring members are N, NR 6 A 9 or 10-membered bicyclic heterocycline independently selected from O and S, which is substituted with 1 or 2 oxos, or unsubstituted, or has 1, 2, 3 or 4 Rs. 12 A 9 or 10-membered bicyclic heterocycline that is substituted with a group and optionally substituted with one or two oxos, xvii) One ring member is NR 6 A six-membered heterocyclyl selected from, which is a six-membered heterocyclyl substituted with an oxo, xviii) A six-membered heteroaryl having a bond site in a carbon atom ring member and a N heteroatom located at the beta (β) position relative to the bond site, wherein the ring member has 0, 1 or 2 additional N heteroatoms and is unsubstituted, or has 1, 2, 3 or 4 R 12 A 6-membered heteroaryl substituted with a group, and xix) A 10-membered bicyclic heterocycline having a bond site in one of its carbon atom ring members, which is substituted with an oxo, and having a carbon atom as a ring member located at the beta (β) position relative to the bond site, wherein N,NR 6 It further has 1, 2, 3, or 4 ring members independently selected from O and S, and is unsubstituted, or has 1, 2, 3, or 4 R 12 A 10-membered bicyclic heterocycline that is substituted with a group and optionally substituted with an additional oxo group. Selected from the group consisting of, R 3a -CN, C3-C8 cycloalkyl, 1, 2 or 3 ring members are N, NR 6 , a 4-7 member heterocycloalkyl group independently selected from O and S, unsubstituted or with one or more R 15 C1-C6 alkyl groups substituted with a group, or unsubstituted, or with one or more R groups. 15The C2-C6 alkenyls are substituted with a group, and the cycloalkyls and heterocycloalkyls are either unsubstituted or substituted with one or two substituents independently selected from the group consisting of CN, -C(=O)OH, NH2, OH, C1-C6 haloalkyl, C1-C6 alkyl, or C1-C6 alkyl substituted with -C(=O)OH, -OH, CN, or NH2. R 3b This is H, C3-C8 cycloalkyl, with 1, 2, or 3 ring members being N, NR 6 , a 4-7 member heterocycloalkyl group independently selected from O and S, unsubstituted or with one or more R 15 C1-C6 alkyl groups substituted with a group, or unsubstituted, or with one or more R groups. 15 The C2-C6 alkenyls are substituted with a group, and the cycloalkyls and heterocycloalkyls are either unsubstituted or substituted with one or two substituents independently selected from the group consisting of CN, -C(=O)OH, NH2, OH, C1-C6 haloalkyl, C1-C6 alkyl, or C1-C6 alkyl substituted with -C(=O)OH, -OH, CN, or NH2. R 4a This is H, C3-C8 cycloalkyl, with 1, 2, or 3 ring members being N, NR 6 , a 4-7 member heterocycloalkyl group independently selected from O and S, unsubstituted or with one or more R 15 C1-C6 alkyl groups substituted with a group, or unsubstituted, or with one or more R groups. 15 The C2-C6 alkenyls are substituted with a group, and the cycloalkyls and heterocycloalkyls are either unsubstituted or substituted with one or two substituents independently selected from the group consisting of CN, -C(=O)OH, NH2, OH, C1-C6 haloalkyl, C1-C6 alkyl, or C1-C6 alkyl substituted with -C(=O)OH, -OH, CN, or NH2. R 4bThis is H, C3-C8 cycloalkyl, with 1, 2, or 3 ring members being N, NR 6 , a 4-7 member heterocycloalkyl group independently selected from O and S, unsubstituted or with one or more R 15 C1-C6 alkyl groups substituted with a group, or unsubstituted, or with one or more R groups. 15 The C2-C6 alkenyls are substituted with a group, and the cycloalkyls and heterocycloalkyls are either unsubstituted or substituted with one or two substituents independently selected from the group consisting of CN, -C(=O)OH, NH2, OH, C1-C6 haloalkyl, C1-C6 alkyl, or C1-C6 alkyl substituted with -C(=O)OH, -OH, CN, or NH2. R 3c This is H, -C(=O)C2~C6 alkenyl or one or more R 15 These are C1-C6 alkyl groups substituted with a group. Each R 5 -CN, -OH, -NR 7 R 8 , NR 6 C(=O)C2~C6 alkenyl, -SF5, S(=O)2C1~C6 alkyl, -C(=O)N(R) 7 )2, C1-C6 haloalkyl, halo, C1-C6 haloalkoxy, C1-C6 alkoxy, C3-C8 cycloalkyl, 1, 2, 3 or 4 ring members are N, NR 6 A cycloalkyl group is independently selected from the group consisting of a 4-6 member heterocycloalkyl group independently selected from O and S, a 5- or 6 member heteroaryl group in which 1, 2, or 3 ring members are independently selected from N, O, and S, and a C1-C6 alkyl group that is unsubstituted or substituted with CN, NH2, or OH, wherein the cycloalkyl and heterocycloalkyl groups are either unsubstituted or have 1, 2, 3, or 4 R groups. 9 It is substituted with the base, Each R 6 These are H, C1-C6 haloalkyl, C1-C6 haloalkoxy, -S(=O)2N(R 7)2, S(=O)2C1~C6 alkyl, S(=O)2C1~C6 haloalkyl, -S(=O)2C3~C6 cycloalkyl, -C(=O)R 7 -C(=O)N(R 7 )2. Independently selected from the group consisting of C3-C6 cycloalkyl and C1-C6 alkyl which are unsubstituted or substituted with -OH, CN, or -C(=O)OH, Each R 7 This is independently selected from the group consisting of H and C1-C6 alkyl groups that are either unsubstituted or substituted with OH or C1-C6 alkoxy groups. R 8 H, unsubstituted C1-C6 alkyl, C3-C8 cycloalkyl, or 1, 2, 3 or 4 ring members are N, NR 6 A 4-6 member heterocycloalkyl group independently selected from O and S, wherein the cycloalkyl and heterocycloalkyl groups are unsubstituted or have 1, 2, 3, or 4 R groups. 9 It is substituted with the base, Each R 9 , NR 10 R 11 -C(=O)N(R 7 )2 and -OH or -N(R 7 Independently selected from the group consisting of C1-C6 alkyl groups substituted with )2, R 10 is H or an unsubstituted C1-C6 alkyl group. R 11 These are H, C1-C6 alkyl or -S(=O)2C1-C6 alkyl, Each R 12 is -C(=O)N(R 7 )2, -C(=O)OH, -N(R 7 )2, -CN, -OH, -S(=O)2R 7 -S(=O)2N(R 7 )2, [ka] Halo, phenyl, C3-C8 cycloalkyl, 1, 2, 3 or 4 ring members are N, NR 6A phenyl, heterocycloalkyl, and heteroaryl group is independently selected from the group consisting of a 4-6 member heterocycloalkyl group independently selected from O and S, a 5 or 6 member heteroaryl group in which 1, 2, or 3 ring members are independently selected from N, O, and S, and a C1-C6 alkyl group that is unsubstituted or substituted with NH2, CN, or OH. The phenyl, heterocycloalkyl, and heteroaryl groups are either unsubstituted or substituted with one or two substituents independently selected from the group consisting of OH. R 13 H, -C(=O)N(R 7 )2 or 1, 2, 3 or 4 ring members are N, NR 6 , a 5 or 6-member heteroaryl selected independently from O and S, R 14 teeth, i) 1, 2, 3 or 4 ring members are N, NR 6 A 5 or 6-membered heterocycline independently selected from O and S, which is unsubstituted or has 1, 2, 3 or 4 R 12 A 5- or 6-membered heterocyclyl that is substituted with a group and optionally substituted with one or two oxos, and ii) 1, 2, 3 or 4 ring members are N, NR 6 A 5 or 6-membered heteroaryl, independently selected from O and S, which is either unsubstituted or has 1, 2, 3, or 4 R 12 Five or six-membered heteroaryls substituted with a specific group Selected from the group consisting of, Each R 15 is CN, NH2, -OH, -C(=O)OH, -C(=O)N(R 7 )2, -C(=O)C(=O)OH, C1-C6 alkoxy, halo, C1-C6 haloalkyl, C3-C8 cycloalkyl, 1, 2, 3 or 4 ring members are N, NR 6 , a 5 or 6-membered heteroaryl selected independently from O and S, and 1, 2 or 3 ring members are N, NR 6A compound according to Embodiment 1, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, independently selected from the group consisting of 3-6 member heterocycloalkyls independently selected from O and S, wherein the cycloalkyl, heteroaryl, and heterocycloalkyl are either unsubstituted or substituted with 1, 2, or 3 substituents independently selected from the group consisting of CN, -C(=O)OH, NH2, OH, and unsubstituted C1-C6 alkyls.

[0075] Embodiment 4.X1 is CR 3a R 3b , C=O or NR 3c And, X2 is CR 4a R 4b Or C=O, R 1 teeth, i) 1, 2, 3 or 4 ring members are N, NR 6 A 5 or 6-membered heteroaryl, independently selected from O and S, which is unsubstituted or has 1 to 4 R 5 A 5- or 6-membered heteroaryl substituted with a group ii) Unsubstituted or with 1 to 4 R 5 Phenyl groups substituted with a group iii) 1, 2, 3 or 4 ring members are N, NR 6 A 4, 5, or 6-membered heterocycloalkyl group independently selected from O and S, which is either unsubstituted or has 1 to 4 R groups. 5 A heterocycloalkyl group substituted with a group, and a 5 or 6-membered heterocycloalkyl group optionally substituted with an oxo group, iv) Unsubstituted or with 1 to 4 R 5 C3-C8 cycloalkyl groups substituted with a group v) Unsubstituted C1-C6 alkyl groups, vi) A 5 or 6-membered heterocycline in which 1, 2 or 3 ring members are independently selected from W, Y and Z, where W is NR 6 , O, S, S=O or S(=O)², and Y is NR 6, O, S, S=O or S(=O)², and Z is NR 6 The heterocyclyl is O or S, and has 5 or 6 members, either unsubstituted or with 1, 2, 3 or 4 R 12 A 5- or 6-membered heterocyclyl that is substituted with a group and optionally substituted with an oxo group, vii) 1, 2, 3, 4 or 5 ring members are N, NR 6 A 9 or 10-membered bicyclic heterocycline independently selected from O and S, which is unsubstituted or has 1 to 4 R 5 A 9 or 10-membered bicyclic heterocycline substituted with a group, viii) Unsubstituted or with 1 to 4 R 5 Spirobond C3-C8 cycloalkyl groups substituted with a group ix) Unsubstituted or with 1 to 4 R 5 Bicyclic C3-C8 cycloalkyl groups substituted with a group x) C5~C6 cycloalkenyl, xi) A 9 or 10-membered bicyclic heteroaryl in which 1, 2, 3, 4, or 5 ring members are independently selected from N, O, and S, and is unsubstituted or has 1 to 4 R 5 9 or 10-membered bicyclic heteroaryls substituted with a specific group Selected from the group consisting of, R 2 teeth, i) A 10-membered bicyclic heteroaryl having a bond site in a carbon atom ring member and a N heteroatom located at the beta (β) position relative to the bond site, wherein the ring member has 0, 1, 2, or 3 additional N heteroatoms and is unsubstituted, or has 1, 2, 3, or 4 R 12 A 10-membered bicyclic heteroaryl substituted with a group ii) A 10-membered bicyclic heteroaryl having a bond site in a carbon atom ring member and a N heteroatom as a ring member located at the beta (β) position relative to the bond site, further comprising 0, 1, 2, 3, or 4 ring members independently selected from N, O, and S, and being unsubstituted or having 1, 2, 3, or 4 R 12A 10-membered bicyclic heteroaryl substituted with a group iii) A nine-membered bicyclic heteroaryl having a bond site in a carbon atom ring member and a N heteroatom located at the beta (β) position relative to the bond site, wherein the ring member has 0, 1, 2, 3 or 4 additional N heteroatoms and is unsubstituted, or has 1, 2, 3 or 4 R 12 A 9-membered bicyclic heteroaryl substituted with a group iv) A nine-membered bicyclic heteroaryl having a bond site in one of the carbon atom ring members, and having a N heteroatom as a ring member located at the beta (β) position relative to the bond site, wherein N,NR 6 It further has 0, 1, 2, 3, or 4 ring members independently selected from O and S, and is unsubstituted, or has 1, 2, 3, or 4 R 12 A 9-membered bicyclic heteroaryl substituted with a group v) A ring member having a bond point and located at the beta (β) position relative to the bond point is NR 6 A 9 or 10-membered bicyclic heterocycline having N, NR 6 It further has 0, 1, 2, 3, or 4 ring members independently selected from O and S, which are substituted with 1 or 2 oxos, or unsubstituted, or 1, 2, 3, or 4 R 12 A 9 or 10-membered bicyclic heterocycline that is substituted with a group and optionally substituted with one or two oxos, vi) A 9 or 10-membered bicyclic heterocycline having a bond site in a carbon atom ring member and an O heteroatom located at the beta (β) position relative to the bond site, wherein N, NR 6 It further has 0, 1, 2, 3, or 4 ring members independently selected from O and S, which are substituted with 1 or 2 oxos, or unsubstituted, or 1, 2, 3, or 4 R 12 A 9 or 10-membered bicyclic heterocycline that is substituted with a group and optionally substituted with one or two oxos, vii) 1, 2, 3, 4 or 5 ring members are N, NR 6A 9 or 10-membered bicyclic heteroaryl, independently selected from O and S, which is either unsubstituted or has 1, 2, 3, or 4 R 12 A 9 or 10-membered bicyclic heteroaryl substituted with a group, viii) 1, 2, 3, 4 or 5 ring members are N, NR 6 A 9 or 10-membered bicyclic heterocycline independently selected from O and S, which is substituted with 1 or 2 oxos, or unsubstituted, or has 1, 2, 3 or 4 Rs. 12 A 9 or 10-membered bicyclic heterocycline that is substituted with a group and optionally substituted with one or two oxos, and ix) A 10-membered bicyclic heterocycline having a bond site in one of its carbon atom ring members, which is substituted with an oxo, and which has a carbon atom as a ring member located at the beta (β) position relative to the bond site, wherein N,NR 6 It further has 1, 2, 3, or 4 ring members independently selected from O and S, and is unsubstituted, or has 1, 2, 3, or 4 R 12 A 10-membered bicyclic heterocycline that is substituted with a group and optionally substituted with an additional oxo group. Selected from the group consisting of, R 3a -CN, C3-C8 cycloalkyl, 1, 2 or 3 ring members are N, NR 6 , a 4-7 member heterocycloalkyl group independently selected from O and S, unsubstituted or with one or more R 15 C1-C6 alkyl groups substituted with a group, or unsubstituted, or with one or more R groups. 15 The C2-C6 alkenyls are substituted with a group, and the cycloalkyls and heterocycloalkyls are either unsubstituted or substituted with one or two substituents independently selected from the group consisting of CN, -C(=O)OH, NH2, OH, C1-C6 haloalkyl, C1-C6 alkyl, or C1-C6 alkyl substituted with -C(=O)OH, -OH, CN, or NH2. R 3bThis is H, C3-C8 cycloalkyl, with 1, 2, or 3 ring members being N, NR 6 , a 4-7 member heterocycloalkyl group independently selected from O and S, unsubstituted or with one or more R 15 C1-C6 alkyl groups substituted with a group, or unsubstituted, or with one or more R groups. 15 The C2-C6 alkenyls are substituted with a group, and the cycloalkyls and heterocycloalkyls are either unsubstituted or substituted with one or two substituents independently selected from the group consisting of CN, -C(=O)OH, NH2, OH, C1-C6 haloalkyl, C1-C6 alkyl, or C1-C6 alkyl substituted with -C(=O)OH, -OH, CN, or NH2. R 4a This is H, C3-C8 cycloalkyl, with 1, 2, or 3 ring members being N, NR 6 , a 4-7 member heterocycloalkyl group independently selected from O and S, unsubstituted or with one or more R 15 C1-C6 alkyl groups substituted with a group, or unsubstituted, or with one or more R groups. 15 The C2-C6 alkenyls are substituted with a group, and the cycloalkyls and heterocycloalkyls are either unsubstituted or substituted with one or two substituents independently selected from the group consisting of CN, -C(=O)OH, NH2, OH, C1-C6 haloalkyl, C1-C6 alkyl, or C1-C6 alkyl substituted with -C(=O)OH, -OH, CN, or NH2. R 4b This is H, C3-C8 cycloalkyl, with 1, 2, or 3 ring members being N, NR 6 , a 4-7 member heterocycloalkyl group independently selected from O and S, unsubstituted or with one or more R 15 C1-C6 alkyl groups substituted with a group, or unsubstituted, or with one or more R groups. 15The C2-C6 alkenyls are substituted with a group, and the cycloalkyls and heterocycloalkyls are either unsubstituted or substituted with one or two substituents independently selected from the group consisting of CN, -C(=O)OH, NH2, OH, C1-C6 haloalkyl, C1-C6 alkyl, or C1-C6 alkyl substituted with -C(=O)OH, -OH, CN, or NH2. R 3c This is H, -C(=O)C2~C6 alkenyl or one or more R 15 These are C1-C6 alkyl groups substituted with a group. Each R 5 -CN, -OH, -NR 7 R 8 , NR 6 C(=O)C2~C6 alkenyl, -SF5, S(=O)2C1~C6 alkyl, -C(=O)N(R) 7 )2, C1-C6 haloalkyl, halo, C1-C6 haloalkoxy, C1-C6 alkoxy, C3-C8 cycloalkyl, 1, 2, 3 or 4 ring members are N, NR 6 A cycloalkyl group is independently selected from the group consisting of a 4-6 member heterocycloalkyl group independently selected from O and S, a 5- or 6 member heteroaryl group in which 1, 2, or 3 ring members are independently selected from N, O, and S, and a C1-C6 alkyl group that is unsubstituted or substituted with CN, NH2, or OH, wherein the cycloalkyl and heterocycloalkyl groups are either unsubstituted or have 1, 2, 3, or 4 R groups. 9 It is substituted with the base, Each R 6 These are H, C1-C6 haloalkyl, C1-C6 haloalkoxy, -S(=O)2N(R 7 )2, S(=O)2C1~C6 alkyl, S(=O)2C1~C6 haloalkyl, -S(=O)2C3~C6 cycloalkyl, -C(=O)R 7 -C(=O)N(R 7 )2. Independently selected from the group consisting of C3-C6 cycloalkyl and C1-C6 alkyl which are unsubstituted or substituted with -OH, CN, or -C(=O)OH, Each R 7This is independently selected from the group consisting of H and C1-C6 alkyl groups that are either unsubstituted or substituted with OH or C1-C6 alkoxy groups. R 8 H, unsubstituted C1-C6 alkyl, C3-C8 cycloalkyl, or 1, 2, 3 or 4 ring members are N, NR 6 A 4-6 member heterocycloalkyl group independently selected from O and S, wherein the cycloalkyl and heterocycloalkyl groups are unsubstituted or have 1, 2, 3, or 4 R groups. 9 It is substituted with the base, Each R 9 , NR 10 R 11 -C(=O)N(R 7 )2 and -OH or -N(R 7 Independently selected from the group consisting of C1-C6 alkyl groups substituted with )2, R 10 is H or an unsubstituted C1-C6 alkyl group. R 11 This is H, an unsubstituted C1-C6 alkyl or -S(=O)2C1-C6 alkyl, Each R 12 is -C(=O)N(R 7 )2, -C(=O)OH, -N(R 7 )2, -CN, -OH, -S(=O)2R 7 -S(=O)2N(R 7 )2, [ka] Halo, phenyl, C3-C8 cycloalkyl, 1, 2, 3 or 4 ring members are N, NR 6, independently selected from the group consisting of 4-6 member heterocycloalkyls independently selected from O and S, 5 or 6 member heteroaryls in which 1, 2 or 3 ring members are independently selected from N, O and S, and C1-C6 alkyls that are unsubstituted or substituted with NH2, CN or OH, and phenyl, heterocycloalkyls and heteroaryls are unsubstituted or substituted with 1 or 2 substituents independently selected from the group consisting of OH, and Each R 15 is CN, NH2, -OH, -C(=O)OH, -C(=O)N(R 7 )2, -C(=O)C(=O)OH, C1-C6 alkoxy, halo, C1-C6 haloalkyl, C3-C8 cycloalkyl, 1, 2, 3 or 4 ring members are N, NR 6 , a 5 or 6-membered heteroaryl selected independently from O and S, and 1, 2 or 3 ring members are N, NR 6 A compound according to Embodiment 1, or a pharmaceutically acceptable salt or stereoisomer thereof, independently selected from the group consisting of 3-6 member heterocycloalkyls independently selected from O and S, wherein the cycloalkyl, heteroaryl, and heterocycloalkyl are either unsubstituted or substituted with 1, 2, or 3 substituents independently selected from the group consisting of CN, -C(=O)OH, NH2, OH, and unsubstituted C1-C6 alkyls.

[0076] Embodiment 5.X1 is CR 3a R 3b And, X2 is CR 4a R 4b And, R 1 teeth, i) 1, 2, 3 or 4 ring members are N, NR 6 A 5 or 6-membered heteroaryl, independently selected from O and S, which is unsubstituted or has 1 to 4 R 5 A 5- or 6-membered heteroaryl substituted with a group ii) Unsubstituted or with 1 to 4 R 5 Phenyl groups substituted with a group iii) 1, 2, 3 or 4 ring members are N, NR 6 A 4, 5, or 6-membered heterocycloalkyl group independently selected from O and S, wherein the 5 or 6-membered heterocycloalkyl group is unsubstituted or has 1 to 4 R groups. 5 A 4, 5, or 6-membered heterocycloalkyl group substituted with a group, iv) Unsubstituted or with 1 to 4 R 5 C3-C8 cycloalkyl groups substituted with a group v) Unsubstituted C1-C6 alkyl groups, vi) A 5 or 6-membered heterocycline in which 1, 2 or 3 ring members are independently selected from W, Y and Z, where W is NR 6 , O, S, S=O or S(=O)², and Y is NR 6 , O, S, S=O or S(=O)², and Z is NR 6 The heterocyclyl is O or S, and has 5 or 6 members, either unsubstituted or with 1 or 2 R 12 A 5- or 6-membered heterocyclyl that is substituted with a group and optionally substituted with an oxo group, vii) One or two ring members are N and NR 6 A 9 or 10-membered bicyclic heterocycline independently selected from each of the following, which is unsubstituted or has 1-2 R 5 A 9 or 10-membered bicyclic heterocycline substituted with a group, and viii) Unsubstituted or with 1 to 4 R 5 Bicyclic C3-C8 cycloalkyl groups substituted with a group Selected from the group consisting of, R 2 teeth, i) A 10-membered bicyclic heteroaryl having a bond site in a carbon atom ring member and a N heteroatom located at the beta (β) position relative to the bond site, wherein the ring member has 0, 1, 2, or 3 additional N heteroatoms and is unsubstituted, or has 1, 2, 3, or 4 R 12 A 10-membered bicyclic heteroaryl substituted with a group, and ii) 1, 2, 3, 4 or 5 ring members are N, NR 6A 9 or 10-membered bicyclic heteroaryl, independently selected from O and S, which is either unsubstituted or has 1, 2, 3, or 4 R 12 9 or 10-membered bicyclic heteroaryls substituted with a specific group Selected from the group consisting of, R 3a is -CN, R 3b is H or an unsubstituted C1-C6 alkyl group. R 4a is H or an unsubstituted C1-C6 alkyl group. R 4b is H or an unsubstituted C1-C6 alkyl group. Each R 5 These are independently selected from the group consisting of CN, -OH, S(=O)2C1~C6 alkyl, C1~C6 haloalkyl, halo, C1~C6 haloalkoxy, C1~C6 alkoxy, unsubstituted C3~C8 cycloalkyl, and unsubstituted or OH-substituted C1~C6 alkyl. Each R 6 These include H, C1-C6 haloalkyl, C1-C6 haloalkoxy, S(=O)2C1-C6 alkyl, S(=O)2C1-C6 haloalkyl, -S(=O)2C3-C6 cycloalkyl, and -C(=O)R 7 , independently selected from the group consisting of C3-C6 cycloalkyl and unsubstituted or -OH-substituted C1-C6 alkyl, Each R 7 These are independently selected from the group consisting of H and C1-C6 alkyl groups that are either unsubstituted or substituted with OH or C1-C6 alkoxy, and Each R 12 is -C(=O)N(R 7 )2, -C(=O)OH, -CN, -S(=O)2R 7 and a compound according to Embodiment 4, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, independently selected from the group consisting of OH-substituted C1-C6 alkyl groups.

[0077] Embodiment 6.X1 is CR 3a R 3b, C=O or NR 3c The compound described in any one of Embodiments 1 to 5, its stereoisomer, or its pharmaceutically acceptable salt.

[0078] Embodiment 7.X1 is CR 3a R 3b The compound described in any one of Embodiments 1 to 5, its stereoisomer, or its pharmaceutically acceptable salt.

[0079] Embodiment 8.X1 is a compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, according to any one of Embodiments 1 to 5, wherein C=O.

[0080] Embodiment 9.X1 is NR 3c The compound described in any one of Embodiments 1 to 5, its stereoisomer, or its pharmaceutically acceptable salt.

[0081] Embodiment 10.X2 is CR 4a R 4b Alternatively, a compound according to any one of Embodiments 1 to 9, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein C=O.

[0082] Embodiment 11.X2 is CR 4a R 4b The compound described in any one of Embodiments 1 to 10, its stereoisomer, or its pharmaceutically acceptable salt.

[0083] Embodiment 12.X2 is a compound, stereoisomer thereof, or pharmaceutically acceptable salt thereof, according to any one of Embodiments 1 to 10, wherein C=O.

[0084] Embodiment 13. A compound of formula (I) described in any one of Embodiments 1 to 5, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, selected from compounds having the following subformulas (formula (Ia), formula (Ib), formula (Ic), formula (Id), formula (Ie), formula (If), and formula (Ig)). [ka]

[0085] Embodiment 14. A compound according to any one of Embodiments 1 to 5, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, selected from compounds having the structure of formula (Ig). [ka]

[0086] Embodiment 15. A compound according to any one of Embodiments 1 to 5, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, selected from a compound having the structure of formula (Ih) or formula (Ii) or a pharmaceutically acceptable salt or stereoisomer thereof. [ka]

[0087] Embodiment 16. A compound having the structure of formula (Ii) or a pharmaceutically acceptable salt or stereoisomer thereof, selected from any one of Embodiments 1 to 5, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. [ka]

[0088] Embodiment 17.R 2 is, -(CH2) 0-6 CHR 13 R 14 The compound described in any one of Embodiments 1 to 16, its stereoisomer, or its pharmaceutically acceptable salt.

[0089] Embodiment 18.R 2 -CHR 13 R 14 The compound described in any one of Embodiments 1 to 16, its stereoisomer, or its pharmaceutically acceptable salt.

[0090] Embodiment 19.R 2 is either unsubstituted or has 1, 2, 3 or 4 R12 A compound according to any one of Embodiments 1 to 16, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the benzyl is substituted with a group.

[0091] Embodiment 20.R 2 is either unsubstituted or one R 12 A compound according to any one of Embodiments 1 to 16, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the benzyl is substituted with a group.

[0092] Embodiment 21.R 2 This is a six-membered heteroaryl in which one, two, or three ring members are independently selected from N, O, and S, and the six-membered heteroaryl is unsubstituted or has one, two, three, or four R members. 12 A compound according to any one of Embodiments 1 to 16, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is substituted with a group.

[0093] Embodiment 22.R 2 This is a six-membered heteroaryl ring in which one member is selected from N, and the six-membered heteroaryl ring is either unsubstituted or has one or two R members. 12 A compound according to any one of Embodiments 1 to 16, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is substituted with a group.

[0094] Embodiment 23.R 2 is either unsubstituted or has 1, 2, 3 or 4 R 12 A compound according to any one of Embodiments 1 to 16, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is a pyridyl substituted with a group.

[0095] Embodiment 24.R 2 is either unsubstituted or has one or two R 12 A compound according to any one of Embodiments 1 to 16, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the pyrido-3-yl is substituted with a group.

[0096] Embodiment 25.R 2This has 1, 2, 3, 4, or 5 ring members, and is N, NR 6 A 9 or 10-membered bicyclic heteroaryl, independently selected from O and S, wherein the 9 or 10-membered bicyclic heteroaryl is unsubstituted or has 1, 2, 3, or 4 R 12 A compound according to any one of Embodiments 1 to 16, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is substituted with a group.

[0097] Embodiment 26.R 2 This has 1, 2, or 3 ring members, which are N, NR 6 A 9 or 10-membered bicyclic heteroaryl selected independently from O and S, wherein the 9 or 10-membered bicyclic heteroaryl is unsubstituted or has 1 or 2 R 12 A compound according to any one of Embodiments 1 to 16, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is substituted with a group.

[0098] Embodiment 27.R 2 Each is either unsubstituted or has 1, 2, 3, or 4 R 12 Compounds according to any one of Embodiments 1 to 16, stereoisomers thereof, or pharmaceutically acceptable salts thereof, which are isoquinolinyl, phthalazinyl, sinnolinyl, imidazo[1,2-c]pyrimidinyl, pyrazolo[1,5-a]pyradinyl, benzo[c]isoxazolyl, imidazo[1,2-a]pyradinyl, imidazo[1,2-a]pyridinyl, or naphthilidinyl substituted with a group.

[0099] Embodiment 28.R 2 Each is either unsubstituted or has 1, 2, 3, or 4 R 12A compound according to any one of Embodiments 1 to 16, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is isoquinoline-4-yl, phthalazine-4-yl, cinnoline-4-yl, imidazo[1,2-c]pyrimidine-8-yl, pyrazolo[1,5-a]pyrazine-7-yl, benzo[c]isoxazole-3-yl, imidazo[1,2-a]pyrazine-5-yl, imidazo[1,2-a]pyridine-3-yl, or naphthyridine-4-yl, substituted with a group.

[0100] Embodiment 29.R 2 Each is either unsubstituted or has one or two R 12 Substituted by the base [ka] The compound described in any one of Embodiments 1 to 16, its stereoisomer, or its pharmaceutically acceptable salt.

[0101] Embodiment 30.R 2 is either unsubstituted or has one or two R 12 A compound according to any one of Embodiments 1 to 16, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is an isoquinolinyl substituted with a group.

[0102] Embodiment 31.R 2 is either unsubstituted or has one or two R 12 A compound according to any one of Embodiments 1 to 16, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the isoquinoline-4-yl is substituted with a group.

[0103] Embodiment 32.R 2 is either unsubstituted or has one or two R 12 A compound according to any one of Embodiments 1 to 16, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is 3-(isoquinoline-4-yl) substituted with a group.

[0104] Embodiment 33.R 2The compound described in any one of Embodiments 1 to 16, its stereoisomer, or its pharmaceutically acceptable salt is an unsubstituted isoquinoline-4-yl.

[0105] Embodiment 34.R 2 The compound described in any one of Embodiments 1 to 16, its stereoisomer, or its pharmaceutically acceptable salt is an unsubstituted 3-(isoquinoline-4-yl).

[0106] Embodiment 35.R 2 is either unsubstituted or has one or two R 12 A compound according to any one of Embodiments 1 to 16, a phthalazinyl substituted with a group, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0107] Embodiment 36.R 2 is either unsubstituted or has one or two R 12 A compound according to any one of Embodiments 1 to 16, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein phthalazidine-4-yl is substituted with a group.

[0108] Embodiment 37.R 2 The compound described in any one of Embodiments 1 to 16, its stereoisomer, or its pharmaceutically acceptable salt is unsubstituted phthalazidine-4-yl.

[0109] Embodiment 38.R 2 This has 1, 2, or 3 ring members, which are N, NR 6 A 5- or 6-membered heterocycloalkyl group independently selected from O and S, wherein the 5- or 6-membered heterocycloalkyl group is substituted with 1 or 2 oxos, or the 5- or 6-membered heterocycloalkyl group is unsubstituted, or has 1, 2, 3, or 4 R atoms. 12 A compound according to any one of Embodiments 1 to 16, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is substituted with a group and optionally substituted with one or two oxos.

[0110] Embodiment 39.R2 This has 1, 2, or 3 ring members, which are N, NR 6 A 5- or 6-membered heterocyclyl independently selected from O and S, wherein the 5- or 6-membered heterocyclyl is substituted with 1 or 2 oxos, or the 5- or 6-membered heterocycloalkyl is unsubstituted, or has 1, 2, 3 or 4 R 12 A compound according to any one of Embodiments 1 to 16, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is substituted with a group and optionally substituted with one or two oxos.

[0111] Embodiment 40.R 2 One ring member is NR 6 A six-membered heterocyclyl selected from, wherein the six-membered heterocyclyl is substituted with an oxo, the compound according to any one of Embodiments 1 to 16, its stereoisomer, or a pharmaceutically acceptable salt thereof.

[0112] Embodiment 41.R 2 is either unsubstituted or has 1, 2, 3 or 4 R 12 A compound according to any one of Embodiments 1 to 16, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is a pyridinyl-2(1H)-one substituted with a group.

[0113] Embodiment 42.R 2 Each is either unsubstituted or has 1, 2, 3, or 4 R 12 A compound according to any one of Embodiments 1 to 16, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is pyridine-3-yl-2(1H)-one or pyridine-4-yl-2(1H)-one substituted with a group.

[0114] Embodiment 43.R 2 Each is either unsubstituted or has one or two R 12 Substituted by the base [ka] The compound described in any one of Embodiments 1 to 16, its stereoisomer, or its pharmaceutically acceptable salt.

[0115] Embodiment 44.R 2 This has 1, 2, 3, 4, or 5 ring members, and is N, NR 6 A 9 or 10-membered bicyclic heterocycline independently selected from O and S, wherein the 9 or 10-membered bicyclic heterocycline is substituted with 1 or 2 oxos, or the 9 or 10-membered bicyclic heterocycline is unsubstituted, or has 1, 2, 3 or 4 R 12 A compound according to any one of Embodiments 1 to 16, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is substituted with a group and optionally substituted with one or two oxos.

[0116] Embodiment 45.R 2 In this case, one ring member is N, NR 6 A compound according to any one of Embodiments 1 to 16, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is a 9 or 10-membered bicyclic heterocyclil selected from and O, wherein the 9 or 10-membered bicyclic heterocyclil is unsubstituted or substituted with an oxo.

[0117] Embodiment 46.R 2 Each is either unsubstituted or has 1, 2, 3, or 4 R 12 Compounds according to any one of Embodiments 1 to 16, stereoisomers thereof, or pharmaceutically acceptable salts thereof, wherein the compound is an isochromanil, quinolinyl-2(1H)-one, 3a,7a-dihydro-1H-pyrrolo[2,3-c]pyridinyl, or 3a,7a-dihydro-1H-indazolyl is substituted with a group.

[0118] Embodiment 47.R 2 Each is either unsubstituted or has 1, 2, 3, or 4 R 12A compound according to any one of Embodiments 1 to 16, which is isochroman-4-yl, quinoline-4-yl-2(1H)-one, 3a,7a-dihydro-1H-pyrrolo[2,3-c]pyridine-4-yl, or 3a,7a-dihydro-1H-indazole-4-yl, substituted with a group, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0119] Embodiment 48.R 2 Each is either unsubstituted or has one or two R 12 Substituted by the base [ka] The compound described in any one of Embodiments 1 to 16, its stereoisomer, or its pharmaceutically acceptable salt.

[0120] Embodiment 49.R 2 Each is either unsubstituted or has one or two R 12 A compound according to any one of Embodiments 1 to 16, which is isoquinolinyl, isochromanil, pyridyl, phthalazinyl, sinnolinyl, imidazo[1,2-c]pyrimidinyl, pyrazolo[1,5-a]pyradinyl, 3a,7a-dihydro-1H-pyrrolo[2,3-c]pyridinyl, benzo[c]isoxazolyl, imidazo[1,2-a]pyradinyl, pyridinyl-2(1H)-one, quinolinyl-2(1H)-one, imidazo[1,2-a]pyridinyl, naphthilidinyl, or 3a,7a-dihydro-1H-indazolyl, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0121] Embodiment 50.R 2 Each is either unsubstituted or has one or two R 12 Substituted by the base [ka] The compound described in any one of Embodiments 1 to 16, its stereoisomer, or its pharmaceutically acceptable salt.

[0122] Embodiment 51.R 2 This is a six-membered heteroaryl having a bond site in a carbon atom ring member and having an N heteroatom as a ring member located at the beta (β) position relative to the bond site, the six-membered heteroaryl having 0, 1 or 2 additional N heteroatoms as ring members, and the six-membered heteroaryl is unsubstituted or has 1, 2, 3 or 4 R 12 A compound according to any one of Embodiments 1 to 16, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is substituted with a group.

[0123] Embodiment 52.R 2 This is a 10-membered bicyclic heteroaryl having a bond site in a carbon atom ring member and a N heteroatom located at the beta (β) position relative to the bond site, the 10-membered bicyclic heteroaryl having 0, 1, 2, or 3 additional N heteroatoms as ring members, and the 10-membered bicyclic heteroaryl is unsubstituted or has 1, 2, 3, or 4 R 12 A compound according to any one of Embodiments 1 to 16, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is substituted with a group.

[0124] Embodiment 53.R 2 This is a 10-membered bicyclic heteroaryl having a bond site in a carbon atom ring member and having an N heteroatom as a ring member located at the beta (β) position relative to the bond site, the 10-membered bicyclic heteroaryl further having 0, 1, 2, 3 or 4 ring members independently selected from N, O and S, and the 10-membered bicyclic heteroaryl is unsubstituted or has 1, 2, 3 or 4 R 12 A compound according to any one of Embodiments 1 to 16, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is substituted with a group.

[0125] Embodiment 54.R 2This is a nine-membered bicyclic heteroaryl having a bond site in a carbon atom ring member and having an N heteroatom as a ring member located at the beta (β) position relative to the bond site, and the nine-membered bicyclic heteroaryl has 0, 1, 2, 3 or 4 additional N heteroatoms as ring members, and the nine-membered bicyclic heteroaryl is unsubstituted or has 1, 2, 3 or 4 R 12 A compound according to any one of Embodiments 1 to 16, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is substituted with a group.

[0126] Embodiment 55.R 2 This is a 9-membered bicyclic heteroaryl having a bond site in the carbon atom ring member and a N heteroatom located at the beta (β) position relative to the bond site, and the 9-membered bicyclic heteroaryl is N,NR 6 The 9-membered bicyclic heteroaryl further has 0, 1, 2, 3, or 4 ring members independently selected from O and S, and the 9-membered bicyclic heteroaryl is unsubstituted or has 1, 2, 3, or 4 R 12 A compound according to any one of Embodiments 1 to 16, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is substituted with a group.

[0127] Embodiment 56.R 2 NR is defined as a ring member having a bond point in a carbon atom ring member and located at the beta (β) position relative to the bond point. 6 A 5 or 6-membered heterocycloalkyl having N,NR 6 The heterocycloalkyl group further has 0, 1, or 2 ring members independently selected from O and S, and the 5 or 6-membered heterocycloalkyl group is substituted with 1 or 2 oxos, or the 5 or 6-membered heterocycloalkyl group is unsubstituted, or has 1, 2, 3, or 4 R 12 A compound according to any one of Embodiments 1 to 16, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is substituted with a group and optionally substituted with one or two oxos.

[0128] Embodiment 57.R 2NR is defined as a ring member having a bond point in a carbon atom ring member and located at the beta (β) position relative to the bond point. 6 A 5 or 6-membered heterocyclyl having N, NR 6 The heterocyclyl further has 0, 1, or 2 ring members independently selected from O and S, and the 5 or 6-membered heterocyclyl is substituted with 1 or 2 oxos, or the 5 or 6-membered heterocyclyl is unsubstituted, or has 1, 2, 3, or 4 R 12 A compound according to any one of Embodiments 1 to 16, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is substituted with a group and optionally substituted with one or two oxos.

[0129] Embodiment 58.R 2 NR is defined as a ring member having a bond point in a carbon atom ring member and located at the beta (β) position relative to the bond point. 6 A 9 or 10-membered bicyclic heterocyclyl having N, NR 6 The heterocyclyl further has 0, 1, 2, 3, or 4 ring members independently selected from O and S, and the 9 or 10-membered heterocyclyl is substituted with 1 or 2 oxos, or the 9 or 10-membered heterocyclyl is unsubstituted, or 1, 2, 3, or 4 R 12 A compound according to any one of Embodiments 1 to 16, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is substituted with a group and optionally substituted with one or two oxos.

[0130] Embodiment 59.R 2 This is a 9 or 10-membered bicyclic heterocycline having a bond site in a carbon atom ring member and an O heteroatom located at the beta (β) position relative to the bond site, and the 9 or 10-membered heterocycline is N, NR 6 The heterocyclyl further has 0, 1, 2, 3, or 4 ring members independently selected from O and S, and the 9 or 10-membered heterocyclyl is substituted with 1 or 2 oxos, or the 9 or 10-membered heterocyclyl is unsubstituted, or 1, 2, 3, or 4 R12 A compound according to any one of Embodiments 1 to 16, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is substituted with a group and optionally substituted with one or two oxos.

[0131] Embodiment 60.R 2 This is a six-membered heterocyclyl having a bond site in the carbon atom ring member, being substituted with an oxo, and having a carbon atom as the ring member located at the beta (β) position relative to the bond site, and the six-membered heterocyclyl is N, NR 6 The 6-membered heterocyclyl further has one or two ring members independently selected from O and S, and the 6-membered heterocyclyl is unsubstituted or has 1, 2, 3 or 4 R 12 A compound according to any one of Embodiments 1 to 16, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is substituted with a group and optionally substituted with an oxo group.

[0132] Embodiment 61.R 2 This is a 10-membered bicyclic heterocycline having a bond site in the carbon atom ring member, being substituted with an oxo, and having a carbon atom as a ring member located at the beta (β) position relative to the bond site, and the 10-membered heterocycline is N, NR 6 The 10-membered heterocyclyl further has 1, 2, 3, or 4 ring members independently selected from O and S, and the 10-membered heterocyclyl is unsubstituted, or the 10-membered heterocyclyl has 1, 2, 3, or 4 R 12 A compound according to any one of Embodiments 1 to 16, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is substituted with a group and optionally substituted with an additional oxo.

[0133] Embodiment 62. Each R 12 is -C(=O)N(R 7 )2, -C(=O)OH, -N(R 7 )2, -CN, -OH, [ka] , Halo and 1, 2, 3 or 4 ring members are N, NR 6 A compound according to any one of Embodiments 1 to 61, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, independently selected from the group consisting of O and 4 to 6 member heterocycloalkyls independently selected from C1 to C6 alkyls that are either unsubstituted or substituted with NH2, CN, or OH, wherein the heterocycloalkyl is either unsubstituted or substituted with one or two substituents independently selected from the group consisting of OH.

[0134] Embodiment 63. Each R 12 is -C(=O)N(R 7 )2, -C(=O)OH, -N(R 7 )2, -CN, -OH, [ka] , a compound according to any one of Embodiments 1 to 61, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, independently selected from the group consisting of unsubstituted C1-C6 alkyl and halo compounds.

[0135] Embodiment 64. Each R 12 is -C(=O)N(R 7 )2, -C(=O)OH, -CN, -S(=O)2R 7 A compound according to any one of Embodiments 1 to 61, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, independently selected from the group consisting of OH-substituted C1 to C6 alkyl groups.

[0136] Embodiment 65. Each R 12 This refers to a compound described in any one of Embodiments 1 to 61, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, independently selected from the group consisting of -C(=O)NH2, -C(=O)NH(CH2)2OCH3, -C(=O)OH, -CN, -S(=O)2CH3, and -C(CH3)2OH.

[0137] Embodiment 66. Each R 12 is -S(=O)2R 6-S(=O)2N(R 7 )2, Phenyl, C3-C8 cycloalkyl, 1, 2, 3 or 4 ring members are N, NR 6 A compound according to any one of Embodiments 1 to 61, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is independently selected from a 4-6 member heterocycloalkyl group independently selected from O and S, and one, two, or three ring members are independently selected from a 5 or 6 member heteroaryl group independently selected from N, O, and S, and the phenyl, heterocycloalkyl, and heteroaryl groups are either unsubstituted or substituted with one or two substituents independently selected from the group consisting of OH.

[0138] Embodiment 67.R 1 Each is either unsubstituted or has 1 to 4 R 5 A compound according to any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a phenyl or pyridyl substituted with a group.

[0139] Embodiment 68.R 1 This is phenyl or one or two ring members are N, NR 6 A 5- or 6-membered heteroaryl compound independently selected from O and S, wherein the phenyl or heteroaryl is unsubstituted or has 1-2 R 5 A compound, stereoisomer thereof, or pharmaceutically acceptable salt thereof, which is substituted with a group, according to any one of Embodiments 1 to 66.

[0140] Embodiment 69.R 1 Each of these is either unsubstituted or consists of 1-2 R molecules independently selected from Cl, F, CF3, -CHF2, -CH3, -CH(CH3)2, -OCH3, -OCHF2, -OCF3, CN, -SO2CH3, and -C(CH3)2OH. 5 A compound according to any one of Embodiments 1 to 66, which is a phenyl, pyridyl, pyridadinyl, pyrimidinyl, or pyrazinyl group substituted with a group, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0141] Embodiment 70.R1 Each of these is either unsubstituted or consists of 1-2 R molecules independently selected from Cl, F, CF3, -CHF2, -CH3, -CH(CH3)2, -OCH3, -OCHF2, -OCF3, CN, -SO2CH3, and -C(CH3)2OH. 5 A compound according to any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a phenyl or pyridyl substituted with a group.

[0142] Embodiment 71.R 1 It is either unsubstituted or contains 1-2 R independently selected from Cl, F, CF3, -CHF2, -CH3, -CH(CH3)2, -OCH3, -OCHF2, -OCF3, CN, -SO2CH3 and -C(CH3)2OH. 5 A compound according to any one of Embodiments 1 to 66, a pyridyl substituted with a group, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0143] Embodiment 72.R 1 The compound according to any one of Embodiments 1 to 66, its stereoisomer, or its pharmaceutically acceptable salt, wherein the pyridyl is either unsubstituted or substituted with CF3.

[0144] Embodiment 73.R 1 The compound described in any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a pyridyl substituted with CF3.

[0145] Embodiment 74.R 1 Each of these is either unsubstituted or consists of 1-2 R molecules independently selected from Cl, F, CF3, -CHF2, -CH3, -CH(CH3)2, -OCH3, -OCHF2, -OCF3, CN, -SO2CH3, and -C(CH3)2OH. 5 A compound according to any one of Embodiments 1 to 66, a pyrazolyl or imidazolyl substituted with a group, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0146] Embodiment 75.R 1Each of these is either unsubstituted or consists of 1-2 R molecules independently selected from the group consisting of Cl, -CH, and -CH3(CH3)2. 5 A compound according to any one of Embodiments 1 to 66, a pyrazolyl or imidazolyl substituted with a group, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0147] Embodiment 76.R 1 is either unsubstituted or has 1 to 4 R 5 A compound according to any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the phenyl is substituted with a group.

[0148] Embodiment 77.R 1 is either unsubstituted or has 1-2 R 5 A compound according to any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the phenyl is substituted with a group.

[0149] Embodiment 78.R 1 Each of these is either unsubstituted or one or two R atoms independently selected from C1-C6 alkyl groups substituted with -CN, -OH, -S(=O)2C1-C6 alkyl, C1-C6 alkyl, C1-C6 haloalkyl, halo, C1-C6 haloalkoxy, C1-C6 alkoxy, C3-C8 cycloalkyl, and OH. 5 A compound according to any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the phenyl is substituted with a group.

[0150] Embodiment 79.R 1 Each of these is either unsubstituted or consists of 1-2 R molecules independently selected from Cl, F, -CF3, -OCF3, -CH3, -OCH3, -CN, -CHF2, -OCHF2, -SO2CH3, -CH(CH3)2, and -C(CH3)2OH. 5 A compound according to any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the phenyl is substituted with a group.

[0151] Embodiment 80.R 1 Each of these is either unsubstituted or consists of 1-2 R molecules independently selected from Cl, F, -CF3, -OCF3, -CH3, -OCH3, -CN, -CHF2, -OCHF2, -SO2CH3, and -C(CH3)2OH. 5 A compound according to any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the phenyl is substituted with a group.

[0152] Embodiment 81.R 1 teeth, [ka] A compound according to any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0153] Embodiment 82.R 1 is either unsubstituted or has 1 to 4 R 5 A compound according to any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is a spirobonded C3-C8 cycloalkyl group substituted with a group.

[0154] Embodiment 83.R 1 is either unsubstituted or has 1 to 4 R 5 A compound according to any one of Embodiments 1 to 66, which is a bicyclic C3-C8 cycloalkyl group substituted with a group, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0155] Embodiment 84.R 1 is either unsubstituted or has 1-2 R 5 A compound according to any one of Embodiments 1 to 66, which is a bicyclic C3-C8 cycloalkyl group substituted with a group, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0156] Embodiment 85.R 1 is either unsubstituted or has 1-2 R 5 It is a bicyclic C3-C8 cycloalkyl group substituted with a group, and each R5 This refers to a compound according to any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, independently selected from the group consisting of halo, C1-C6 haloalkyl, and unsubstituted C1-C6 alkyl.

[0157] Embodiment 86.R 1 Each is either unsubstituted or has 1-2 R 5 (Bicyclo[1.1.1]pentan-1-yl) substituted with a group, (spiro[3.3]heptan-2-yl) or (spiro[2.3]hexane-5-yl), and each R 5 This refers to a compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, independently selected from the group consisting of F, -CF3, and -CH3, according to any one of Embodiments 1 to 66.

[0158] Embodiment 87.R 1 is either unsubstituted or has 1 to 4 R 5 A compound according to any one of Embodiments 1 to 66, a C3-C8 cycloalkyl group substituted with a group, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0159] Embodiment 88.R 1 is either unsubstituted or has 1-2 R 5 A compound according to any one of Embodiments 1 to 66, a C3-C8 cycloalkyl group substituted with a group, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0160] Embodiment 89.R 1 is either unsubstituted or has 1-2 R 5 It is a C3-C8 cycloalkyl group substituted with a group, and each R 5 This refers to a compound according to any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, independently selected from the group consisting of halo, OH, C1-C6 haloalkyl, unsubstituted C1-C6 alkyl, and unsubstituted C3-C8 cycloalkyl.

[0161] Embodiment 90.R 1Each is either unsubstituted or has 1-2 R 5 Cyclobutyl, cyclopentyl, or cyclohexyl substituted with a group, each R 5 This refers to a compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, independently selected from the group consisting of F, -CF3, -CH3, -CH(CH3)2, and cyclopropyl, as described in any one of Embodiments 1 to 66.

[0162] Embodiment 91.R 1 Each is either unsubstituted or has 1-2 R 5 A compound according to any one of Embodiments 1 to 66, which is a C3-C8 cycloalkyl or bicyclic C3-C8 cycloalkyl substituted with a group, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0163] Embodiment 92.R 1 Each is either unsubstituted or has 1-2 R 5 It is a C3-C8 cycloalkyl or bicyclic C3-C8 cycloalkyl substituted with a group, and each R 5 This refers to a compound according to any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, independently selected from the group consisting of halo, OH, C1-C6 haloalkyl, unsubstituted C1-C6 alkyl, and unsubstituted C3-C8 cycloalkyl.

[0164] Embodiment 93.R 1 Each is either unsubstituted or has 1-2 R 5 Cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[1.1.1]pentan-1-yl), (spiro[3.3]heptan-2-yl), or (spiro[2.3]hexane-5-yl) are substituted with a group, and each R 5 This refers to a compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, independently selected from the group consisting of F, -CF3, -CH3, -CH(CH3)2, and cyclopropyl, as described in any one of Embodiments 1 to 66.

[0165] Embodiment 94.R 1This has 1, 2, 3, or 4 ring members, which are N, NR 6 , a 5 or 6-membered heteroaryl independently selected from O and S, wherein the 5 or 6-membered heteroaryl is unsubstituted or has 1 to 4 R 5 A compound, stereoisomer thereof, or pharmaceutically acceptable salt thereof, which is substituted with a group, according to any one of Embodiments 1 to 66.

[0166] Embodiment 95.R 1 This is where 1 or 2 ring members are N, NR 6 , a 5 or 6-membered heteroaryl independently selected from O and S, wherein the 5 or 6-membered heteroaryl is unsubstituted or has 1 to 4 R 5 A compound, stereoisomer thereof, or pharmaceutically acceptable salt thereof, which is substituted with a group, according to any one of Embodiments 1 to 66.

[0167] Embodiment 96.R 1 This is where 1 or 2 ring members are N, NR 6 , a 5 or 6-membered heteroaryl selected independently from O and S, wherein the 5 or 6-membered heteroaryl is unsubstituted or has 1-2 R 5 A compound, stereoisomer thereof, or pharmaceutically acceptable salt thereof, which is substituted with a group, according to any one of Embodiments 1 to 66.

[0168] Embodiment 97.R 1 In this case, one ring member is N, NR 6 A 5 or 6-membered heteroaryl selected from O and S, wherein the 5 or 6-membered heteroaryl is unsubstituted or has 1 to 4 R 5 A compound, stereoisomer thereof, or pharmaceutically acceptable salt thereof, which is substituted with a group, according to any one of Embodiments 1 to 66.

[0169] Embodiment 98.R 1 Each is either unsubstituted or has 1 to 4 R 5A compound according to any one of Embodiments 1 to 66, which is a pyridyl, pyrazinyl, pyrimidinyl, pyridadinyl, pyrazolyl, pyrrolyl, imidazolyl, thienyl, furyl, thiazolyl, oxazolyl, isoxazolyl, or triazolyl substituted with a group, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0170] Embodiment 99.R 1 teeth, [ka] A compound according to any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0171] Embodiment 100.R 1 Each is either unsubstituted or has 1 to 4 R 5 A compound according to any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is a pyridyl or pyrazolyl substituted with a group.

[0172] Embodiment 101.R 1 teeth, [ka] A compound according to any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0173] Embodiment 102.R 1 The compound is a C1-C6 alkyl compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, as described in any one of Embodiments 1 to 66.

[0174] Embodiment 103.R 1 The compound described in any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, is neopentyl.

[0175] Embodiment 104.R 1The compound described in any one of Embodiments 1 to 66, which is a C5-C6 cycloalkenyl, is a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0176] Embodiment 105.R 1 The compound described in any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, is a C5 cycloalkenyl.

[0177] Embodiment 106.R 1 The compound described in any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is cyclopenta-1-enyl or cyclopenta-1,3-dienyl.

[0178] Embodiment 107.R 1 The compound described in any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, is a C6 cycloalkenyl.

[0179] Embodiment 108.R 1 The compound described in any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein is cyclohexa-1-enyl or cyclohexa-1,3-dienyl.

[0180] Embodiment 109.R 1 is a 5 or 6-membered heterocycline in which 1, 2, or 3 ring members are independently selected from W, Y, and Z, respectively, where W is NR 6 , O, S, S=O or S(=O)², and Y is NR 6 , O, S, S=O or S(=O)², and Z is NR 6 The heterocyclyl is O or S, and has 5 or 6 members, either unsubstituted or with 1, 2, 3 or 4 R 12 A compound according to any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is substituted with a group and optionally substituted with an oxo group.

[0181] Embodiment 110.R 1is a 5 or 6-membered heterocycline, in which 1, 2, or 3 ring members are independently selected from W, Y, and Z, and W is NR 6 , O, S, S=O or S(=O)², and Y is NR 6 , O, S, S=O or S(=O)², and Z is NR 6 The heterocyclyl is O or S, and has 5 or 6 members, which is substituted with oxo, and R 5 A compound, stereoisomer thereof, or pharmaceutically acceptable salt thereof, which is substituted with a group, according to any one of Embodiments 1 to 66.

[0182] Embodiment 111.R 1 is a 5 or 6-membered heterocycline, in which 1, 2, or 3 ring members are independently selected from W, Y, and Z, and W is NR 6 , O, S, S=O or S(=O)², and Y is NR 6 , O, S, S=O or S(=O)², and Z is NR 6 The heterocyclyl is O or S, and has 5 or 6 members, which is substituted with oxo, and R 6 is H or -CH3, and R 5 The compound described in any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, is -CF3.

[0183] Embodiment 112.R 1 The compound described in any one of Embodiments 1 to 66, its stereoisomer, or its pharmaceutically acceptable salt is 1,2-dihydropyridinyl substituted with oxo, -CH3, and -CF3.

[0184] Embodiment 113.R 1 The compound described in any one of Embodiments 1 to 66, is a stereoisomer thereof or a pharmaceutically acceptable salt thereof, wherein the compound is 1,2-dihydropyridinyl, pyridinyl-2(1H)-one, 2,3-dihydro-1H-pyrrolyl, or 1,3-dihydro-2H-pyrrolyl-2-one.

[0185] Embodiment 114.R 1This is a 9 or 10-membered bicyclic heteroaryl in which 1, 2, 3, 4, or 5 ring members are independently selected from N, O, and S, and the 9 or 10-membered bicyclic heteroaryl is unsubstituted or has 1 to 4 R 5 A compound, stereoisomer thereof, or pharmaceutically acceptable salt thereof, which is substituted with a group, according to any one of Embodiments 1 to 66.

[0186] Embodiment 115.R 1 This has 1, 2, 3, 4, or 5 ring members, and is N, NR 6 A 9 or 10-membered bicyclic heterocycline independently selected from O and S, wherein the 9 or 10-membered bicyclic heterocycline is unsubstituted or has 1 to 4 R 5 A compound, stereoisomer thereof, or pharmaceutically acceptable salt thereof, which is substituted with a group, according to any one of Embodiments 1 to 66.

[0187] Embodiment 116.R 1 This has 1, 2, 3, 4, or 5 ring members, and is N, NR 6 A 9 or 10-membered bicyclic heterocycline independently selected from O and S, wherein the 9 or 10-membered bicyclic heterocycline is unsubstituted or has 1-2 R 5 A compound, stereoisomer thereof, or pharmaceutically acceptable salt thereof, which is substituted with a group, according to any one of Embodiments 1 to 66.

[0188] Embodiment 117.R 1 This is where one or two ring members are N and NR 6 A 9 or 10-membered bicyclic heterocycline independently selected from each of the following, wherein the 9 or 10-membered bicyclic heterocycline is unsubstituted or has 1-2 R 5 A compound, stereoisomer thereof, or pharmaceutically acceptable salt thereof, which is substituted with a group, according to any one of Embodiments 1 to 66.

[0189] Embodiment 118.R 1 The compound described in any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is 1H-indazolyl or indazolyl.

[0190] Embodiment 119. R 1 is a 9 or 10-membered bicyclic heterocyclyl, wherein one ring member is selected from N, NR 6 , O and S, and the 9 or 10-membered bicyclic heterocyclyl is unsubstituted or substituted with 1 to 2 R 5 groups, the compound according to any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0191] Embodiment 120. R 1 is a 9 or 10-membered bicyclic heterocyclyl, wherein one ring member is selected from NR 6 , and the 9 or 10-membered bicyclic heterocyclyl is unsubstituted or substituted with 1 to 2 R 5 groups, the compound according to any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0192] Embodiment 121. R 1 is a 5 or 6-membered heterocycloalkyl, wherein 1, 2, 3 or 4 ring members are each independently selected from N, NR 6 , O and S, and the 5 or 6-membered heterocycloalkyl is optionally substituted with oxo, the compound according to any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0193] Embodiment 122. R 1 is a 4, 5 or 6-membered heterocycloalkyl, wherein 1, 2, 3 or 4 ring members are each independently selected from N, NR 6 , O and S, and the 4, 5 or 6-membered heterocycloalkyl is unsubstituted or substituted with 1 to 4 R 5 groups, the compound according to any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0194] Embodiment 123. R 1 is a heterocyclic group, wherein 1 or 2 ring members are N, NR 6A compound according to any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the 4, 5, or 6-membered heterocycloalkyl is independently selected from O and S, and the 4, 5, or 6-membered heterocycloalkyl is unsubstituted.

[0195] Embodiment 124.R 1 In this case, one ring member is N, NR 6 , a 4 or 5-membered heterocycloalkyl selected from O and S, R 6 The compound described in any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, is -C(=O)CH2OH, -(CH2)2OH, -(CH2)2CF3, -CH2CF3, -C(=O)CH3, -SO2CH3, -SO2CF3, -SO2-cyclopropyl, or cyclopropyl.

[0196] Embodiment 125.R 1 The compound described in any one of Embodiments 1 to 66, its stereoisomer, or its pharmaceutically acceptable salt, wherein each of the three groups is an azetidinyl or pyrrolidinyl substituted with a group selected from -C(=O)CH2OH, -(CH2)2OH, -(CH2)2CF3, -CH2CF3, -C(=O)CH3, -SO2CH3, -SO2CF3, -SO2-cyclopropyl, and cyclopropyl, respectively.

[0197] Embodiment 126.R 1 The compound described in any one of Embodiments 1 to 66, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof is pyrrolidinyl-2-one.

[0198] Embodiment 127.R 1 This is a 9 or 10-membered bicyclic heteroaryl in which 1, 2, 3, 4, or 5 ring members are independently selected from N, O, and S, and the 9 or 10-membered bicyclic heteroaryl is unsubstituted or has 1 to 4 R 5 A compound, stereoisomer thereof, or pharmaceutically acceptable salt thereof, which is substituted with a group, according to any one of Embodiments 1 to 66.

[0199] Embodiment 128. Each R 5 , NR 6 The C(=O)C2-C6 alkenyl, -SF5, unsubstituted C1-C6 alkyl, C1-C6 haloalkyl, halo, C1-C6 haloalkoxy, C1-C6 alkoxy, and C3-C8 cycloalkyl groups are independently selected from the group consisting of C(=O)C2-C6 alkenyl, -SF5, unsubstituted C1-C6 alkyl, C1-C6 haloalkyl, halo, C1-C6 haloalkoxy, C1-C6 alkoxy, and C3-C8 cycloalkyl groups are either unsubstituted or have 1, 2, 3, or 4 R groups. 9 A compound according to any one of Embodiments 1 to 127, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is substituted by .

[0200] Embodiment 129. Each R 5 , NR 6 Independently selected from the group consisting of C(=O)C2~C6 alkenyl, -SF5, unsubstituted C1~C6 alkyl, C1~C6 haloalkyl, halo, C1~C6 haloalkoxy, C1~C6 alkoxy, and C3~C8 cycloalkyl, wherein the cycloalkyl is either unsubstituted or has one R 9 A compound according to any one of Embodiments 1 to 127, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is substituted by .

[0201] Embodiment 130. Each R 5 , NR 6 A C(=O)C2-C6 alkenyl, -SF5, unsubstituted C1-C6 alkyl, C1-C6 haloalkyl, halo, C1-C6 haloalkoxy, C1-C6 alkoxy, and C3-C8 cycloalkyl group is independently selected from the group consisting of C(=O)C2-C6 alkenyl, -SF5, unsubstituted C1-C6 alkyl, C1-C6 haloalkyl, halo, C1-C6 haloalkoxy, C1-C6 alkoxy, and C3-C8 cycloalkyl groups are either unsubstituted or have one or two R groups. 9 A compound according to any one of Embodiments 1 to 127, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is substituted by .

[0202] Embodiment 131. Each R 5 -OH, -NR 7 R 8 -C(=O)N(R 7 ) 2, 1, 2, 3 or 4 ring members are N, NR 6A heterocycloalkyl group independently selected from the group consisting of a 4-6 member heterocycloalkyl group independently selected from O and S, a 5- or 6 member heteroaryl group in which 1, 2, or 3 ring members are independently selected from N, O, and S, and a C1-C6 alkyl group substituted with CN, NH2, or OH, wherein the heterocycloalkyl group is either unsubstituted or has 1, 2, 3, or 4 R groups. 9 A compound according to any one of Embodiments 1 to 127, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, substituted with a group.

[0203] Embodiment 132. Each R 5 -OH, -NR 7 R 8 -C(=O)N(R 7 ) 2, 1, 2, 3 or 4 ring members are N, NR 6 A heterocycloalkyl group is independently selected from the group consisting of a 4-6 member heterocycloalkyl group independently selected from O and S, a 5 or 6 member heteroaryl group in which 1, 2, or 3 ring members are independently selected from N, O, and S, and a C1-C6 alkyl group substituted with CN, NH2, or OH, wherein the heterocycloalkyl group is either unsubstituted or has 1 or 2 R groups. 9 A compound according to any one of Embodiments 1 to 127, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, substituted with a group.

[0204] Embodiment 133. Each R 5 This refers to a compound according to any one of Embodiments 1 to 127, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, independently selected from the group consisting of CN, -OH, S(=O)2C1~C6 alkyl, C1~C6 haloalkyl, halo, C1~C6 haloalkoxy, C1~C6 alkoxy, C3~C8 cycloalkyl, and C1~C6 alkyl that is unsubstituted or substituted with OH.

[0205] Embodiment 134. Each R 5The group is independently selected from Cl, F, CF3, -CHF2, -CH3, -CH(CH3)2, -OCH3, -OCHF2, -OCF3, CN, -SO2CH3, and -C(CH3)2OH, and is a compound according to any one of Embodiments 1 to 127, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0206] Embodiment 135.R 5 The compound described in any one of Embodiments 1 to 127, which is a C1-C6 haloalkyl, halo, or C1-C6 haloalkoxy, its stereoisomer, or a pharmaceutically acceptable salt thereof.

[0207] Embodiment 136.R 5 The compound described in any one of Embodiments 1 to 127, its stereoisomer, or its pharmaceutically acceptable salt is -CF3, F, Cl, -OCHF2, or -OCF3.

[0208] Embodiment 137. Each R 5 This refers to a compound according to any one of Embodiments 1 to 127, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, independently selected from the group consisting of halo, OH, C1-C6 haloalkyl, unsubstituted C1-C6 alkyl, and unsubstituted C3-C8 cycloalkyl.

[0209] Embodiment 138. Each R 5 This refers to a compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, independently selected from the group consisting of F, -CF3, -CH3, -CH(CH3)2, and cyclopropyl, as described in any one of Embodiments 1 to 127.

[0210] Embodiment 139. Each R 6 This refers to a compound according to any one of Embodiments 1 to 138, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, independently selected from the group consisting of H and unsubstituted C1 to C6 alkyl groups.

[0211] Embodiment 140. Each R 6These include H, C1-C6 haloalkyl, C1-C6 haloalkoxy, S(=O)2C1-C6 alkyl, S(=O)2C1-C6 haloalkyl, -S(=O)2C3-C6 cycloalkyl, and -C(=O)R 7 A compound according to any one of Embodiments 1 to 138, independently selected from the group consisting of C3-C6 cycloalkyls and C1-C6 alkyls that are unsubstituted or substituted with -OH or C1-C6 haloalkyls, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0212] Embodiment 141. Each R 6 This is a compound described in any one of Embodiments 1 to 138, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, independently selected from the group consisting of H, -CH3, -C(=O)CH2OH, -(CH2)2OH, -(CH2)2CF3, -CH2CF3, -C(=O)CH3, -SO2CH3, -SO2CF3, -SO2-cyclopropyl, or cyclopropyl.

[0213] Embodiment 142.R 3a This is H, -CN, C3-C8 cycloalkyl, with 1, 2, or 3 ring members being N, NR 6 , a 4-7 member heterocycloalkyl group independently selected from O and S, unsubstituted or with one or more R 15 C1-C6 alkyl groups substituted with a group, or unsubstituted, or with one or more R groups. 15 A compound according to any one of Embodiments 1 to 141, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the C2-C6 alkenyl is substituted with a group, and the cycloalkyl and heterocycloalkyl are either unsubstituted, or the cycloalkyl and heterocycloalkyl are substituted with one or two substituents independently selected from the group consisting of CN, -C(=O)OH, NH2, OH, C1-C6 haloalkyl, C1-C6 alkyl, or C1-C6 alkyl substituted with -C(=O)OH, -OH, CN, or NH2.

[0214] Embodiment 143.R 3a H, -CN, 1, 2 or 3 ring members are N, NR6 , a 4-7 member heterocycloalkyl group independently selected from O and S, or one or more R 15 A compound according to any one of Embodiments 1 to 141, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is a C1-C6 alkyl group substituted with a group.

[0215] Embodiment 144.R 3a -CN or one or more R 15 A compound according to any one of Embodiments 1 to 141, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is a C1-C6 alkyl group substituted with a group.

[0216] Embodiment 145.R 3a is a compound according to any one of Embodiments 1 to 141, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein is -CN or -CH3.

[0217] Embodiment 146.R 3a The compound, stereoisomer thereof, or pharmaceutically acceptable salt thereof is -CN.

[0218] Embodiment 147.R 3b This is H, -CN, C3-C8 cycloalkyl, with 1, 2, or 3 ring members being N, NR 6 , a 4-7 member heterocycloalkyl group independently selected from O and S, unsubstituted or with one or more R 15 C1-C6 alkyl groups substituted with a group, or unsubstituted, or with one or more R groups. 15 A compound according to any one of Embodiments 1 to 146, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the C2-C6 alkenyl is substituted with a group, and the cycloalkyl and heterocycloalkyl are either unsubstituted, or the cycloalkyl and heterocycloalkyl are substituted with one or two substituents independently selected from the group consisting of CN, -C(=O)OH, NH2, OH, C1-C6 haloalkyl, C1-C6 alkyl, or C1-C6 alkyl substituted with -C(=O)OH, -OH, CN, or NH2.

[0219] Embodiment 148. R 3b is H, -CN, a 4- to 7-membered heterocycloalkyl in which 1, 2 or 3 ring members are each independently selected from N, NR 6 , O and S, or C1-C6 alkyl which is unsubstituted or substituted with one or more R 15 groups, the compound according to any one of Embodiments 1 to 146, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0220] Embodiment 149. R 3b is H, -CN or C1-C6 alkyl which is unsubstituted or substituted with one or more R 15 groups, the compound according to any one of Embodiments 1 to 146, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0221] Embodiment 150. R 3b is H or unsubstituted C1-C6 alkyl, the compound according to any one of Embodiments 1 to 146, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0222] Embodiment 151. R 3b is H or -CH3, the compound according to any one of Embodiments 1 to 146, or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

[0223] Embodiment 152. R 4a is H, -CN, C3-C8 cycloalkyl, a 4- to 7-membered heterocycloalkyl in which 1, 2 or 3 ring members are each independently selected from N, NR 6 , O and S, C1-C6 alkyl which is unsubstituted or substituted with one or more R 15 groups, or unsubstituted or substituted with one or more R 15A compound according to any one of Embodiments 1 to 151, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the C2-C6 alkenyl is substituted with a group, and the cycloalkyl and heterocycloalkyl are either unsubstituted, or the cycloalkyl and heterocycloalkyl are substituted with one or two substituents independently selected from the group consisting of CN, -C(=O)OH, NH2, OH, C1-C6 haloalkyl, C1-C6 alkyl, or C1-C6 alkyl substituted with -C(=O)OH, -OH, CN, or NH2.

[0224] Embodiment 153.R 4a H, -CN, 1, 2 or 3 ring members are N, NR 6 , a 4-7 member heterocycloalkyl or unsubstituted group independently selected from O and S, or one or more R 15 A compound according to any one of Embodiments 1 to 151, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is a C1-C6 alkyl group substituted with a group.

[0225] Embodiment 154.R 4a is either H, -CN, or unsubstituted, or contains one or more R 15 A compound according to any one of Embodiments 1 to 151, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is a C1-C6 alkyl group substituted with a group.

[0226] Embodiment 155.R 4a The compound described in any one of Embodiments 1 to 151, its stereoisomer, or its pharmaceutically acceptable salt, wherein is H or an unsubstituted C1-C6 alkyl group.

[0227] Embodiment 156.R 4a The compound, stereoisomer thereof, or pharmaceutically acceptable salt thereof, wherein is H or -CH3.

[0228] Embodiment 157.R 4b This is H, -CN, C3-C8 cycloalkyl, with 1, 2, or 3 ring members being N, NR 6, a 4-7 member heterocycloalkyl group independently selected from O and S, unsubstituted or with one or more R 15 C1-C6 alkyl groups substituted with a group, or unsubstituted, or with one or more R groups. 15 A compound according to any one of Embodiments 1 to 156, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the C2-C6 alkenyl is substituted with a group, and the cycloalkyl and heterocycloalkyl are either unsubstituted, or the cycloalkyl and heterocycloalkyl are substituted with one or two substituents independently selected from the group consisting of CN, -C(=O)OH, NH2, OH, C1-C6 haloalkyl, C1-C6 alkyl, or C1-C6 alkyl substituted with -C(=O)OH, -OH, CN, or NH2.

[0229] Embodiment 158.R 4b H, -CN, 1, 2 or 3 ring members are N, NR 6 , a 4-7 member heterocycloalkyl or unsubstituted group independently selected from O and S, or one or more R 15 A compound according to any one of Embodiments 1 to 156, a C1-C6 alkyl group substituted with a group, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0230] Embodiment 159.R 4b is either H, -CN, or unsubstituted, or contains one or more R 15 A compound according to any one of Embodiments 1 to 156, a C1-C6 alkyl group substituted with a group, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0231] Embodiment 160.R 4b The compound described in any one of Embodiments 1 to 156, its stereoisomer, or its pharmaceutically acceptable salt, wherein is H or an unsubstituted C1-C6 alkyl group.

[0232] Embodiment 161.R 4bThe compound, stereoisomer thereof, or pharmaceutically acceptable salt thereof, wherein is H or -CH3.

[0233] Embodiment 162.R 3c This is H, -C(=O)C2~C6 alkenyl or one or more R 15 A compound according to any one of Embodiments 1 to 161, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is a C1-C6 alkyl group substituted with a group.

[0234] Embodiment 163.R 3c This is a -C(=O)C2~C6 alkenyl or one or more R 15 A compound according to any one of Embodiments 1 to 161, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is a C1-C6 alkyl group substituted with a group.

[0235] Embodiment 164.R 3c The compound described in any one of Embodiments 1 to 161, its stereoisomer, or its pharmaceutically acceptable salt is a -C(=O)C2~C6 alkenyl.

[0236] Embodiment 165.R 3c is one or more R 15 A compound according to any one of Embodiments 1 to 161, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is a C1-C6 alkyl group substituted with a group.

[0237] Embodiment 166. Each R 6 H, C1-C6 alkyl, -S(=O)2N(R 7 )2, -C(=O)N(R 7 )2, and a compound according to any one of Embodiments 1 to 165, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, independently selected from the group consisting of C1 to C6 alkyl groups substituted with -OH, CN, or -C(=O)OH.

[0238] Embodiment 167. Each R 6This refers to a compound according to any one of Embodiments 1 to 165, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, independently selected from the group consisting of H and unsubstituted C1 to C6 alkyl groups.

[0239] Embodiment 168. Each R 6 is -S(=O)2N(R 7 )2, -C(=O)N(R 7 )2, and a compound according to any one of Embodiments 1 to 165, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, independently selected from the group consisting of C1 to C6 alkyl groups substituted with -OH, CN, or -C(=O)OH.

[0240] Embodiment 169. Each R 7 The compound, stereoisomer thereof, or pharmaceutically acceptable salt thereof, wherein is H.

[0241] Embodiment 170. Each R 7 The compound described in any one of Embodiments 1 to 168, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is an unsubstituted C1-C6 alkyl group.

[0242] Embodiment 171. Each R 7 The compound described in any one of Embodiments 1 to 168, its stereoisomer, or its pharmaceutically acceptable salt, is independently selected from the group consisting of H and C1 to C6 alkyl groups that are unsubstituted or substituted with OH or C1 to C6 alkoxy groups.

[0243] Embodiment 172. Each R 7 This refers to a compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, independently selected from the group consisting of H, -CH3, and -(CH2)2OCH3, as described in any one of Embodiments 1 to 168.

[0244] Embodiment 173.R 8 The compound, stereoisomer thereof, or pharmaceutically acceptable salt thereof, wherein is H.

[0245] Embodiment 174.R 8 The compound described in any one of Embodiments 1 to 172, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is an unsubstituted C1-C6 alkyl group.

[0246] Embodiment 175.R 8 The C3-C8 cycloalkyl group is either unsubstituted or has 1, 2, 3, or 4 R atoms. 9 A compound according to any one of Embodiments 1 to 172, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, substituted with a group.

[0247] Embodiment 176.R 8 The C3-C8 cycloalkyl group is either unsubstituted or has one or two R groups. 9 A compound according to any one of Embodiments 1 to 172, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, substituted with a group.

[0248] Embodiment 177.R 8 This has 1, 2, 3, or 4 ring members, which are N, NR 6 , a 4-6 member heterocycloalkyl group independently selected from O and S, wherein the heterocycloalkyl group is unsubstituted or has 1, 2, 3, or 4 R groups. 9 A compound according to any one of Embodiments 1 to 172, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, substituted with a group.

[0249] Embodiment 178.R 8 This has 1, 2, 3, or 4 ring members, which are N, NR 6 A 4-6 member heterocycloalkyl group independently selected from O and S, wherein the heterocycloalkyl group is unsubstituted or has 1 or 2 R atoms. 9 A compound according to any one of Embodiments 1 to 172, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, substituted with a group.

[0250] Embodiment 179.R 9 , NR 10R 11 A compound according to any one of Embodiments 1 to 178, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0251] Embodiment 180.R 9 is -C(=O)N(R 7 )2, the compound described in any one of Embodiments 1 to 178, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0252] Embodiment 181.R 9 is -OH or -N(R 7 A compound according to any one of Embodiments 1 to 178, a C1-C6 alkyl substituted with )2, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0253] Embodiment 182.R 10 The compound, stereoisomer thereof, or pharmaceutically acceptable salt thereof, wherein is H.

[0254] Embodiment 183.R 10 The compound described in any one of Embodiments 1 to 181, its stereoisomer, or its pharmaceutically acceptable salt is an unsubstituted C1-C6 alkyl group.

[0255] Embodiment 184.R 11 The compound, stereoisomer thereof, or pharmaceutically acceptable salt thereof, wherein is H.

[0256] Embodiment 185.R 11 The compound described in any one of Embodiments 1 to 183, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is an unsubstituted C1-C6 alkyl group.

[0257] Embodiment 186.R 11 The compound is a -S(=O)2C1~C6 alkyl compound, one of the compounds described in any one of Embodiments 1 to 183, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0258] Embodiment 187.R 13 The compound, stereoisomer thereof, or pharmaceutically acceptable salt thereof, wherein is H.

[0259] Embodiment 188.R 13 is -C(=O)N(R 7 )2, the compound described in any one of Embodiments 1 to 186, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0260] Embodiment 189.R 13 This has 1, 2, 3, or 4 ring members, which are N, NR 6 A compound according to any one of Embodiments 1 to 186, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is a 5 or 6-membered heteroaryl, independently selected from O and S.

[0261] Embodiment 190.R 14 This has 1, 2, 3, or 4 ring members, which are N, NR 6 A 5- or 6-membered heterocycline independently selected from O and S, wherein the 5- or 6-membered heterocycline is unsubstituted or has 1, 2, 3, or 4 R 4 A compound according to any one of Embodiments 1 to 189, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is substituted with and optionally substituted with one or two oxos.

[0262] Embodiment 191.R 14 This has 1, 2, 3, or 4 ring members, which are N, NR 6 A six-membered heterocycline independently selected from O and S, wherein the six-membered heterocycline is either unsubstituted or has 1, 2, 3, or 4 R atoms. 4 A compound according to any one of Embodiments 1 to 189, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is substituted with and optionally substituted with one or two oxos.

[0263] Embodiment 192.R 14 In this case, one ring member is N, NR6 A compound according to any one of Embodiments 1 to 189, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a six-membered heterocyclyl selected from O and S, the six-membered heterocyclyl being substituted with an oxo.

[0264] Embodiment 193.R 14 One ring member is NR 6 A six-membered heterocyclyl selected from, wherein the six-membered heterocyclyl is substituted with an oxo, the compound according to any one of Embodiments 1 to 189, its stereoisomer, or a pharmaceutically acceptable salt thereof.

[0265] Embodiment 194.R 14 This has 1, 2, 3, or 4 ring members, which are N, NR 6 A 5- or 6-membered heteroaryl selected independently from O and S, wherein the 5- or 6-membered heteroaryl is unsubstituted or has 1, 2, 3, or 4 R 4 A compound according to any one of Embodiments 1 to 189, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is substituted with .

[0266] Embodiment 195.R 14 This has 1, 2, 3, or 4 ring members, which are N, NR 6 A 5- or 6-membered heteroaryl selected independently from O and S, wherein the 5- or 6-membered heteroaryl is unsubstituted or has 1 or 2 R 4 A compound according to any one of Embodiments 1 to 189, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is substituted with .

[0267] Embodiment 196. Each R 15 is CN, NH2, -OH, -C(=O)OH, -C(=O)N(R 7 )2, -C(=O)C(=O)OH, C1-C6 alkoxy, halo, C1-C6 haloalkyl, C3-C8 cycloalkyl, 1, 2, 3 or 4 ring members are N, NR 6 , a 5 or 6-membered heteroaryl selected independently from O and S, and 1, 2 or 3 ring members are N, NR6 A compound according to any one of Embodiments 1 to 195, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, independently selected from the group consisting of 3 to 6-membered heterocycloalkyls independently selected from O and S, wherein the cycloalkyl, heteroaryl, and heterocycloalkyl are either unsubstituted or substituted with 1, 2, or 3 substituents independently selected from the group consisting of CN, -C(=O)OH, NH2, OH, and unsubstituted C1 to C6 alkyls.

[0268] Embodiment 197. Each R 15 CN, 1, 2, 3 or 4 ring members are N, NR 6 , a 5 or 6-membered heteroaryl selected independently from O and S, and 1, 2 or 3 ring members are N, NR 6 A compound according to any one of Embodiments 1 to 195, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, independently selected from the group consisting of 3 to 6-membered heterocycloalkyl groups independently selected from O and S.

[0269] Embodiment 198. Each R 15 CN and 1, 2, or 3 ring members are N, NR 6 A compound according to any one of Embodiments 1 to 195, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, independently selected from the group consisting of 3 to 6-membered heterocycloalkyl groups independently selected from O and S.

[0270] Embodiment 199. Each R 15 CN and 1, 2, or 3 ring members are N, NR 6 A compound according to any one of Embodiments 1 to 195, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, independently selected from the group consisting of 3 to 6-membered heterocycloalkyl groups independently selected from O and S.

[0271] Embodiment 200. Each R 15This refers to a compound, stereoisomer thereof, or pharmaceutically acceptable salt thereof, independently selected from the group consisting of CN and oxyranil, as described in any one of Embodiments 1 to 195.

[0272] Embodiment 201.X1 is CR 3a R 3b , C=O or NR 3c And, X2 is CR 4a R 4b Or C=O, R 1 teeth, i) Unsubstituted or with 1 to 4 R 5 Phenyl groups substituted with a group ii) Unsubstituted or with 1 to 4 R 5 Spirobond C3-C8 cycloalkyl groups substituted with a group iii) Unsubstituted or with 1 to 4 R 5 Bicyclic C3-C8 cycloalkyl groups substituted with a group iv) Unsubstituted or with 1 to 4 R 5 C3-C8 cycloalkyl groups substituted with a group v) 1, 2, 3 or 4 ring members are N, NR 6 A 5 or 6-membered heteroaryl, independently selected from O and S, which is unsubstituted or has 1 to 4 R 5 A 5- or 6-membered heteroaryl substituted with a group vi) Unsubstituted C1-C6 alkyl groups, vii) 1, 2, 3, 4 or 5 ring members are N, NR 6 A 9 or 10-membered bicyclic heterocycline independently selected from O and S, which is unsubstituted or has 1 to 4 R 5 A 9 or 10-membered bicyclic heterocycline substituted with a group, and viii) 1, 2, 3 or 4 ring members are N, NR 6 A 5 or 6-membered heterocycloalkyl group independently selected from O and S, which is either unsubstituted or has 1 to 4 R groups. 5A 5- or 6-membered heterocycloalkyl group that is substituted with a group and optionally substituted with an oxo group. Selected from the group consisting of, R 2 teeth, i) A 10-membered bicyclic heteroaryl having a bond site in a carbon atom ring member and a N heteroatom located at the beta (β) position relative to the bond site, wherein the ring member has 0, 1, 2, or 3 additional N heteroatoms, and is unsubstituted or has 1 or 2 R 12 A 10-membered bicyclic heteroaryl substituted with a group ii) A 10-membered bicyclic heteroaryl having a bond site in a carbon atom ring member and a N heteroatom as a ring member located at the beta (β) position relative to the bond site, further comprising 0, 1, 2, 3, or 4 ring members independently selected from N, O, and S, and being unsubstituted or having 1 or 2 R 12 A 10-membered bicyclic heteroaryl substituted with a group, and iii) 1, 2, 3, 4 or 5 ring members are N, NR 6 A 9 or 10-membered bicyclic heteroaryl, independently selected from O and S, which is unsubstituted or has 1 or 2 R 12 9 or 10-membered bicyclic heteroaryls substituted with a specific group Selected from the group consisting of, R 3a -CN or one or more R 15 These are C1-C6 alkyl groups substituted with a group. R 3b is H or an unsubstituted C1-C6 alkyl group. R 4a is H or an unsubstituted C1-C6 alkyl group. R 4b H is, R 3c This is H, -C(=O)C2~C6 alkenyl or one or more R 15 These are C1-C6 alkyl groups substituted with a group. Each R 5These are independently selected from the group consisting of unsubstituted C1-C6 alkyl, C1-C6 haloalkyl, and halo, and Each R 6 This is a compound of Embodiment 1, its stereoisomer, or a pharmaceutically acceptable salt thereof, independently selected from the group consisting of H and unsubstituted C1-C6 alkyl groups.

[0273] Embodiment 202.X1 is CR 3a R 3b , C=O or NR 3c And, X2 is CR 4a R 4b Or C=O, R 1 Each is either unsubstituted or has 1 to 4 R 5 It is a phenyl or pyridyl substituted with a group, R 2 teeth, i) A 10-membered bicyclic heteroaryl having a bond site in a carbon atom ring member and a N heteroatom located at the beta (β) position relative to the bond site, wherein the ring member has 0, 1, 2, or 3 additional N heteroatoms, and is unsubstituted or has 1 R 12 A 10-membered bicyclic heteroaryl substituted with a group, and ii) A 9 or 10-membered bicyclic heteroaryl in which 1, 2, 3, 4, or 5 ring members are independently selected from N, and which is unsubstituted or has 1 R 12 9 or 10-membered bicyclic heteroaryls substituted with a specific group Selected from the group consisting of, R 3a is -CN, R 3b H is, R 4a H is H, and R 4b The compound of Embodiment 1, its stereoisomer, or its pharmaceutically acceptable salt is H.

[0274] Embodiment 203.R 1 Each is either unsubstituted or has 1 to 4 R5 It is a phenyl or pyridyl substituted with a group, R 2 teeth, i) A 10-membered bicyclic heteroaryl having a bond site in a carbon atom ring member and a N heteroatom located at the beta (β) position relative to the bond site, wherein the ring member has 0, 1, 2, or 3 additional N heteroatoms, and is unsubstituted or has 1 R 12 A 10-membered bicyclic heteroaryl substituted with a group, and ii) A 9 or 10-membered bicyclic heteroaryl in which 1, 2, 3, 4, or 5 ring members are independently selected from N, and which is unsubstituted or has 1 R 12 9 or 10-membered bicyclic heteroaryls substituted with a specific group Selected from the group consisting of, R 3a is -CN, R 3b H is, R 4a H is H, and R 4b The compound of Embodiment 16, its stereoisomer, or its pharmaceutically acceptable salt is H.

[0275] Embodiment 204.R 1 Each is either unsubstituted or one R 5 It is a phenyl or pyridyl substituted with a group, R 2 teeth, i) A 10-membered bicyclic heteroaryl having a bond site in a carbon atom ring member and a N heteroatom located at the beta (β) position relative to the bond site, wherein the ring member has 0, 1, 2, or 3 additional N heteroatoms, and is unsubstituted or has 1 R 12 A 10-membered bicyclic heteroaryl substituted with a group, and ii) A 9 or 10-membered bicyclic heteroaryl in which 1, 2, 3, 4, or 5 ring members are independently selected from N, and which is unsubstituted or has 1 R 12 9 or 10-membered bicyclic heteroaryls substituted with a specific group Selected from the group consisting of, R 3a is -CN, R 3b H is, R 4a H is, R 4b H is H, and R 5 The compound of Embodiment 16, its stereoisomer, or its pharmaceutically acceptable salt is a C1-C6 haloalkyl, halo, or C1-C6 haloalkoxy.

[0276] Embodiment 205.R 1 This is pyridine-3-yl substituted with -CF3, R 2 is the unsubstituted 3-(isoquinoline-4-yl), and R 3a The compound of Embodiment 16, its stereoisomer, or its pharmaceutically acceptable salt is -CN.

[0277] Embodiment 206. 3-(isoquinoline-4-yl)-2-oxo-1-phenylimidazolidined-4-carbonitrile, 1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidined-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridine-2-yl)imidazolidined-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethyl)phenyl)imidazolidined-4-carbonitrile, 1-(4-chlorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidined-4-carbonitrile, 1-(4-fluorophenyl)-3-(isoquino Compounds of Embodiment 1, stereoisomers thereof, or pharmaceutically acceptable salts thereof, selected from phosphorus-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(5-fluoropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-3-yl)imidazolidine-4-carbonitrile and 1-(5-chloropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile.

[0278] Embodiment 207.3-(isoquinoline-4-yl)-2-oxo-1-phenylimidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-phenylimidazolidin-4-carbonnitrile, (S)-3-(isoquinoline-4-yl)-2-oxo-1-phenylimidazolidin-4-carbonnitrile, 1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridine-2-yl)imidazolidined-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridine-2-yl)imidazolidined-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridine-2-yl)imidazolidined-4-carbonil, 3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethyl)phenyl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethyl)phenyl)imidazolidined-4-carbonitrile, (S)-3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethyl)phenyl)imidazolidined-4-carbonitrile, 1-(4-chlorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-chlorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonnitrile, (S)-1-(4-chlorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonnitrile, 1-(4-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-(4-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-(3-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(5-fluoropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(5-fluoropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-1-(5-fluoropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-3-yl)imidazolidined-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-3-yl)imidazolidined-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-3-yl)imidazolidined-4-carbonilicate, 1-(5-chloropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(5-chloropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, and (S)-1-(5-chloropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonil A compound of Embodiment 1, its stereoisomer, or a pharmaceutically acceptable salt thereof, selected from the above.

[0279] Embodiment 208.3-(isoquinoline-4-yl)-2-oxo-1-phenylimidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-phenylimidazolidin-4-carbonnitrile, (S)-3-(isoquinoline-4-yl)-2-oxo-1-phenylimidazolidin-4-carbonnitrile, 1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridine-2-yl)imidazolidined-4-carbonilicate, 3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethyl)phenyl)imidazolidin-4-carbonitrile, 1-(4-chlorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(4-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(5-fluoropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-3-yl)imidazolidined-4-carbonilicate, 1-(5-chloropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-3-yl)imidazolidined-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-3-yl)imidazolidined-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(2-methoxy-4-(trifluoromethyl)phenyl)-2-oxoimidazolidine-4-carbonitrile (R)-3-(isoquinoline-4-yl)-1-(2-methoxy-4-(trifluoromethyl)phenyl)-2-oxoimidazolidine-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-1-(2-methoxy-4-(trifluoromethyl)phenyl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridazine-4-yl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridazine-4-yl)imidazolidined-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridazine-4-yl)imidazolidined-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(5-methoxy-2-(trifluoromethyl)pyridine-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(5-methoxy-2-(trifluoromethyl)pyridine-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-1-(5-methoxy-2-(trifluoromethyl)pyridine-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(5-cyano-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-cyano-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonnitrile, (S)-1-(5-cyano-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonnitrile, 1-(5-chloropyrimidine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(5-chloropyrimidine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-1-(5-chloropyrimidine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(2-methoxy-5-(trifluoromethyl)phenyl)-2-oxoimidazolidine-4-carbonitrile (R)-3-(isoquinoline-4-yl)-1-(2-methoxy-5-(trifluoromethyl)phenyl)-2-oxoimidazolidine-4-carbonitrile, (S)-3-(isoquinoline-4-yl)-1-(2-methoxy-5-(trifluoromethyl)phenyl)-2-oxoimidazolidine-4-carbonilicate, 5-(4-cyano-3-(isoquinoline-4-yl)-2-oxoimidazolidine-1-yl)-2-(trifluoromethyl)isonicotinonitrile, (R)-5-(4-cyano-3-(isoquinoline-4-yl)-2-oxoimidazolidine-1-yl)-2-(trifluoromethyl)isonicotinonitrile, (S)-5-(4-cyano-3-(isoquinoline-4-yl)-2-oxoimidazolidine-1-yl)-2-(trifluoromethyl)isonicotinonitrile, 1-(4-cyano-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-cyano-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitri (S)-1-(4-cyano-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonnitrile, 1-(5-chloro-2-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-chloro-2-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-(5-chloro-2-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(5-fluoro-2-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-fluoro-2-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-(5-fluoro-2-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3-(difluoromethyl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-(difluoromethyl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-1-(3-(difluoromethyl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(2-methoxypyridine-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(2-methoxypyridine-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-1-(2-methoxypyridine-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(2-methyl-5-(trifluoromethyl)phenyl)-2-oxoimidazolidine-4-carbonitrile (R)-3-(isoquinoline-4-yl)-1-(2-methyl-5-(trifluoromethyl)phenyl)-2-oxoimidazolidine-4-carbonitrile, (S)-3-(isoquinoline-4-yl)-1-(2-methyl-5-(trifluoromethyl)phenyl)-2-oxoimidazolidine-4-carbonitrile, 1-((R)-1-(2-hydroxyacetyl)pyrrolidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((R)-1-(2-hydroxyacetyl)pyrrolidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-((R)-1-(2-hydroxyacetyl)pyrrolidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-((R)-1-(3,3,3-trifluoropropyl)pyrrolidine-3-yl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-((R)-1-(3,3,3-trifluoropropyl)pyrrolidine-3-yl)imidazolidined-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-2-oxo-1-((R)-1-(3,3,3-trifluoropropyl)pyrrolidine-3-yl)imidazolidined-4-carbonilicate, 1-(3,3-difluorocyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3-hydroxy-3-(trifluoromethyl)cyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3,3-difluorocyclohexyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridazine-3-yl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridazine-3-yl)imidazolidined-4-carbonitrile, (S)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridazine-3-yl)imidazolidined-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(5-methoxy-2-(trifluoromethyl)pyrimidine-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(5-methoxy-2-(trifluoromethyl)pyrimidine-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-1-(5-methoxy-2-(trifluoromethyl)pyrimidine-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyrazine-2-yl)imidazolidined-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyrazine-2-yl)imidazolidined-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyrazine-2-yl)imidazolidined-4-carbonilicate, 4-(3-(3-chlorophenyl)-5-cyano-2-oxoimidazolidine-1-yl)isoquinoline-6-carboxylic acid, (R)-4-(3-(3-chlorophenyl)-5-cyano-2-oxoimidazolidine-1-yl)isoquinoline-6-carboxylic acid, (S)-4-(3-(3-chlorophenyl)-5-cyano-2-oxoimidazolidine-1-yl)isoquinoline-6-carboxylic acid, 1-(3-chlorophenyl)-3-(6-(2-hydroxypropane-2-yl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 4-(3-(3-chlorophenyl)-5-cyano-2-oxoimidazolidine-1-yl)isoquinoline-6-carboxamide, 4-(3-(3-chlorophenyl)-5-cyano-2-oxoimidazolidine-1-yl)-N-(2-methoxyethyl)isoquinoline-6-carboxamide, 1-(3-chlorophenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-chlorophenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-1-(3-chlorophenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(2-Methoxy-5-(trifluoromethyl)phenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(2-Methoxy-5-(trifluoromethyl)phenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-(2-Methoxy-5-(trifluoromethyl)phenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 4-(3-(3-chlorophenyl)-5-cyano-2-oxoimidazolidine-1-yl)isoquinoline-6-carbonitrile, (R)-4-(3-(3-chlorophenyl)-5-cyano-2-oxoimidazolidine-1-yl)isoquinoline-6-carbonitrile, (S)-4-(3-(3-chlorophenyl)-5-cyano-2-oxoimidazolidine-1-yl)isoquinoline-6-carbonitrile, 1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-4-methyl-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-4-methyl-2-oxoimidazolidine-4-carbonitrile, (S)-1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-4-methyl-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-chloropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-1-(5-chloropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyrimidine-2-yl)imidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyrimidine-2-yl)imidazolidined-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyrimidine-2-yl)imidazolidined-4-carbonilicate, (5S)-1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-5-methyl-2-oxoimidazolidine-4-carbonil, (4R,5S)-1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-5-methyl-2-oxoimidazolidine-4-carbonilicate, (4S,5S)-1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-5-methyl-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(2-methylpyridine-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(2-methylpyridine-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-1-(2-methylpyridine-4-yl)-2-oxoimidazolidine-4-carbonil, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(3-(trifluoromethyl)cyclobutyl)imidazolidin-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-((1r,3R)-3-(trifluoromethyl)cyclobutyl)imidazolidin-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-((1s,3S)-3-(trifluoromethyl)cyclobutyl)imidazolidin-4-carbonilicate, 1-((R)-1-(2-hydroxyethyl)pyrrolidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((R)-1-(2-hydroxyethyl)pyrrolidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-1-((R)-1-(2-hydroxyethyl)pyrrolidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(3-methoxy-6-(trifluoromethyl)pyridine-2-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(3-methoxy-6-(trifluoromethyl)pyridine-2-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-1-(3-methoxy-6-(trifluoromethyl)pyridine-2-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(3-(methylsulfonyl)phenyl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(3-(methylsulfonyl)phenyl)-2-oxoimidazolidine-4-carbonitrile, (S)-3-(isoquinoline-4-yl)-1-(3-(methylsulfonyl)phenyl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethyl)pyrimidine-2-yl)imidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethyl)pyrimidine-2-yl)imidazolidined-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethyl)pyrimidine-2-yl)imidazolidined-4-carbonilicate, 1-(4-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-(4-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-2-yl)imidazolidined-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-2-yl)imidazolidined-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-2-yl)imidazolidined-4-carbonilicate, 1-(3-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonnitrile, (S)-1-(3-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(4-methylpyrimidine-2-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(4-methylpyrimidine-2-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-1-(4-methylpyrimidine-2-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(5-chloropyridazine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(5-chloropyridazine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-1-(5-chloropyridazine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(6-fluoropyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(6-fluoropyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-1-(6-fluoropyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(2-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(2-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-(2-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(2-(trifluoromethyl)pyridine-4-yl)imidazolidined-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(2-(trifluoromethyl)pyridine-4-yl)imidazolidined-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-2-oxo-1-(2-(trifluoromethyl)pyridine-4-yl)imidazolidined-4-carbonilicate, 1-(5-chloro-3-methoxypyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(5-chloro-3-methoxypyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-1-(5-chloro-3-methoxypyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(5-(difluoromethoxy)-2-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-(difluoromethoxy)-2-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-(5-(difluoromethoxy)-2-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(4-chloro-2-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-chloro-2-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonnitrile, (S)-1-(4-chloro-2-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(6-fluoropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(6-fluoropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-1-(6-fluoropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(5-methyl-2-(trifluoromethyl)pyrimidine-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(5-methyl-2-(trifluoromethyl)pyrimidine-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-1-(5-methyl-2-(trifluoromethyl)pyrimidine-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(1H-indazole-7-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(1H-indazole-7-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-1-(1H-indazole-7-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(1-isopropyl-1H-pyrazole-4-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(1-isopropyl-1H-pyrazole-4-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-1-(1-isopropyl-1H-pyrazole-4-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(1-methyl-1H-pyrazole-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(1-methyl-1H-pyrazole-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-1-(1-methyl-1H-pyrazole-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(2,4-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(2,4-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-(2,4-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(1-methyl-2-oxo-1,2-dihydropyridine-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(1-methyl-2-oxo-1,2-dihydropyridine-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-3-(isoquinoline-4-yl)-1-(1-methyl-2-oxo-1,2-dihydropyridine-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)-1H-imidazole-2-yl)imidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)-1H-imidazole-2-yl)imidazolidine-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)-1H-imidazole-2-yl)imidazolidine-4-carbonilicate, 1-(3-(2-hydroxypropane-2-yl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-(2-hydroxypropan-2-yl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-(3-(2-hydroxypropan-2-yl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(5-chloro-2-(trifluoromethyl)pyridine-4-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(5-methyl-2-(trifluoromethyl)pyridine-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(5-methyl-2-(trifluoromethyl)pyridine-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-1-(5-methyl-2-(trifluoromethyl)pyridine-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(4-(difluoromethoxy)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-(difluoromethoxy)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-1-(4-(difluoromethoxy)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(3,4-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3,4-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-(3,4-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(4-cyano-3-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile (R)-1-(4-cyano-3-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-(4-cyano-3-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(2-methylpyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(2-methylpyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-1-(2-methylpyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(6-(difluoromethyl)pyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(6-(difluoromethyl)pyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-1-(6-(difluoromethyl)pyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(3-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-(3-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(5-fluoro-6-(trifluoromethyl)pyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(5-fluoro-6-(trifluoromethyl)pyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-1-(5-fluoro-6-(trifluoromethyl)pyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(5-(difluoromethyl)pyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(5-(difluoromethyl)pyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-1-(5-(difluoromethyl)pyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(2-methylpyrimidine-5-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(2-methylpyrimidine-5-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-1-(2-methylpyrimidine-5-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(5-chloro-3-methylpyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-chloro-3-methylpyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-1-(5-chloro-3-methylpyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridazine-3-yl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridazine-3-yl)imidazolidined-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridazine-3-yl)imidazolidined-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(3-methyl-6-(trifluoromethyl)pyridine-2-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(3-methyl-6-(trifluoromethyl)pyridine-2-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-1-(3-methyl-6-(trifluoromethyl)pyridine-2-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(4-(difluoromethoxy)-2-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-(difluoromethoxy)-2-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-(4-(difluoromethoxy)-2-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(4-(2-hydroxypropane-2-yl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-(2-hydroxypropan-2-yl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-(4-(2-hydroxypropan-2-yl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3,4-difluorophenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3,4-difluorophenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-(3,4-difluorophenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3,5-difluorophenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3,5-difluorophenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-(3,5-difluorophenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3-chloro-4-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-chloro-4-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonnitrile, (S)-1-(3-chloro-4-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(2-methyl-5-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(2-methyl-5-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-1-(2-methyl-5-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(3-(difluoromethoxy)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-(difluoromethoxy)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-1-(3-(difluoromethoxy)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(2-cyano-5-(trifluoromethyl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(2-cyano-5-(trifluoromethyl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-1-(2-cyano-5-(trifluoromethyl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethoxy)phenyl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethoxy)phenyl)imidazolidined-4-carbonitrile, (S)-3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethoxy)phenyl)imidazolidin-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(3-(trifluoromethoxy)phenyl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(3-(trifluoromethoxy)phenyl)imidazolidined-4-carbonitrile, (S)-3-(isoquinoline-4-yl)-2-oxo-1-(3-(trifluoromethoxy)phenyl)imidazolidined-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(2-(trifluoromethyl)pyrimidine-5-yl)imidazolidined-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(2-(trifluoromethyl)pyrimidine-5-yl)imidazolidined-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-2-oxo-1-(2-(trifluoromethyl)pyrimidine-5-yl)imidazolidined-4-carbonilicate, 1-(6-isopropylpyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(6-isopropylpyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-1-(6-isopropylpyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(2-methoxy-6-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(2-methoxy-6-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-1-(2-methoxy-6-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(1-methyl-2-oxo-6-(trifluoromethyl)-1,2-dihydropyridine-3-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(1-methyl-2-oxo-6-(trifluoromethyl)-1,2-dihydropyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-1-(1-methyl-2-oxo-6-(trifluoromethyl)-1,2-dihydropyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridine-2-yl)imidazolidined-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridine-2-yl)imidazolidined-4-carbonil, 1-(5,6-dimethylpyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5,6-dimethylpyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-1-(5,6-dimethylpyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethyl)phenyl)imidazolidined-4-carbonitrile, (S)-3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethyl)phenyl)imidazolidined-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(2-methoxy-5-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(2-methoxy-5-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-1-(2-methoxy-5-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(5-(difluoromethoxy)-2-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-(difluoromethoxy)-2-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-1-(5-(difluoromethoxy)-2-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(2,6-dimethylpyridine-4-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(2,6-dimethylpyridine-4-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-1-(2,6-dimethylpyridine-4-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(4-chloro-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-chloro-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonnitrile, (S)-1-(4-chloro-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitri 3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridine-3-yl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridine-3-yl)imidazolidined-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridine-3-yl)imidazolidined-4-carbonil, 1-(5-fluoro-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-fluoro-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-(5-fluoro-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)imidazolidined-4-carbonitrile, (S)-3-(isoquinoline-4-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)imidazolidined-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(4-methoxy-6-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(4-methoxy-6-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-1-(4-methoxy-6-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(4-(difluoromethyl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-(difluoromethyl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-(4-(difluoromethyl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(2,5-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(2,5-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-(2,5-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3,5-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3,5-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-(3,5-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(6-chloropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(6-chloropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-1-(6-chloropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(6-methoxypyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(6-methoxypyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-1-(6-methoxypyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-2-oxo-1-(6-oxo-1,6-dihydropyridine-3-yl)imidazolidined-4-carbonilicate, 1-(5-chloro-2-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-chloro-2-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-(5-chloro-2-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(5-chloro-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-chloro-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonnitrile, (S)-1-(5-chloro-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonnitrile, 1-(2-cyano-5-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(2-cyano-5-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-(2-cyano-5-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 4-(4-cyano-3-(isoquinoline-4-yl)-2-oxoimidazolidine-1-yl)-6-(trifluoromethyl)nicotinonitrile, (R)-4-(4-cyano-3-(isoquinoline-4-yl)-2-oxoimidazolidine-1-yl)-6-(trifluoromethyl)nicotinonitrile, (S)-4-(4-cyano-3-(isoquinoline-4-yl)-2-oxoimidazolidine-1-yl)-6-(trifluoromethyl)nicotinonitrile, 3-(isoquinoline-4-yl)-1-(4-methyl-1H-imidazole-2-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(4-methyl-1H-imidazole-2-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-1-(4-methyl-1H-imidazole-2-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(4-chloro-1H-imidazole-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-chloro-1H-imidazole-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-(4-chloro-1H-imidazole-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(3-methylcyclobutyl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-((1s,3S)-3-methylcyclobutyl)-2-oxoimidazolidine-4-carbonil, (R)-3-(isoquinoline-4-yl)-1-((1r,3R)-3-methylcyclobutyl)-2-oxoimidazolidine-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-1-((1s,3R)-3-methylcyclobutyl)-2-oxoimidazolidine-4-carbonil, (S)-3-(isoquinoline-4-yl)-1-((1r,3S)-3-methylcyclobutyl)-2-oxoimidazolidine-4-carbonilicate, 1-(4-fluorocyclohexyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((1r,4R)-4-fluorocyclohexyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((1s,4S)-4-fluorocyclohexyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-((1r,4S)-4-fluorocyclohexyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-((1s,4R)-4-fluorocyclohexyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(spiro[3,3]heptan-2-yl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(spiro[3.3]heptan-2-yl)imidazolidined-4-carbonitrile, (S)-3-(isoquinoline-4-yl)-2-oxo-1-(spiro[3.3]heptan-2-yl)imidazolidined-4-carbonitrile, 1-(3-isopropylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((1s,3S)-3-isopropylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((1r,3R)-3-isopropylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonil, (S)-1-((1s,3R)-3-isopropylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-1-((1r,3S)-3-isopropylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(3-cyclopropylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-((1s,3S)-3-cyclopropylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((1r,3R)-3-cyclopropylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-((1r,3S)-3-cyclopropylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonil, (S)-1-((1s,3R)-3-cyclopropylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonil, 3-(isoquinoline-4-yl)-2-oxo-1-(spiro[2,3]hexane-5-yl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(spiro[2,3]hexane-5-yl)imidazolidin-4-carbonitrile, (S)-3-(isoquinoline-4-yl)-2-oxo-1-(spiro[2,3]hexane-5-yl)imidazolidin-4-carbonitrile, 1-(3,3-dimethylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3,3-dimethylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitri, (S)-1-(3,3-dimethylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitri 1-(6,6-difluorospiro[3,3]heptan-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(6,6-difluorospiro[3.3]heptan-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-1-(6,6-difluorospiro[3.3]heptan-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-((1r,4r)-4-(trifluoromethyl)cyclohexyl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-((1r,4R)-4-(trifluoromethyl)cyclohexyl)imidazolidined-4-carbonitrile, (S)-3-(isoquinoline-4-yl)-2-oxo-1-((1r,4S)-4-(trifluoromethyl)cyclohexyl)imidazolidined-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(1-((trifluoromethyl)sulfonyl)azetidine-3-yl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(1-((trifluoromethyl)sulfonyl)azetidine-3-yl)imidazolidined-4-carbonitrile, (S)-3-(isoquinoline-4-yl)-2-oxo-1-(1-((trifluoromethyl)sulfonyl)azetidine-3-yl)imidazolidined-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(1-(methylsulfonyl)azetidine-3-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(1-(methylsulfonyl)azetidine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-1-(1-(methylsulfonyl)azetidine-3-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(1-(cyclopropylsulfonyl)azetidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(1-(cyclopropylsulfonyl)azetidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-1-(1-(cyclopropylsulfonyl)azetidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(1-methylazetidine-3-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(1-(2,2,2-trifluoroethyl)azetidine-3-yl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(1-(2,2,2-trifluoroethyl)azetidine-3-yl)imidazolidined-4-carbonitrile, (S)-3-(isoquinoline-4-yl)-2-oxo-1-(1-(2,2,2-trifluoroethyl)azetidine-3-yl)imidazolidined-4-carbonitrile, 1-(1-acetylazetidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(1-acetylazetidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-(1-acetylazetidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(1-cyclopropylazetidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(1-cyclopropylazetidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-1-(1-cyclopropylazetidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-2-oxo-1-(3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl)imidazolidined-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl)imidazolidined-4-carbonilicate, (S)-3-(isoquinoline-4-yl)-2-oxo-1-(3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl)imidazolidined-4-carbonil, 1-(4,4-difluorocyclohexyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4,4-difluorocyclohexyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-(4,4-difluorocyclohexyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3-fluorobicyclo[1.1.1]pentan-1-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-fluorobicyclo[1.1.1]pentan-1-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (S)-1-(3-fluorobicyclo[1.1.1]pentan-1-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-neopentyl-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-neopentyl-2-oxoimidazolidine-4-carbonitrile, (S)-3-(isoquinoline-4-yl)-1-neopentyl-2-oxoimidazolidine-4-carbonitrile, 1-(3,3-difluorocyclopentyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((R or S)-3,3-difluorocyclopentyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-((R or S)-3,3-difluorocyclopentyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (S)-1-((R or S)-3,3-difluorocyclopentyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, and (R)-1-((R or S)-3,3-difluorocyclopentyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile A compound of Embodiment 1, its stereoisomer, or a pharmaceutically acceptable salt thereof, selected from the above.

[0280] Embodiment 209.3-(isoquinoline-4-yl)-2-oxo-1-phenylimidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-phenylimidazolidin-4-carbonnitrile, 1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridine-2-yl)imidazolidined-4-carbonilicate, 3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethyl)phenyl)imidazolidin-4-carbonitrile, 1-(4-chlorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(4-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(5-fluoropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-3-yl)imidazolidined-4-carbonilicate, 1-(5-chloropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-3-yl)imidazolidined-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(2-methoxy-4-(trifluoromethyl)phenyl)-2-oxoimidazolidine-4-carbonitrile (R)-3-(isoquinoline-4-yl)-1-(2-methoxy-4-(trifluoromethyl)phenyl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridazine-4-yl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridazine-4-yl)imidazolidined-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(5-methoxy-2-(trifluoromethyl)pyridine-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(5-methoxy-2-(trifluoromethyl)pyridine-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(5-cyano-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-cyano-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonnitrile, 1-(5-chloropyrimidine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(5-chloropyrimidine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(2-methoxy-5-(trifluoromethyl)phenyl)-2-oxoimidazolidine-4-carbonitrile (R)-3-(isoquinoline-4-yl)-1-(2-methoxy-5-(trifluoromethyl)phenyl)-2-oxoimidazolidine-4-carbonitrile, 5-(4-cyano-3-(isoquinoline-4-yl)-2-oxoimidazolidine-1-yl)-2-(trifluoromethyl)isonicotinonitrile, (R)-5-(4-cyano-3-(isoquinoline-4-yl)-2-oxoimidazolidine-1-yl)-2-(trifluoromethyl)isonicotinonitrile, 1-(4-cyano-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-cyano-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitri 1-(5-chloro-2-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-chloro-2-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(5-fluoro-2-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-fluoro-2-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3-(difluoromethyl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-(difluoromethyl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(2-methoxypyridine-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(2-methoxypyridine-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(2-methyl-5-(trifluoromethyl)phenyl)-2-oxoimidazolidine-4-carbonitrile (R)-3-(isoquinoline-4-yl)-1-(2-methyl-5-(trifluoromethyl)phenyl)-2-oxoimidazolidine-4-carbonitrile, 1-((R)-1-(2-hydroxyacetyl)pyrrolidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((R)-1-(2-hydroxyacetyl)pyrrolidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-((R)-1-(3,3,3-trifluoropropyl)pyrrolidine-3-yl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-((R)-1-(3,3,3-trifluoropropyl)pyrrolidine-3-yl)imidazolidined-4-carbonilicate, 1-(3,3-difluorocyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3-hydroxy-3-(trifluoromethyl)cyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3,3-difluorocyclohexyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridazine-3-yl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridazine-3-yl)imidazolidined-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(5-methoxy-2-(trifluoromethyl)pyrimidine-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(5-methoxy-2-(trifluoromethyl)pyrimidine-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyrazine-2-yl)imidazolidined-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyrazine-2-yl)imidazolidined-4-carbonilicate, 4-(3-(3-chlorophenyl)-5-cyano-2-oxoimidazolidine-1-yl)isoquinoline-6-carboxylic acid, (R)-4-(3-(3-chlorophenyl)-5-cyano-2-oxoimidazolidine-1-yl)isoquinoline-6-carboxylic acid, 1-(3-chlorophenyl)-3-(6-(2-hydroxypropane-2-yl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 4-(3-(3-chlorophenyl)-5-cyano-2-oxoimidazolidine-1-yl)isoquinoline-6-carboxamide, 4-(3-(3-chlorophenyl)-5-cyano-2-oxoimidazolidine-1-yl)-N-(2-methoxyethyl)isoquinoline-6-carboxamide, 1-(3-chlorophenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-chlorophenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(2-Methoxy-5-(trifluoromethyl)phenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(2-Methoxy-5-(trifluoromethyl)phenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 4-(3-(3-chlorophenyl)-5-cyano-2-oxoimidazolidine-1-yl)isoquinoline-6-carbonitrile, (R)-4-(3-(3-chlorophenyl)-5-cyano-2-oxoimidazolidine-1-yl)isoquinoline-6-carbonitrile, 1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-4-methyl-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-4-methyl-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-chloropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyrimidine-2-yl)imidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyrimidine-2-yl)imidazolidined-4-carbonilicate, (5S)-1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-5-methyl-2-oxoimidazolidine-4-carbonil, (4R,5S)-1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-5-methyl-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(2-methylpyridine-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(2-methylpyridine-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-((1r,3R)-3-(trifluoromethyl)cyclobutyl)imidazolidin-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-((1s,3S)-3-(trifluoromethyl)cyclobutyl)imidazolidin-4-carbonilicate, 1-((R)-1-(2-hydroxyethyl)pyrrolidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((R)-1-(2-hydroxyethyl)pyrrolidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(3-methoxy-6-(trifluoromethyl)pyridine-2-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(3-methoxy-6-(trifluoromethyl)pyridine-2-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(3-(methylsulfonyl)phenyl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(3-(methylsulfonyl)phenyl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethyl)pyrimidine-2-yl)imidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethyl)pyrimidine-2-yl)imidazolidined-4-carbonilicate, 1-(4-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-2-yl)imidazolidined-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-2-yl)imidazolidined-4-carbonilicate, 1-(3-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonnitrile, 3-(isoquinoline-4-yl)-1-(4-methylpyrimidine-2-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(4-methylpyrimidine-2-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(5-chloropyridazine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(5-chloropyridazine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(6-fluoropyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(6-fluoropyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(2-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(2-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(2-(trifluoromethyl)pyridine-4-yl)imidazolidined-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(2-(trifluoromethyl)pyridine-4-yl)imidazolidined-4-carbonilicate, 1-(5-chloro-3-methoxypyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(5-chloro-3-methoxypyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(5-(difluoromethoxy)-2-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-(difluoromethoxy)-2-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(4-chloro-2-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-chloro-2-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonnitrile, 1-(6-fluoropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(6-fluoropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(5-methyl-2-(trifluoromethyl)pyrimidine-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(5-methyl-2-(trifluoromethyl)pyrimidine-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(1H-indazole-7-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(1H-indazole-7-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(1-isopropyl-1H-pyrazole-4-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(1-isopropyl-1H-pyrazole-4-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(1-methyl-1H-pyrazole-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(1-methyl-1H-pyrazole-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(2,4-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(2,4-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(1-methyl-2-oxo-1,2-dihydropyridine-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(1-methyl-2-oxo-1,2-dihydropyridine-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)-1H-imidazole-2-yl)imidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)-1H-imidazole-2-yl)imidazolidine-4-carbonilicate, 1-(3-(2-hydroxypropane-2-yl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-(2-hydroxypropan-2-yl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(5-chloro-2-(trifluoromethyl)pyridine-4-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(5-methyl-2-(trifluoromethyl)pyridine-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(5-methyl-2-(trifluoromethyl)pyridine-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(4-(difluoromethoxy)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-(difluoromethoxy)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(3,4-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3,4-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(4-cyano-3-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile (R)-1-(4-cyano-3-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(2-methylpyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(2-methylpyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(6-(difluoromethyl)pyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(6-(difluoromethyl)pyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(3-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(5-fluoro-6-(trifluoromethyl)pyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(5-fluoro-6-(trifluoromethyl)pyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(5-(difluoromethyl)pyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(5-(difluoromethyl)pyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(2-methylpyrimidine-5-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(2-methylpyrimidine-5-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(5-chloro-3-methylpyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-chloro-3-methylpyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridazine-3-yl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridazine-3-yl)imidazolidined-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(3-methyl-6-(trifluoromethyl)pyridine-2-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(3-methyl-6-(trifluoromethyl)pyridine-2-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(4-(difluoromethoxy)-2-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-(difluoromethoxy)-2-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(4-(2-hydroxypropane-2-yl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-(2-hydroxypropan-2-yl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3,4-difluorophenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3,4-difluorophenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3,5-difluorophenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3,5-difluorophenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3-chloro-4-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-chloro-4-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonnitrile, 3-(isoquinoline-4-yl)-1-(2-methyl-5-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(2-methyl-5-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(3-(difluoromethoxy)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-(difluoromethoxy)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(2-cyano-5-(trifluoromethyl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(2-cyano-5-(trifluoromethyl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethoxy)phenyl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethoxy)phenyl)imidazolidined-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(3-(trifluoromethoxy)phenyl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(3-(trifluoromethoxy)phenyl)imidazolidined-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(2-(trifluoromethyl)pyrimidine-5-yl)imidazolidined-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(2-(trifluoromethyl)pyrimidine-5-yl)imidazolidined-4-carbonilicate, 1-(6-isopropylpyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(6-isopropylpyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(2-methoxy-6-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(2-methoxy-6-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(1-methyl-2-oxo-6-(trifluoromethyl)-1,2-dihydropyridine-3-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(1-methyl-2-oxo-6-(trifluoromethyl)-1,2-dihydropyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridine-2-yl)imidazolidined-4-carbonilicate, 1-(5,6-dimethylpyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5,6-dimethylpyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethyl)phenyl)imidazolidined-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(2-methoxy-5-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(2-methoxy-5-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(5-(difluoromethoxy)-2-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-(difluoromethoxy)-2-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(2,6-dimethylpyridine-4-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(2,6-dimethylpyridine-4-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(4-chloro-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-chloro-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonnitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridine-3-yl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridine-3-yl)imidazolidined-4-carbonilicate, 1-(5-fluoro-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-fluoro-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)imidazolidined-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(4-methoxy-6-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(4-methoxy-6-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(4-(difluoromethyl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-(difluoromethyl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(2,5-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(2,5-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3,5-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3,5-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(6-chloropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(6-chloropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(6-methoxypyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(6-methoxypyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-2-oxo-1-(6-oxo-1,6-dihydropyridine-3-yl)imidazolidined-4-carbonilicate, 1-(5-chloro-2-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-chloro-2-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(5-chloro-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-chloro-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonnitrile, 1-(2-cyano-5-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(2-cyano-5-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 4-(4-cyano-3-(isoquinoline-4-yl)-2-oxoimidazolidine-1-yl)-6-(trifluoromethyl)nicotinonitrile, (R)-4-(4-cyano-3-(isoquinoline-4-yl)-2-oxoimidazolidine-1-yl)-6-(trifluoromethyl)nicotinonitrile, 3-(isoquinoline-4-yl)-1-(4-methyl-1H-imidazole-2-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(4-methyl-1H-imidazole-2-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(4-chloro-1H-imidazole-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-chloro-1H-imidazole-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(3-methylcyclobutyl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-((1s,3S)-3-methylcyclobutyl)-2-oxoimidazolidine-4-carbonil, (R)-3-(isoquinoline-4-yl)-1-((1r,3R)-3-methylcyclobutyl)-2-oxoimidazolidine-4-carbonilicate, 1-(4-fluorocyclohexyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((1r,4R)-4-fluorocyclohexyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((1s,4S)-4-fluorocyclohexyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(spiro[3,3]heptan-2-yl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(spiro[3.3]heptan-2-yl)imidazolidined-4-carbonitrile, 1-(3-isopropylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((1s,3S)-3-isopropylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((1r,3R)-3-isopropylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonil, 1-(3-cyclopropylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-((1s,3S)-3-cyclopropylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((1r,3R)-3-cyclopropylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(spiro[2,3]hexane-5-yl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(spiro[2,3]hexane-5-yl)imidazolidin-4-carbonitrile, 1-(3,3-dimethylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3,3-dimethylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitri, 1-(6,6-difluorospiro[3,3]heptan-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(6,6-difluorospiro[3.3]heptan-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-2-oxo-1-((1r,4r)-4-(trifluoromethyl)cyclohexyl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-((1r,4R)-4-(trifluoromethyl)cyclohexyl)imidazolidined-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(1-((trifluoromethyl)sulfonyl)azetidine-3-yl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(1-((trifluoromethyl)sulfonyl)azetidine-3-yl)imidazolidined-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(1-(methylsulfonyl)azetidine-3-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(1-(methylsulfonyl)azetidine-3-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(1-(cyclopropylsulfonyl)azetidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(1-(cyclopropylsulfonyl)azetidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(1-methylazetidine-3-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(1-(2,2,2-trifluoroethyl)azetidine-3-yl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(1-(2,2,2-trifluoroethyl)azetidine-3-yl)imidazolidined-4-carbonitrile, 1-(1-acetylazetidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(1-acetylazetidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(1-cyclopropylazetidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(1-cyclopropylazetidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-2-oxo-1-(3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl)imidazolidined-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl)imidazolidined-4-carbonilicate, 1-(4,4-difluorocyclohexyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4,4-difluorocyclohexyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3-fluorobicyclo[1.1.1]pentan-1-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-fluorobicyclo[1.1.1]pentan-1-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-neopentyl-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-neopentyl-2-oxoimidazolidine-4-carbonitrile, 1-(3,3-difluorocyclopentyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((R or S)-3,3-difluorocyclopentyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, and (R)-1-((R or S)-3,3-difluorocyclopentyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile A compound of Embodiment 1, its stereoisomer, or a pharmaceutically acceptable salt thereof, selected from the above.

[0281] Embodiment 210.3-(isoquinoline-4-yl)-2-oxo-1-phenylimidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-phenylimidazolidin-4-carbonnitrile, 1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridine-2-yl)imidazolidined-4-carbonilicate, 3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethyl)phenyl)imidazolidin-4-carbonitrile, 1-(4-chlorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(4-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(5-fluoropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-3-yl)imidazolidined-4-carbonilicate, 1-(5-chloropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-3-yl)imidazolidined-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(2-methoxy-4-(trifluoromethyl)phenyl)-2-oxoimidazolidine-4-carbonitrile (R)-3-(isoquinoline-4-yl)-1-(2-methoxy-4-(trifluoromethyl)phenyl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridazine-4-yl)imidazolidined-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(5-methoxy-2-(trifluoromethyl)pyridine-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(5-cyano-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-cyano-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonnitrile, (R)-1-(5-chloropyrimidine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(2-methoxy-5-(trifluoromethyl)phenyl)-2-oxoimidazolidine-4-carbonitrile, (R)-5-(4-cyano-3-(isoquinoline-4-yl)-2-oxoimidazolidine-1-yl)-2-(trifluoromethyl)isonicotinonitrile, 1-(4-cyano-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-cyano-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitri 1-(5-chloro-2-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-chloro-2-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-fluoro-2-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-(difluoromethyl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(2-methoxypyridine-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(2-methyl-5-(trifluoromethyl)phenyl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((R)-1-(2-hydroxyacetyl)pyrrolidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-((R)-1-(3,3,3-trifluoropropyl)pyrrolidine-3-yl)imidazolidined-4-carbonilicate, 1-(3,3-difluorocyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3-hydroxy-3-(trifluoromethyl)cyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3,3-difluorocyclohexyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridazine-3-yl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(5-methoxy-2-(trifluoromethyl)pyrimidine-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyrazine-2-yl)imidazolidined-4-carbonilicate, 4-(3-(3-chlorophenyl)-5-cyano-2-oxoimidazolidine-1-yl)isoquinoline-6-carboxylic acid, (R)-4-(3-(3-chlorophenyl)-5-cyano-2-oxoimidazolidine-1-yl)isoquinoline-6-carboxylic acid, 1-(3-chlorophenyl)-3-(6-(2-hydroxypropane-2-yl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 4-(3-(3-chlorophenyl)-5-cyano-2-oxoimidazolidine-1-yl)isoquinoline-6-carboxamide, 4-(3-(3-chlorophenyl)-5-cyano-2-oxoimidazolidine-1-yl)-N-(2-methoxyethyl)isoquinoline-6-carboxamide, 1-(3-chlorophenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-chlorophenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(2-Methoxy-5-(trifluoromethyl)phenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-4-(3-(3-chlorophenyl)-5-cyano-2-oxoimidazolidine-1-yl)isoquinoline-6-carbonitrile, (R)-1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-4-methyl-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-chloropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyrimidine-2-yl)imidazolidined-4-carbonilicate, (4R,5S)-1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-5-methyl-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(2-methylpyridine-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-((1r,3R)-3-(trifluoromethyl)cyclobutyl)imidazolidin-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-((1s,3S)-3-(trifluoromethyl)cyclobutyl)imidazolidin-4-carbonilicate, (R)-1-((R)-1-(2-hydroxyethyl)pyrrolidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(3-methoxy-6-(trifluoromethyl)pyridine-2-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(3-(methylsulfonyl)phenyl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethyl)pyrimidine-2-yl)imidazolidined-4-carbonilicate, (R)-1-(4-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-2-yl)imidazolidined-4-carbonilicate, (R)-1-(3-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonnitrile, (R)-3-(isoquinoline-4-yl)-1-(4-methylpyrimidine-2-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(5-chloropyridazine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(6-fluoropyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(2-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(2-(trifluoromethyl)pyridine-4-yl)imidazolidined-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(2-(trifluoromethyl)pyridine-4-yl)imidazolidined-4-carbonilicate, 1-(5-chloro-3-methoxypyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(5-chloro-3-methoxypyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(5-(difluoromethoxy)-2-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(4-chloro-2-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-chloro-2-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonnitrile, (R)-1-(6-fluoropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(5-methyl-2-(trifluoromethyl)pyrimidine-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(1H-indazole-7-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(1-isopropyl-1H-pyrazole-4-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(1-isopropyl-1H-pyrazole-4-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-1-(1-methyl-1H-pyrazole-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(1-methyl-1H-pyrazole-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(2,4-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(2,4-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(1-methyl-2-oxo-1,2-dihydropyridine-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)-1H-imidazole-2-yl)imidazolidine-4-carbonilicate, (R)-1-(3-(2-hydroxypropan-2-yl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(5-chloro-2-(trifluoromethyl)pyridine-4-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(5-methyl-2-(trifluoromethyl)pyridine-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(4-(difluoromethoxy)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(3,4-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3,4-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-cyano-3-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(2-methylpyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(2-methylpyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(6-(difluoromethyl)pyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(3-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-fluoro-6-(trifluoromethyl)pyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(5-(difluoromethyl)pyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(2-methylpyrimidine-5-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(5-chloro-3-methylpyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-chloro-3-methylpyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridazine-3-yl)imidazolidined-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(3-methyl-6-(trifluoromethyl)pyridine-2-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(4-(difluoromethoxy)-2-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-(2-hydroxypropan-2-yl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3,4-difluorophenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3,5-difluorophenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3-chloro-4-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-chloro-4-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonnitrile, (R)-3-(isoquinoline-4-yl)-1-(2-methyl-5-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(3-(difluoromethoxy)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-(difluoromethoxy)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(2-cyano-5-(trifluoromethyl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(2-cyano-5-(trifluoromethyl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethoxy)phenyl)imidazolidined-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(3-(trifluoromethoxy)phenyl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(3-(trifluoromethoxy)phenyl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(2-(trifluoromethyl)pyrimidine-5-yl)imidazolidined-4-carbonilicate, (R)-1-(6-isopropylpyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(2-methoxy-6-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(1-methyl-2-oxo-6-(trifluoromethyl)-1,2-dihydropyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridine-2-yl)imidazolidined-4-carbonilicate, (R)-1-(5,6-dimethylpyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethyl)phenyl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(2-methoxy-5-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(5-(difluoromethoxy)-2-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(2,6-dimethylpyridine-4-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(4-chloro-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-chloro-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonnitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridine-3-yl)imidazolidined-4-carbonilicate, (R)-1-(5-fluoro-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(4-methoxy-6-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(4-(difluoromethyl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(2,5-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3,5-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3,5-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(6-chloropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(6-methoxypyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(5-chloro-2-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-chloro-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonnitrile, 1-(2-cyano-5-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(2-cyano-5-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-4-(4-cyano-3-(isoquinoline-4-yl)-2-oxoimidazolidine-1-yl)-6-(trifluoromethyl)nicotinonitrile, 3-(isoquinoline-4-yl)-1-(4-methyl-1H-imidazole-2-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(4-methyl-1H-imidazole-2-yl)-2-oxoimidazolidine-4-carbonilicate, 1-(4-chloro-1H-imidazole-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-chloro-1H-imidazole-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-((1s,3S)-3-methylcyclobutyl)-2-oxoimidazolidine-4-carbonil, (R)-3-(isoquinoline-4-yl)-1-((1r,3R)-3-methylcyclobutyl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-((1r,4R)-4-fluorocyclohexyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((1s,4S)-4-fluorocyclohexyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(spiro[3.3]heptan-2-yl)imidazolidined-4-carbonitrile, (R)-1-((1s,3S)-3-isopropylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((1r,3R)-3-isopropylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonil, (R)-1-((1s,3S)-3-cyclopropylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((1r,3R)-3-cyclopropylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(spiro[2,3]hexane-5-yl)imidazolidin-4-carbonitrile, (R)-1-(3,3-dimethylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitri, 1-(6,6-difluorospiro[3,3]heptan-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(6,6-difluorospiro[3.3]heptan-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-2-oxo-1-((1r,4r)-4-(trifluoromethyl)cyclohexyl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-((1r,4R)-4-(trifluoromethyl)cyclohexyl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(1-((trifluoromethyl)sulfonyl)azetidine-3-yl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(1-(methylsulfonyl)azetidine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(1-(cyclopropylsulfonyl)azetidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, 3-(isoquinoline-4-yl)-2-oxo-1-(1-(2,2,2-trifluoroethyl)azetidine-3-yl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(1-(2,2,2-trifluoroethyl)azetidine-3-yl)imidazolidined-4-carbonitrile, (R)-1-(1-acetylazetidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(1-cyclopropylazetidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(1-cyclopropylazetidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl)imidazolidined-4-carbonilicate, (R)-1-(4,4-difluorocyclohexyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3-fluorobicyclo[1.1.1]pentan-1-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-fluorobicyclo[1.1.1]pentan-1-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-neopentyl-2-oxoimidazolidine-4-carbonitrile, (R)-1-((R or S)-3,3-difluorocyclopentyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, and (R)-1-((R or S)-3,3-difluorocyclopentyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile A compound of Embodiment 1, its stereoisomer, or a pharmaceutically acceptable salt thereof, selected from the above.

[0282] Embodiment 211. (R)-3-(isoquinoline-4-yl)-2-oxo-1-phenylimidazolidin-4-carbonitrile, (R)-1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-3-yl)imidazolidined-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(2-methoxy-4-(trifluoromethyl)phenyl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridazine-4-yl)imidazolidined-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(5-methoxy-2-(trifluoromethyl)pyridine-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(5-cyano-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonnitrile, (R)-1-(5-chloropyrimidine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(2-methoxy-5-(trifluoromethyl)phenyl)-2-oxoimidazolidine-4-carbonitrile, (R)-5-(4-cyano-3-(isoquinoline-4-yl)-2-oxoimidazolidine-1-yl)-2-(trifluoromethyl)isonicotinonitrile, (R)-1-(4-cyano-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitri (R)-1-(5-chloro-2-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-fluoro-2-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-(difluoromethyl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(2-methoxypyridine-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(2-methyl-5-(trifluoromethyl)phenyl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((R)-1-(2-hydroxyacetyl)pyrrolidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-((R)-1-(3,3,3-trifluoropropyl)pyrrolidine-3-yl)imidazolidined-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridazine-3-yl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(5-methoxy-2-(trifluoromethyl)pyrimidine-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyrazine-2-yl)imidazolidined-4-carbonilicate, (R)-4-(3-(3-chlorophenyl)-5-cyano-2-oxoimidazolidine-1-yl)isoquinoline-6-carboxylic acid, (R)-1-(3-chlorophenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(2-Methoxy-5-(trifluoromethyl)phenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-4-(3-(3-chlorophenyl)-5-cyano-2-oxoimidazolidine-1-yl)isoquinoline-6-carbonitrile, (R)-1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-4-methyl-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-chloropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyrimidine-2-yl)imidazolidined-4-carbonilicate, (4R,5S)-1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-5-methyl-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(2-methylpyridine-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-((1r,3R)-3-(trifluoromethyl)cyclobutyl)imidazolidin-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-((1s,3S)-3-(trifluoromethyl)cyclobutyl)imidazolidin-4-carbonilicate, (R)-1-((R)-1-(2-hydroxyethyl)pyrrolidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(3-methoxy-6-(trifluoromethyl)pyridine-2-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(3-(methylsulfonyl)phenyl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethyl)pyrimidine-2-yl)imidazolidined-4-carbonilicate, (R)-1-(4-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-2-yl)imidazolidined-4-carbonilicate, (R)-1-(3-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonnitrile, (R)-3-(isoquinoline-4-yl)-1-(4-methylpyrimidine-2-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(5-chloropyridazine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(6-fluoropyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(2-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(2-(trifluoromethyl)pyridine-4-yl)imidazolidined-4-carbonilicate, (R)-1-(5-chloro-3-methoxypyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(5-(difluoromethoxy)-2-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-chloro-2-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonnitrile, (R)-1-(6-fluoropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(5-methyl-2-(trifluoromethyl)pyrimidine-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(1H-indazole-7-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(1-isopropyl-1H-pyrazole-4-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(1-methyl-1H-pyrazole-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(2,4-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(1-methyl-2-oxo-1,2-dihydropyridine-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)-1H-imidazole-2-yl)imidazolidine-4-carbonilicate, (R)-1-(3-(2-hydroxypropan-2-yl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(5-methyl-2-(trifluoromethyl)pyridine-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(4-(difluoromethoxy)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(3,4-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-cyano-3-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(2-methylpyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(6-(difluoromethyl)pyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(3-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-fluoro-6-(trifluoromethyl)pyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(5-(difluoromethyl)pyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(2-methylpyrimidine-5-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(5-chloro-3-methylpyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridazine-3-yl)imidazolidined-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(3-methyl-6-(trifluoromethyl)pyridine-2-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(4-(difluoromethoxy)-2-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-(2-hydroxypropan-2-yl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3,4-difluorophenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3,5-difluorophenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-chloro-4-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonnitrile, (R)-3-(isoquinoline-4-yl)-1-(2-methyl-5-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(3-(difluoromethoxy)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(2-cyano-5-(trifluoromethyl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethoxy)phenyl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(3-(trifluoromethoxy)phenyl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(2-(trifluoromethyl)pyrimidine-5-yl)imidazolidined-4-carbonilicate, (R)-1-(6-isopropylpyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(2-methoxy-6-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(1-methyl-2-oxo-6-(trifluoromethyl)-1,2-dihydropyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridine-2-yl)imidazolidined-4-carbonilicate, (R)-1-(5,6-dimethylpyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethyl)phenyl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(2-methoxy-5-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(5-(difluoromethoxy)-2-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(2,6-dimethylpyridine-4-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(4-chloro-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonnitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridine-3-yl)imidazolidined-4-carbonilicate, (R)-1-(5-fluoro-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(4-methoxy-6-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(4-(difluoromethyl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(2,5-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3,5-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(6-chloropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-(6-methoxypyridine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(5-chloro-2-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-chloro-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonnitrile, (R)-1-(2-cyano-5-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-4-(4-cyano-3-(isoquinoline-4-yl)-2-oxoimidazolidine-1-yl)-6-(trifluoromethyl)nicotinonitrile, (R)-3-(isoquinoline-4-yl)-1-(4-methyl-1H-imidazole-2-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(4-chloro-1H-imidazole-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-((1s,3S)-3-methylcyclobutyl)-2-oxoimidazolidine-4-carbonil, (R)-3-(isoquinoline-4-yl)-1-((1r,3R)-3-methylcyclobutyl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-((1r,4R)-4-fluorocyclohexyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((1s,4S)-4-fluorocyclohexyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(spiro[3.3]heptan-2-yl)imidazolidined-4-carbonitrile, (R)-1-((1s,3S)-3-isopropylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((1r,3R)-3-isopropylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonil, (R)-1-((1s,3S)-3-cyclopropylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((1r,3R)-3-cyclopropylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(spiro[2,3]hexane-5-yl)imidazolidin-4-carbonitrile, (R)-1-(3,3-dimethylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitri, (R)-1-(6,6-difluorospiro[3.3]heptan-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-((1r,4R)-4-(trifluoromethyl)cyclohexyl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(1-((trifluoromethyl)sulfonyl)azetidine-3-yl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(1-(methylsulfonyl)azetidine-3-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-1-(1-(cyclopropylsulfonyl)azetidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(1-(2,2,2-trifluoroethyl)azetidine-3-yl)imidazolidined-4-carbonitrile, (R)-1-(1-acetylazetidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(1-cyclopropylazetidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl)imidazolidined-4-carbonilicate, (R)-1-(4,4-difluorocyclohexyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-fluorobicyclo[1.1.1]pentan-1-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonilicate, (R)-3-(isoquinoline-4-yl)-1-neopentyl-2-oxoimidazolidine-4-carbonitrile, (R)-1-((R or S)-3,3-difluorocyclopentyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, and (R)-1-((R or S)-3,3-difluorocyclopentyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile A compound of Embodiment 1, its stereoisomer, or a pharmaceutically acceptable salt thereof, selected from the above.

[0283] Embodiment 212. The compound is (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-3-yl)imidazolidin-4-carbonitrile, [ka] A compound of formula (I) described in any one of embodiments 1 to 5 or 16, having the structure of [the given formula].

[0284] Embodiment 213. The compound according to Embodiment 212, wherein the compound is crystalline (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-3-yl)imidazolidined-4-carbonitrile.

[0285] Embodiment 214.0.154 When measured at temperatures in the range of 20-40°C using Cu-Kα rays with a wavelength of 18 nm, the values ​​were (6.85±0.2)°, (8.52±0.2)°, (10.41±0.2)°, (13.71±0.2)°, (16.90±0.2)°, (17.06±0.2)°, (18.40±0.2)°, and (19.05±0.2)°. The compound according to Embodiment 213, characterized by having a powder X-ray diffractogram that includes at least four reflections at 2θ angles selected from the group consisting of (21.76±0.2)°, (22.55±0.2)°, (23.50±0.2)°, (24.82±0.2)°, (26.89±0.2)° and (28.17±0.2)°.

[0286] Embodiment 215.0.154 The compound according to Embodiment 213, characterized by having a powder X-ray diffractogram that includes reflections at 2θ angles of (10.41±0.2)°, (16.90±0.2)°, (17.06±0.2)° and (21.76±0.2)° when measured at a temperature in the range of 20 to 40°C using Cu-Kα rays having a wavelength of 18 nm.

[0287] Embodiment 216. The compound according to any one of Embodiments 213 to 215, characterized by having a differential scanning thermal analysis curve that includes an endothermic peak having a peak temperature of (235.2°C ± 0.5)°C when measured at a heating rate of 10 K / min.

[0288] Embodiment 217. The compound according to any one of Embodiments 213 to 216, characterized by having a thermogravimetric analysis curve showing a mass loss of 0.51% by weight or less based on the weight of the crystalline form when heated from 30°C to 210°C at a rate of 10 K / min.

[0289] Embodiment 218. The compound described in Embodiment 213, which is a variation A of (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-3-yl)imidazolidined-4-carbonitrile.

[0290] Embodiment 213 is characterized by having a powder X-ray diffractogram that includes at least four reflections at 2θ angles selected from the group consisting of (6.99±0.2)°, (9.11±0.2)°, (13.99±0.2)°, (15.96±0.2)°, (18.26±0.2)°, (19.82±0.2)°, (20.63±0.2)°, (22.03±0.2)°, (23.80±0.2)°, (25.29±0.2)°, (27.30±0.2)°, (30.57±0.2)° and (33.47±0.2)° when measured at a temperature in the range of 20 to 40°C using Cu-Kα rays having a wavelength of 418 nm.

[0291] The compound according to Embodiment 219, characterized by having a powder X-ray diffractogram that includes reflections at 2θ angles of (15.96±0.2)°, (18.26±0.2)°, (19.82±0.2)° and (23.80±0.2)° when measured at a temperature in the range of 20 to 40°C using Cu-Kα rays having a wavelength of 18 nm.

[0292] The compound according to Embodiment 219 or 220, characterized by having a differential scanning thermal analysis curve that includes an endothermic peak having a peak temperature of (161.3°C ± 0.5)°C when measured at a heating rate of 10 K / min.

[0293] Embodiment 222. The compound according to any one of Embodiments 219 to 221, characterized by having a thermogravimetric analysis curve showing a mass loss of 0.21% by weight or less based on the weight of the crystalline form when heated from 30°C to 150°C at a rate of 10 K / min.

[0294] Embodiment 223. The compound described in Embodiment 213, which is a variation B of (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-3-yl)imidazolidined-4-carbonitrile.

[0295] Embodiment 224. The compound according to Embodiment 212, wherein the amorphous (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-3-yl)imidazolidined-4-carbonitrile.

[0296] Depending on the selection of starting materials and procedures, compounds may exist in one form of possible isomers or as mixtures thereof, for example, depending on the number of chiral carbon atoms, as pure optical isomers or as isomer mixtures such as racemic and diastereomer mixtures. The present invention shall include all such possible isomers, including racemic mixtures, diastereomer mixtures and optically pure forms. Optically active (R)- and (S)-isomers may be prepared using chiral synthons or chiral reagents, or may be divided using the prior art. If the compound contains a double bond, the substituent may be in an E configuration or a Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis or trans configuration. All tautomer forms shall also be included.

[0297] As used herein, the term “salt” refers to an acid-addition salt or base-addition salt of the compound of the present invention. “Salt” particularly includes “pharmaceutically acceptable salt.” As used herein, the term “pharmaceutically acceptable salt” refers to a salt that retains the biological efficacy and properties of the compound of the present invention and is not generally biologically or otherwise undesirable. In many cases, the compounds of the present invention can form acid and / or base salts in the presence of an amino and / or carboxyl group or similar group.

[0298] Pharmaceutically acceptable acid addition salts can be forme...

Claims

1. Formula (I) 【Chemistry 1】 A compound thereof, its stereoisomer, or a pharmaceutically acceptable salt thereof, In the formula, X １ CR ３ａ R ３ｂ And, X ２ CR ４ａ R ４ｂ And, R １ teeth, i) 1, 2, 3 or 4 ring members are N, NR ６ , a 5- or 6-membered heteroaryl each independently selected from O and S, which is unsubstituted or has 1 to 4 R ５ a 5- or 6-membered heteroaryl substituted with a group, ii) Unsubstituted or with 1 to 4 R ５ Phenyl groups substituted with a group iii) 1, 2, 3 or 4 ring members are N, NR ６ A 4, 5, or 6-membered heterocycloalkyl group independently selected from O and S, wherein the 4, 5, or 6-membered heterocycloalkyl group is unsubstituted or has 1 to 4 R groups. ５ A 4, 5, or 6-membered heterocycloalkyl group substituted with a group, iv) Unsubstituted or with 1 to 4 R ５ C substituted with a group ３ ~C ８ Cycloalkyl, v) C is non-substituted １ ~C ６ Alkyl, vi) A six-membered heterocyclyl in which one ring member is NR 6, wherein the six-membered heterocyclyl is substituted with an oxo, vii) One or two ring members are N and NR ６ A 9 or 10-membered bicyclic heterocycline independently selected from each of the following, which is unsubstituted or has 1-2 R ５ A 9 or 10-membered bicyclic heterocycline substituted with a group, and viiii) Unsubstituted or with 1 to 4 R ５ A biring C substituted with a base. ３ ~C ８ Cycloalkyl Selected from the group consisting of, R ２ isoquinoline-4-yl, which is either unsubstituted or substituted with one or two R12 groups. R ３ａ It is -CN, R ３ｂ is H or unsubstituted C １ ~C ６ It is alkyl, R ４ａ is H or unsubstituted C １ ~C ６ It is alkyl, R ４ｂ is H or unsubstituted C １ ~C ６ It is alkyl, Each R ５ is CN, -OH, S(=O) ２ C １ ~C ６ Alkyl, C １ ~C ６ Haloalkyl, Halo, C １ ~C ６ Haloalkoxy, C １ ~C ６ Alkoxy, C ３ ~C ８ Cycloalkyl and unsubstituted or OH-substituted C １ ~C ６ Independently selected from the group consisting of alkyls, Each R ６ H, C １ ~C ６ Haloalkyl, C １ ~C ６ Haloalkoxy, S (=O) ２ C １ ~C ６ Alkyl, S (=O) ２ C １ ~C ６ Haloalkyl, -S (=O) ２ C ３ ~C ６ Cycloalkyl, -C(=O)R ７ , C ３ ~C ６ Cycloalkyl and unsubstituted or -OH-substituted C １ ~C ６ Independently selected from the group consisting of alkyls, Each R ７ is either H and unsubstituted, or OH or C １ ~C ６ C substituted with alkoxy １ ~C ６ Independently selected from the group consisting of alkyl, and Each R １２ is -C(=O)N(R ７ ) ２ , -C(=O)OH, -CN, -S(=O) ２ R ７ and C substituted with OH １ ~C ６ Independently selected from the group consisting of alkyl groups, A compound, its stereoisomer, or a pharmaceutically acceptable salt thereof.

2. R １ is phenyl or one or two ring members are N, NR ６ A 5- or 6-membered heteroaryl compound independently selected from O and S, wherein the phenyl or heteroaryl compound is unsubstituted or has 1-2 R members. ５ A compound according to claim 1, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is substituted with a group.

3. R １ are each unsubstituted, or are independently substituted with 1 to 2 R selected from Cl, F, CF ３ , -CHF ２ , -CH ３ , -CH(CH ３ ) ２ , -OCH ３ , -OCHF ２ , -OCF ３ , CN, -SO ２ CH ３ and -C(CH ３ ) ２ OH ５ groups, and are phenyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl, the compound according to claim 2, a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

4. R １ is unsubstituted, or is substituted with 1 to 2 R ３ groups independently selected from Cl, F, CF ２ , -CHF ３ , -CH ３ , -CH(CH ２ ) ３ , -OCH ２ , -OCHF ３ , -OCF ２ , CN, -SO ３ CH ３ , and -C(CH ２ ) ５ OH, and is pyridyl; the compound according to claim 3, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

5. R １ These are either unsubstituted or Cl, F, CF ３ ,-CHF ２ ien-CH ３ , -CH(CH ３ ) ２ , -OCH ３ , -OCHF ２ , -OCF ３ , CN, -SO ２ CH ３ and -C(CH ３ ) ２ One or two R selected independently of OH ５ A compound according to any one of claims 1 to 4, which is a pyrazolyl or imidazolyl substituted with a group, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

6. i. R １ Each is either unsubstituted or has 1-2 R ５ C substituted with a group ３ ~C ８ Cycloalkyl or bicyclic C ３ ~C ８ It is a cycloalkyl, ii. R １ is a six-membered heterocyclyl in which one ring member is NR 6, and the six-membered heterocyclyl is substituted with an oxo, or iii. R １ The ring members are N, NR ６ , a 4, 5, or 6-membered heterocycloalkyl group independently selected from O and S, wherein the 4, 5, or 6-membered heterocycloalkyl group is unsubstituted. The compound described in claim 1, its stereoisomer, or a pharmaceutically acceptable salt thereof.

7. Equation (I - i) 【Transformation 3】 (In the formula, R １ -CF ３ It is pyridine-3-yl substituted with, R ２ is an unsubstituted isoquinoline-4-yl, and R ３ａ (This is -CN) The compound according to claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, having the structure of the compound or a pharmaceutically acceptable salt or stereoisomer thereof.

8. 3-(isoquinoline-4-yl)-2-oxo-1-phenylimidazolidin-4-carbonitrile (R)-3-(isoquinoline-4-yl)-2-oxo-1-phenylimidazolidin-4-carbonitrile, 1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridine-2-yl)imidazolidin-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethyl)phenyl)imidazolidin-4-carbonitrile, 1-(4-chlorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(4-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(5-fluoropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-3-yl)imidazolidin-4-carbonitrile, 1-(5-chloropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-3-yl)imidazolidin-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(2-methoxy-4-(trifluoromethyl)phenyl)-2-oxoimidazolidine-4-carbonitrile (R)-3-(isoquinoline-4-yl)-1-(2-methoxy-4-(trifluoromethyl)phenyl)-2-oxoimidazolidine-4-carbonitrile 3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridazine-4-yl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridazine-4-yl)imidazolidin-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(5-methoxy-2-(trifluoromethyl)pyridine-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(5-methoxy-2-(trifluoromethyl)pyridine-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(5-cyano-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-cyano-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(5-chloropyrimidine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-chloropyrimidine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(2-methoxy-5-(trifluoromethyl)phenyl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(2-methoxy-5-(trifluoromethyl)phenyl)-2-oxoimidazolidine-4-carbonitrile 5-(4-cyano-3-(isoquinoline-4-yl)-2-oxoimidazolidine-1-yl)-2-(trifluoromethyl)isonicotinonitrile, (R)-5-(4-cyano-3-(isoquinoline-4-yl)-2-oxoimidazolidine-1-yl)-2-(trifluoromethyl)isonicotinonitrile, 1-(4-cyano-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-cyano-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile 1-(5-chloro-2-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-chloro-2-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile 1-(5-fluoro-2-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-fluoro-2-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3-(difluoromethyl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-(difluoromethyl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(2-methoxypyridine-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(2-methoxypyridine-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(2-methyl-5-(trifluoromethyl)phenyl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(2-methyl-5-(trifluoromethyl)phenyl)-2-oxoimidazolidine-4-carbonitrile 1-((R)-1-(2-hydroxyacetyl)pyrrolidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((R)-1-(2-hydroxyacetyl)pyrrolidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-((R)-1-(3,3,3-trifluoropropyl)pyrrolidine-3-yl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-((R)-1-(3,3,3-trifluoropropyl)pyrrolidine-3-yl)imidazolidin-4-carbonitrile, 1-(3,3-difluorocyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3-hydroxy-3-(trifluoromethyl)cyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3,3-difluorocyclohexyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridazine-3-yl)imidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridazine-3-yl)imidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(5-methoxy-2-(trifluoromethyl)pyrimidine-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(5-methoxy-2-(trifluoromethyl)pyrimidine-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyrazine-2-yl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyrazine-2-yl)imidazolidin-4-carbonitrile, 4-(3-(3-chlorophenyl)-5-cyano-2-oxoimidazolidine-1-yl)isoquinoline-6-carboxylic acid, (R)-4-(3-(3-chlorophenyl)-5-cyano-2-oxoimidazolidine-1-yl)isoquinoline-6-carboxylic acid, 1-(3-chlorophenyl)-3-(6-(2-hydroxypropane-2-yl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 4-(3-(3-chlorophenyl)-5-cyano-2-oxoimidazolidine-1-yl)isoquinoline-6-carboxamide, 4-(3-(3-chlorophenyl)-5-cyano-2-oxoimidazolidine-1-yl)-N-(2-methoxyethyl)isoquinoline-6-carboxamide, 1-(3-chlorophenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-chlorophenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(2-methoxy-5-(trifluoromethyl)phenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(2-methoxy-5-(trifluoromethyl)phenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 4-(3-(3-chlorophenyl)-5-cyano-2-oxoimidazolidine-1-yl)isoquinoline-6-carbonitrile, (R)-4-(3-(3-chlorophenyl)-5-cyano-2-oxoimidazolidine-1-yl)isoquinoline-6-carbonitrile, 1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-4-methyl-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-4-methyl-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-chloropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyrimidine-2-yl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyrimidine-2-yl)imidazolidine-4-carbonitrile, (5S)-1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-5-methyl-2-oxoimidazolidine-4-carbonitrile (4R,5S)-1-(3-chlorophenyl)-3-(isoquinoline-4-yl)-5-methyl-2-oxoimidazolidine-4-carbonitrile 3-(isoquinoline-4-yl)-1-(2-methylpyridine-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(2-methylpyridine-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-((1r,3R)-3-(trifluoromethyl)cyclobutyl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-((1s,3S)-3-(trifluoromethyl)cyclobutyl)imidazolidin-4-carbonitrile, 1-((R)-1-(2-hydroxyethyl)pyrrolidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((R)-1-(2-hydroxyethyl)pyrrolidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(3-methoxy-6-(trifluoromethyl)pyridine-2-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(3-methoxy-6-(trifluoromethyl)pyridine-2-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(3-(methylsulfonyl)phenyl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(3-(methylsulfonyl)phenyl)-2-oxoimidazolidine-4-carbonitrile 3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethyl)pyrimidine-2-yl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethyl)pyrimidine-2-yl)imidazolidin-4-carbonitrile, 1-(4-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-2-yl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-2-yl)imidazolidin-4-carbonitrile, 1-(3-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(4-methylpyrimidine-2-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(4-methylpyrimidine-2-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(5-chloropyridazine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-chloropyridazine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(6-fluoropyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(6-fluoropyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(2-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(2-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(2-(trifluoromethyl)pyridine-4-yl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(2-(trifluoromethyl)pyridine-4-yl)imidazolidin-4-carbonitrile, 1-(5-chloro-3-methoxypyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-chloro-3-methoxypyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(5-(difluoromethoxy)-2-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-(difluoromethoxy)-2-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile 1-(4-chloro-2-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-chloro-2-cyanophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile 1-(6-fluoropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(6-fluoropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(5-methyl-2-(trifluoromethyl)pyrimidine-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(5-methyl-2-(trifluoromethyl)pyrimidine-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(1H-indazole-7-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(1H-indazole-7-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(1-isopropyl-1H-pyrazole-4-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(1-isopropyl-1H-pyrazole-4-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(1-methyl-1H-pyrazole-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(1-methyl-1H-pyrazole-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(2,4-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(2,4-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(1-methyl-2-oxo-1,2-dihydropyridine-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(1-methyl-2-oxo-1,2-dihydropyridine-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)-1H-imidazole-2-yl)imidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)-1H-imidazole-2-yl)imidazolidine-4-carbonitrile, 1-(3-(2-hydroxypropane-2-yl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-(2-hydroxypropane-2-yl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile 1-(5-chloro-2-(trifluoromethyl)pyridine-4-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(5-methyl-2-(trifluoromethyl)pyridine-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(5-methyl-2-(trifluoromethyl)pyridine-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(4-(difluoromethoxy)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-(difluoromethoxy)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile 1-(3,4-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3,4-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(4-cyano-3-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-cyano-3-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(2-methylpyridine-3-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(2-methylpyridine-3-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(6-(difluoromethyl)pyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(6-(difluoromethyl)pyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(5-fluoro-6-(trifluoromethyl)pyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-fluoro-6-(trifluoromethyl)pyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(5-(difluoromethyl)pyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-(difluoromethyl)pyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(2-methylpyrimidine-5-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(2-methylpyrimidine-5-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(5-chloro-3-methylpyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-chloro-3-methylpyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridazine-3-yl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridazine-3-yl)imidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(3-methyl-6-(trifluoromethyl)pyridine-2-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(3-methyl-6-(trifluoromethyl)pyridine-2-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(4-(difluoromethoxy)-2-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-(difluoromethoxy)-2-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(4-(2-hydroxypropane-2-yl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-(2-hydroxypropane-2-yl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3,4-difluorophenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3,4-difluorophenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3,5-difluorophenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3,5-difluorophenyl)-3-(6-(methylsulfonyl)isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3-chloro-4-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-chloro-4-fluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(2-methyl-5-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(2-methyl-5-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3-(difluoromethoxy)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-(difluoromethoxy)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(2-cyano-5-(trifluoromethyl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(2-cyano-5-(trifluoromethyl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethoxy)phenyl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethoxy)phenyl)imidazolidin-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(3-(trifluoromethoxy)phenyl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(3-(trifluoromethoxy)phenyl)imidazolidin-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(2-(trifluoromethyl)pyrimidine-5-yl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(2-(trifluoromethyl)pyrimidine-5-yl)imidazolidin-4-carbonitrile, 1-(6-isopropylpyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(6-isopropylpyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(2-methoxy-6-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(2-methoxy-6-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(1-methyl-2-oxo-6-(trifluoromethyl)-1,2-dihydropyridine-3-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(1-methyl-2-oxo-6-(trifluoromethyl)-1,2-dihydropyridine-3-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridine-2-yl)imidazolidin-4-carbonitrile, 1-(5,6-dimethylpyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5,6-dimethylpyridine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(4-(trifluoromethyl)phenyl)imidazolidin-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(2-methoxy-5-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(2-methoxy-5-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(5-(difluoromethoxy)-2-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-(difluoromethoxy)-2-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(2,6-dimethylpyridine-4-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(2,6-dimethylpyridine-4-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(4-chloro-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-chloro-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile 3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridine-3-yl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(5-(trifluoromethyl)pyridine-3-yl)imidazolidin-4-carbonitrile, 1-(5-fluoro-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-fluoro-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)imidazolidin-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(4-methoxy-6-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(4-methoxy-6-(trifluoromethyl)pyridine-3-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(4-(difluoromethyl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-(difluoromethyl)phenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile 1-(2,5-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(2,5-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3,5-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3,5-difluorophenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(6-chloropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(6-chloropyridine-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(6-methoxypyridine-3-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(6-methoxypyridine-3-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(6-oxo-1,6-dihydropyridine-3-yl)imidazolidin-4-carbonitrile, 1-(5-chloro-2-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-chloro-2-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(5-chloro-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(5-chloro-2-methoxyphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(2-cyano-5-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(2-cyano-5-methylphenyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 4-(4-cyano-3-(isoquinoline-4-yl)-2-oxoimidazolidine-1-yl)-6-(trifluoromethyl)nicotinonitrile, (R)-4-(4-cyano-3-(isoquinoline-4-yl)-2-oxoimidazolidine-1-yl)-6-(trifluoromethyl)nicotinonitrile, 3-(isoquinoline-4-yl)-1-(4-methyl-1H-imidazole-2-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(4-methyl-1H-imidazole-2-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(4-chloro-1H-imidazole-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4-chloro-1H-imidazole-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile 3-(isoquinoline-4-yl)-1-(3-methylcyclobutyl)-2-oxoimidazolidine-4-carbonitrile (R)-3-(isoquinoline-4-yl)-1-((1s,3S)-3-methylcyclobutyl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-((1r,3R)-3-methylcyclobutyl)-2-oxoimidazolidine-4-carbonitrile, 1-(4-fluorocyclohexyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((1r,4R)-4-fluorocyclohexyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((1s,4S)-4-fluorocyclohexyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(spiro[3,3]heptan-2-yl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(spiro[3,3]heptan-2-yl)imidazolidin-4-carbonitrile, 1-(3-isopropylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((1s,3S)-3-isopropylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((1r,3R)-3-isopropylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3-cyclopropylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((1s,3S)-3-cyclopropylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((1r,3R)-3-cyclopropylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(spiro[2,3]hexane-5-yl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(spiro[2,3]hexane-5-yl)imidazolidin-4-carbonitrile, 1-(3,3-dimethylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3,3-dimethylcyclobutyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(6,6-difluorospiro[3,3]heptan-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(6,6-difluorospiro[3,3]heptan-2-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-((1r,4r)-4-(trifluoromethyl)cyclohexyl)imidazolidined-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-((1r,4R)-4-(trifluoromethyl)cyclohexyl)imidazolidined-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(1-((trifluoromethyl)sulfonyl)azetidine-3-yl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(1-((trifluoromethyl)sulfonyl)azetidine-3-yl)imidazolidin-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(1-(methylsulfonyl)azetidine-3-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-1-(1-(methylsulfonyl)azetidine-3-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(1-(cyclopropylsulfonyl)azetidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(1-(cyclopropylsulfonyl)azetidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-1-(1-methylazetidine-3-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(1-(2,2,2-trifluoroethyl)azetidine-3-yl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(1-(2,2,2-trifluoroethyl)azetidine-3-yl)imidazolidin-4-carbonitrile, 1-(1-acetylazetidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(1-acetylazetidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(1-cyclopropylazetidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(1-cyclopropylazetidine-3-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-2-oxo-1-(3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl)imidazolidin-4-carbonitrile, (R)-3-(isoquinoline-4-yl)-2-oxo-1-(3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl)imidazolidin-4-carbonitrile, 1-(4,4-difluorocyclohexyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(4,4-difluorocyclohexyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 1-(3-fluorobicyclo[1.1.1]pentan-1-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-(3-fluorobicyclo[1.1.1]pentan-1-yl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, 3-(isoquinoline-4-yl)-1-neopentyl-2-oxoimidazolidine-4-carbonitrile (R)-3-(isoquinoline-4-yl)-1-neopentyl-2-oxoimidazolidine-4-carbonitrile, 1-(3,3-difluorocyclopentyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, (R)-1-((R or S)-3,3-difluorocyclopentyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile, and (R)-1-((R or S)-3,3-difluorocyclopentyl)-3-(isoquinoline-4-yl)-2-oxoimidazolidine-4-carbonitrile A compound according to claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, selected from the above.

9. A pharmaceutical composition comprising the compound described in claim 1, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

10. A composition comprising the compound according to claim 1, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, for the treatment, management, and / or prevention of coronavirus-related diseases.

11. The composition according to claim 10, wherein the coronavirus-related disease is COVID-19.

12. (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-3-yl)imidazolidin-4-carbonitrile, and 【Chemistry 4】 A compound of formula (I) according to claim 1, having the structure of [the compound].

13. The compound according to claim 12, wherein the compound is crystalline (R)-3-(isoquinoline-4-yl)-2-oxo-1-(6-(trifluoromethyl)pyridine-3-yl)imidazolidin-4-carbonitrile.

14. The compound according to claim 13, characterized by having a powder X-ray diffractogram that includes at least four reflections at 2θ angles selected from the group consisting of (6.85±0.2)°, (8.52±0.2)°, (10.41±0.2)°, (13.71±0.2)°, (16.90±0.2)°, (17.06±0.2)°, (18.40±0.2)°, (19.05±0.2)°, (21.76±0.2)°, (22.55±0.2)°, (23.50±0.2)°, (24.82±0.2)°, (26.89±0.2)° and (28.17±0.2)°, when measured using Cu-Kα rays having a wavelength of 0.15418 nm at a temperature in the range of 20 to 40°C.

15. The compound according to claim 14, characterized by having a differential scanning thermal analysis curve that includes an endothermic peak having a peak temperature of (235.2°C ± 0.5)°C when measured at a heating rate of 10 K / min.

16. The compound according to claim 14, characterized by having a thermogravimetric analysis curve showing a mass loss of 0.51% by weight or less, based on the weight of the crystalline form, when heated from 30°C to 210°C at a rate of 10 K / min.

17. The compound according to claim 13, characterized by having a powder X-ray diffractogram that includes at least four reflections at 2θ angles selected from the group consisting of (6.99±0.2)°, (9.11±0.2)°, (13.99±0.2)°, (15.96±0.2)°, (18.26±0.2)°, (19.82±0.2)°, (20.63±0.2)°, (22.03±0.2)°, (23.80±0.2)°, (25.29±0.2)°, (27.30±0.2)°, (30.57±0.2)° and (33.47±0.2)°, when measured at a temperature in the range of 20 to 40°C using Cu-Kα rays having a wavelength of 0.15418 nm.

18. The compound according to claim 17, characterized by having a differential scanning thermal analysis curve that includes an endothermic peak having a peak temperature of (161.3°C ± 0.5)°C when measured at a heating rate of 10 K / min.

19. The compound according to claim 17, characterized by having a thermogravimetric analysis curve showing a mass loss of 0.21% by weight or less, based on the weight of the crystalline form, when heated from 30°C to 150°C at a rate of 10 K / min.

Images